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Abstract 
ABSTRACT 
This thesis examines ways in which the chemical reactivity of benzimidazole-, pyrrole- or 
pyrrolizinone-based heterocycles can be modulated. The latent reactivity of these systems 
has been used to develop enzyme inhibitors, antitumour compounds and a novel amino 
acid derivatisation technique. 
Chapter One introduces the concept of modulated chemical reactivity, with illustrative 
examples from biochemistry, synthesis and medicinal chemistry. The application of latent 
reactivity towards the inhibition of serine proteases, a class of proteolytic enzymes, is then 
reviewed. Two inhibitor classes are discussed, the first of which require an inorganic 
cofactor, e.g. a metal ion, for enhanced activity. Secondly, mechanism-based inhibitors, 
which rely on activation by the protease to covalently derivatise the enzyme, are discussed. 
The application of latent reactivity to effect DNA alkylation, and hence inhibit tumour cell 
growth, is also reviewed. This section places particular emphasis on alkylators that arc 
attached to an intercalator to enhance their affinity for DNA. 
Chapter Two describes the inhibition of a-chymotrypsin, a representative serine protease, 
by compounds that were proposed to exhibit enhanced activity upon the coordination of 
Zn2+. The attempted synthesis of the putative inhibitors 2.1a-b was hindered by the 
instability of the diamine precursors 2.2a-b. The model compound 2.1c was prepared, 
however this compound was prone to deuteration and oxidation at its methylene bridge. 
Benzimidazoles 2.14a-c were subsequently prepared, in addition to the dihydrochloride 
salt of 2.14a. These compounds were moderate to weak inhibitors of a-chymotrypsin, and 
no Zn2+-mediated enhancement of inhibition was observed. Benzimidazole 2.14b was 
shown to coordinate Zn(OAc)2 by IH NMR spectroscopy, which illustrated that the lack of 
Zn2+-enhanced inhibition of a-chymotrypsin by compounds of type 2.14 did not result 
from an inability to complex metal ions. 
Abstract 
Chapter Three describes the inhibition of a-chymotrypsin by a new series of C2-acyl-C5-
(hydroxyalkyl)pyrroles. These compounds are postulated to be mechanism-based 
inhibitors. The pyrrole-based peptidomimetics 3.13a and 3.14a were prepared and assayed 
against a-chymotrypsin. Minimal difference in activity was observed between these 
compounds, despite the bulky hydrophobic moiety at C5 of 3.14a, which was proposed to 
bind more tightly to the S1 subsite than the 5-(hydroxymethyl) group of 3.13a. Mass 
spectrometry of 3.13a incubated with a-chymotrypsin suggested that inhibition was non-
covalent in nature. Modifications at the C2 position of 3.13a led to the preparation of 
3.13b, 3.24 and 3.25, of which the latter was the optimal inhibitor, and an IC50 value of 
108 flM was determined for this compound. The attempted solid phase synthcsis of 3.13a 
was ineffectual due to the instability of the 5-(hydroxymethyl)pyrrole moiety to TF A. 
Solid phase synthesis of a 5-formylpyrrole precursor to 3.13a gave the desired product 
3.36 as an inseparable mixture with pyrrole acid 3.16b. Solution phase synthesis of the 5-
(hydroxymethyl)pyrrole 3.35, which possessed a carboxylic acid moiety, afforded an 
unstable compound. 
Chapter Four details a novel derivatisation method for amino acids, whereby the amine is 
first "capped" by pyrrole acid 3.16b. Subsequent reaction with hydrocinnamoyl chloride 
releases the latent spectrophotometric properties of the pyrrole-amino acid adduct. A 
previous study afforded pyrrolizinones 4.11a-c, and this study expanded the range of 
pyrrolizinones available for analysis to include 4.11d-i and 4.17a-b. Initial UV-vis 
spectroscopic analysis revealed that methanol degraded pyrrolizinone 4.11e. UV-vis 
spectroscopy of 4.11a-il4.17a-b in acetonitrile revealed that the variable Rl and R2 groups 
did not affect the Amax and 8 values in a systematic manner. Analysis of the LRMS 
fragmentation patterns for 4.11a-il4.17a-b, and their pyrrole precursors 3.18a-il3.29a-b, 
revealed that a product ion was generated whose mass was dependent on the Rl group. 
The abundance of the diagnostic product ion was dependent on the nature of Rl and R2. 
Fragmentation was increascd by the technique of electron impact, compared to 
electro spray ionisation. 
Abstract 
Chapter Five describes the application of 5-(hydroxymethyl)pyrroles towards the 
development of DNA alkylators with latent reactivity. Attachment of an intercalator to the 
pyrrole moiety via an alkyl linker was proposed to increase cytotoxicity. Model studies 
afforded 5.21 (naphthyl-based) and 5.31 (quinolyl-based), however the synthetic 
methodology was not amenable to compounds that incorporated anthryl or acridine 
moieties, i.e. "true intercalators". Compounds 5.21 and 5.31 displayed moderate activity 
against the P388 cancer cell line. The 5-(hydroxymethyl)pyrrole substructure analogue 
(5.41) elicited no activity in the P388 assay. Compound 5.31 did not react with aniline, 
which suggested that compounds of this type would not effect DNA alkylation in vivo. A 
DNA binding assay revealed that 5.31 had a low affinity for the genetic material, which 
rationalised its moderate P388 activity. Compounds 5.21 and 5.31 displayed minimal 
antiviral and antimicrobial activity. 
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INTRODUCTION 
Chapter One - Introduction 2 
1.1 OVERVIEW 
Selective and controlled manipulation of the chemical and physical properties possessed by 
a molecule is of extreme importance in many areas of chemistry and biology. Without the 
modulation of reactivity, a molecule that is too reactive may form undesired side products. 
Conversely, a chemically stable molecule may not undergo the desired transformation. 
Nature controls chemical.reactivity to perform a wide array of essential reactions. An 
example is the formation of steroids from the acyclic precursor squalene (1.1, Scheme 
1.1 ).1 The reactivity inherent within the structure of 1.1 is released only upon the 
formation of squalene monoepoxide (1.2), after which cyclisation occurs. 
1.1 
Steroids etc 
Scheme 1.1. Formation of steroids by the conversion of squalene (1.1) to squalene 
monoepoxide (1.2). 
The concept of modulation of chemical reactivity is also evident in synthetic chemistry. 
The latent reactivity possessed by a synthetic intermediate often complements, or is an 
alternative to, the use of protecting groups to effect the desired timing and outcome of a 
reaction. One example is the exposure of 1.3 (Scheme 1.2), aD-xylulose-based 
intermediate, to basic alumina, which results in a triple cyclisation to give syringolide 2 
(1.4) as a single stereoisomer.2 
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o 0 
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1.3 
Scheme 1.2. Key cyclisation step in the synthesis of syringolide 2 (1.4). 
The controlled release of chemical reactivity is also utilised by medicinal chemists. Highly 
specific interactions between a molecule and a particular biological target can be effected 
by unmasking the molecules latent reactivity. One example of such an activation process 
is illustrated in Scheme 1.3, whereby the benzamide prodrug 1.5 was selectively reduced at 
the 4-nitro position by DT diaphorase,3 an enzyme expressed at high levels in the Walker 
256 rat carcinoma, to the hydroxylamine 1.6. Subsequent acetylation by thioesters such as 
acetyl-Coenzyme A further activates 1.6, which allowed it to act as a cytotoxic agent 
towards cancerous cells. 
NOz 
(yCONHz 
OzNY 
N 
D 
1.5 
DT diaphorase 
NOz (YCONHz __ _ 
HORNY 
N 
D 
1.6 
Scheme 1.3. Activation of 1.5, an anti tumour prodrug. 
Antitumour 
activity 
An important application of latent reactivity within medicinal chemistry involves 
modulating the activity of enzymes as a result of specific interactions elicited by 
compounds that possess latent reactivity. An example of such a process developed in these 
laboratories is illustrated in Figure 1.1. Irradiating the isomer of azobenzene 1.7 at 
approximately 350 nm gave (Z)-1.7, a two-fold more effective inhibitor of (l-
chymotrypsin.4 The altered shape of the Z isomer resulted in tighter binding of 1.7 to the 
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enzyme active site, i.e. the azobenzene moiety is a photobiological switch that increases 
enzyme inhibition upon adopting the correct conformation. 
A 350nm d o (PhI -;:/' I Nlf 'OMe ~ H 0 N 
N~ (Z)-1.7 V 
Figure 1.1. Photoisomerism of azobenzene 1.7. 
The remainder of this introduction is divided into two sections. The first discusses the 
inhibition of serine proteases, a subclass of proteolytic enzymes, by compounds whose 
activity is dependent on modulated chemical reactivity. The second section deals with 
compounds that act as anticancer agents by the alkylation of DNA only upon the formation 
of reactive intermediates. This section also addresses how the affinity of alkylators for the 
genetic material is increased by incorporation of an intercalating moiety. 
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1.2 INHIBITION OF SERINE PROTEASES BY COMPOUNDS WITH 
CHEMICALLY MODULATED ACTIVITY 
Proteases are a class of enzyme that catalyse the hydrolysis of peptide bonds found in 
proteins and polypeptides (represented by 1.8 in Scheme 1.4) to give an N-terminal 
fragment (1.9) and a C-terminal fragment (1.10).5 
Rl 0 Rl 0 H Protease H2N~ ~N~~ .. ~OH + H2O """N 
H 0 =2 H 0 R2 R 
1.8 1.9 1.10 
Scheme 1.4. Hydrolysis of the peptide 1.8 by a protease gives fragments 1.9 and 1.10. 
The point of cleavage is represented by a bold arrow. 
There are four subclasses of proteases; serine, cysteine, aspartic and metalloproteases.6 
Classification of these subclasses is defined by the amino acids present within the enzyme 
active site that are directly involved in hydrolysis. Proteolytic enzymes perform a diverse 
range of biological functions, including blood coagulation and fibrinolysis, peptide 
hormone processmg, transportation of secretory proteins across membranes, 
macromolecular structure assembly, fertilisation and digestion.7 An imbalance in the 
normal function of these enzymes can lead to the development of a wide range of disease 
states. 
Serine proteases contain a highly conserved catalytic triad of amino acids, denoted as 
Ser195, His57 and Asp102.8 The numbers denote the position of the residue in the 
polypeptide chain. Scheme 1.5 illustrates the serine protease catalysed hydrolysis of a 
peptide bond. NUcleophilic attack by the hydroxyl group of Ser195 upon the peptide 
substrate 1.8 leads to the formation of the tetrahedral intermediate 1.11. The 
nucleophilicity of Ser195 is enhanced by the His57 and Asp102 residues, which act as an 
electron sink and source respectively in a charge-transfer system. The oxyanion of 1.11 is 
stabilised by hydrogen bonding to NH groups in an active site region termed the "oxyanion 
hole". Conversion of 1.11 to the acyl-enzyme intermediate 1.12 is accompanied by release 
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of the C-terminal fragment 1.10 into the surrounding milieu. Hydrolysis of 1.12 by an 
active site water molecule releases the N-terminal fragment 1.9, and the catalytic triad is 
regenerated. 
"Oxyanion hole" 
Ser 195 His57 
0, r=< 
H------N N- 8 
V H-- -OyAsPl02 
° 
1.9 
Scheme 1.5. Serine protease catalysed hydrolysis of a peptide bond. 
The highly conserved mechanism of peptide bond hydrolysis by serine proteases does not 
restrict this class of enzymes to a narrow range of functions in biological systems. This is 
illustrated by the diversity of physiological roles performed by the representative serine 
proteases displayed in Table 1.1.9 
Chapter One - Introduction 7 
Enzyme Source Function Peptide bond cleaved 
(i.e. PI-PI') 
Trypsin Pancreas Digestion of proteins Arg-X or Lys-X 
Chymotrypsin Pancreas Digestion of proteins Large hydrophobic-X 
Elastase Pancreas Digestion of elastin Ala-X or Gly-X 
Thrombin Blood serum Blood clotting Arg-Gly in fibrinogen 
Kallikrein Many tissues and Generation ofkinins, Arg-X 
body fluids . . pam sensmg 
Acrosomal Acrosome of sperm Penetration of zona Arg-X or Lys-X 
protease pellucida of ovum 
Lysosomal Animal cells, plant Cell destruction, defence 
proteases roots against microbes 
Table 1.1. Examples of serine proteases, showing source, function and site of cleavage. 
Proteolytic enzyme cleavage sites are dictated by the chemical nature of the residues 
adjacent to the site of peptide bond hydrolysis (see right-hand colunm of Table 1.1). In 
general, the affinity of an enzyme for a particular substrate or inhibitor is defined by the 
nature of specificity "pockets" within the active site.7,IO For example, a pocket of a non-
polar nature would rather be occupied by a non-polar amino acid side chain than a polar 
one. Schechter and Berger devised a nomenclature systemll to describe the binding 
between an enzyme and its substrate. Amino acid residues from the N-terminus of the 
substrate cleavage point are named PI, P2 etc, and" the corresponding subsites of the 
enzymes are termed S1, S2, etc (Figure 1.2). From the C-terminus ofthe substrate cleavage 
point the residues are named PI', P2', etc, while the corresponding subsites are denoted Sl', 
S2', etc. It can be seen from Table 1.1 that each serine protease has a specific site of 
cleavage, e.g. chymotrypsin-like enzymes prefer a large hydrophobic residue at Pl. 
However, interactions are not wholly dictated by the PIISI contact, and residues as distant 
as P14' have been determined to influence binding. 12 
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N-terminus C-terminus 
of substrate ...... --
,. 
of substrate 
Figure 1.2. Schematic representation of Schechter-Berger nomenclature. The point of 
cleavage is represented bya bold arrow. 
An imbalance in the activity of a particular senne protease can result in an adverse 
pathological condition. The following serine proteases have been implicated in specific 
disease states: a-chymotrypsin (digestive disorders); cathepsin G (inflammation); mast cell 
chymase (inflammation and psoriasis); human leukocyte elastase (acute respiratory distress 
syndrome, rheumatoid arthritis, atherosclerosis, pulmonary emphysema and cystic 
fibrosis); and kallikrein (imbalance with the enzyme renin to give renal failure).13 Control 
of the over-activity of these enzymes with potent and specific inhibitors is considered a 
means to develop efficient therapies for these diseases. 
One approach to reduce protease activity is to develop enzyme inhibitors. Three binding 
modes, from which new classes of serine protease inhibitors can be generated, are outlined 
below. The first is the design of a scaffold where binding to the enzyme is enhanced by 
the presence of a metal ion relative to the inhibition elicited by the scaffold itself.14 A 
second mode of inhibition is derived from a relatively inactive precursor that possesses 
latent reactivity, which is released in the enzyme active site upon initiation of the enzymes 
normal catalytic cycle. This mechanism-based or "suicide" inhibition allows for the 
formation of a covalent bond between the inhibitor and its target enzyme. IS The third 
inhibitory mode relies on conformationally restricted molecules that mimic the peptide 
bond of the natural substrate. The peptide bond isostere is "locked" into the desired shape 
by a cyclic structure.16 There is a general focus in these laboratories toward the design and 
synthesis of a-chymotrypsin inhibitors that utilise one of the binding modes described 
above. a-Chymotrypsin is an excellent model system for serine protease inhibition due to 
its well-defined active site structureI7 and substrate specificity.7a,1O,18 Inhibition of a-
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chymotrypsin is also regarded as an important step in the development of inhibitors for 
chymotrypsin-like enzymes such as cathepsin G, mast cell chymase and human leukocyte 
elastase. l3e 
What follows in the remainder of Section 1.2 is a discussion of serine protease inhibition 
by two methods mentioned in the previous paragraph. In both cases, compounds with 
latent reactivity are utilised to elicit a specific interaction with the biological target. 
Specifically, the metal-enhanced binding of selected scaffolds to serine proteases, and the 
application of mechanism-based inhibition towards a-chymotrypsin, is addressed. 
1.2.1 Enzyme inhibitors with metal-ion enhanced activity 
One issue of concern in the· discipline of medicinal chemistry is that compromised 
bioavailability can arise in enzyme inhibitors that possess complex peptidomimetic 
structures and a high molecular weight. 14 An improvement in bioavailability can be 
obtained by decreasing the peptidic character of inhibitors (i.e. fewer amide bonds, achiral) 
and of a molecular weight lower than 500 Da. 14 The development of structures that 
incorporate the aforementioned structural features and exhibit high affinity and selectivity 
for a particular target is of ongoing concern. 
Katz, et aZ19 effected inhibition of the representative serine proteases trypsin, tryptase and 
thrombin with benzimidazole-based compounds of type 1.13. A selection of the structures 
(1. 13 a-e) is illustrated in Figure 1.3. Note that these compounds possessed the desired 
features of a nonpeptidic structure and low molecular weight. 
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P\-R1 H2N // N 
6 H 
NH 
1.13 a l.13b l.13c l.13d 1.13e 
(BABIM) 
NH2 NV NV ~ ~-O Rl N~NH ~ ~ I ~J~ ~JN ~-?~ H 0 
Figure 1.3. Serine protease inhibitors 1.13a-e. 
The inhibition data for 1.13a-e against a range of serine proteases is presented in Table 1.2. 
Inhibition constant (Ki) values are a measure of the dissociation constant for the enzyme-
inhibitor complex2o - the lower the number, the greater the level of inhibition. Addition of 
Zn2+ at concentrations as low as 100 nM gave a significant increase in the potency of these 
compounds. The increase was quantified as the "Zn2+ factor" (right-hand column of Table 
1.2), which was given by the Ki value for a compound in the presence of EDT A divided by 
the Ki observed for the same compound when Zn2+ was present. EDT A was added to 
determine the activity of the compounds when no metal ions were present. An example is 
inhibitor 1.13a (BABIM), which inhibited trypsin in the presence of EDTA with Ki = 
18.8 ~M. Addition of Zn2+ lowered the Ki value to 90 nM, i.e. an increase in activity by a 
factor of210. The closely related analogue 1.13c had a remarkable 17,000-fold increase in 
inhibitory activity against trypsin, with Ki = 87.5 )!M in the presence of EDTA lowered to 
Ki = 5.2 nM when Zn2+ is present. The activity towards serine proteases of l.13a-e is 
modulated upon Zn2+ binding, i. e. a change in physical properties effects greater inhibition. 
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No. Human protease Inhibition (Ki, ~M) ZnH factor, 
+ EDTA(1) + Zn2\2) i.e. (1)/(2) 
1.l3a Trypsin 18.8 0.09 210 
Tryptase 2.5 0.005 500 
Thrombin 3.7 0.023 160 
Chymotrypsin 710 120 6 
Chymase >1,000 >1,000 -
1.l3b Trypsin 182 0.0235 7,700 
Tryptase 13.5 0.0695 190 
Thrombin 2.31 0.0058 410 
1.l3e Trypsin 87.5 0.0052 17,000 
Tryptase 5.72 0.05 110 
Thrombin >1,000 0.101 >9,900 
1.l3d Trypsin >1,000 136 >7 
Tryptase 358 0.31 1,200 
Thrombin >1,000 10.5 >95 
1.l3e Trypsin 101 20.9 5 
Tryptase 19.3 1.6 12 
Thrombin 81.5 0.721 110 
Table 1.2. Inhibition data for 1.l3a-e against a range of serine proteases in the presence of 
EDTA or Zn2+. 
The mode of binding for 1.l3a to trypsin was determined by X-ray crystallography, and it 
revealed that the enzyme was inhibited by the formation of a ternary complex between 
active site residues, a Zn2+ ion and the inhibitor. The nature ofthis complex is displayed in 
Figure 1.4, whereby the Zn2+ ion was tetrahedrally coordinated by one nitrogen from each 
of the two benzimidazole ring systems of 1.l3a, a nitrogen from the imidazole side chain 
of His 57, and the hydroxyl group oxygen of Ser195. 
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Figure 1.4. Structure of the ternary complex fonned between BABIM (1.13a), Zn2+ and 
the Ser195 and His5? residues of trypsin. The interaction between Asp 189 at the base of 
the SI sub site oftrypsin and the amidine group of 1.13a is also illustrated. 
Specificity for inhibitors of type 1.13 against trypsin-like enzymes was conferred by the 
ami dine group at C6. The ami dine functionality fonns a salt bridge with residue Asp189 at 
the base of the SI subsite, as illustrated in Figure 1.4. Trypsin-like enzymes prefer basic 
residues such as lysine or arginine at the PI position of its natural substrate,10 which 
suggested that an interaction between Asp 189 and the amidine group would be favoured. 
As demonstrated by the Ki values and Zn2+ factors obtained, 1.13a was not an effective 
inhibitor of chymotrypsin and chymase. These enzymes have a preference for substrates 
with an aromatic group at the PI position,10 therefore the ami dine group of 1.13a would not 
favourably interact with the SI subsite of chymotrypsin or chymase. 
The choice of metal ion was discovered to be important for the enhancement of tryptase 
inhibition by 1.13a, with Zn2+ detennined as the optimal metal ion.21 Ca2+, Cu2+, Mg2+ and 
Ni2+ elicited no additional inhibition compared to when EDTA was present, and only slight 
enhancements (less than IO-fold) were observed with Cd2+, C02+ and Mn2+. 
Further publications have diversified the scaffolds upon which the metal ion-enhanced 
inhibition of serine protease can be based. Jane, et az21 synthesised a series of compounds 
based on the bis(benzimidazole)methane scaffold utilised by Katz, et al. 19 One such 
Chapter One - Introduction 13 
inhibitor (1.14, Figure 1.5) displayed a remarkable enhancement of 97,OOO-fold for 
tryptase in the presence of Zn2+, compared to when ternary complex formation was 
prevented by the addition of EDTA. In addition, a high degree of selectivity for tryptase 
over trypsin and thrombin was exhibited. 
Tryptase Ki (EDTA) = 6.6 IlM 
Ki (Zn2+) = 0.068 nM 
Zn2+ factor = 97,000 
1.14 
2+ Trypsin Ki (Zn ) = 670 nM Thrombin Ki (Zn2+) = > 1 ruM 
Figure 1.5. Structure of 1.14 and its inhibition data against tryptase, trypsin and thrombin. 
Compounds 1.1522 and 1.1623 were synthesised as part of a study towards inhibition of 
hepatitis C virus NS3 serine protease (Figure 1.6). NS3 protease is a chymotrypsin-like 
viral enzyme involved in polyprotein processing, an integral step towards the production of 
viable viral particles?4 The inhibition data for 1.15 was expressed as an IC50 value - this is 
the concentration of inhibitor required for half-maximal inhibition of the target enzyme.25 
Inhibitory activity of 1.15 was improved by conversion of the amide functionality on the 
left-hand side ofthe molecule to a phosphonoalanine, replacement of the methylene bridge 
by a difluoromethylene group, and elaboration of the right-hand phosphonoalanine into a 
more complex phosphonate derivative to afford 1.16. These findings showed that the 
phenomenon of zinc-enhanced inhibition can be extended to non-mammalian serine 
proteases. 
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Figure 1.6. Structure of 1.15 and 1.16, and the data for inhibition against hepatitis C virus 
NS3 serine protease. 
Metal ion-mediated inhibition of viral enzymes has also been applied to the human 
cytomegalovirus serine protease.26 The bis(benzimidazole)methane template of an 
inhibitor such as 1.13a was considered too large to be accommodated in the enzyme active 
site. Therefore, inhibitor 1.17 was based on a less sterically demanding 
bis(imidazole)methane motif (Figure 1.7). The 4,4'-bis(imidazole)methane system was 
chosen over the 2,2' isomer to minimize the potential of oxidation at the methylene linker. 
However, 1.17 was only a moderate inhibitor of the target viral protease, and it exhibited 
minimal enhancement of activity III the presence of Zn2+. The other 
bis(imidazole)methane-based analogues prepared in this study had little or no activity in 
the absence of free Zn2+, but on the addition of the metal ion inhibition was observed. This 
was consistent with the formation of a ternary complex to aid inhibition. 
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Figure 1.7. Structure of 1.17 and the data for inhibition against human cytomegalovirus 
serine protease. 
The enhanced inhibition of bovine ~-trypsin has been achieved in a metal ion-mediated 
manner.27 Benzamidines 1.18 and 1.19 were moderate inhibitors of this enzyme 
(inhibition data displayed in Schemes 1.6a and 1.6b). Upon the addition of Cu2+ or Fe3+ 
ions, the activity of 1.18 and 1.19 was enhanced to some degree. The metal ions differed 
in that Cu2+ formed a 1: 1 complex with either benzamidine, whereas Fe3+ existed in 1:2 
complexes with either 1.18 or 1.19. Activity against bovine ~-trypsin of 1.18 and 1.19 was 
enhanced to a greater degree by Fe3+ in comparison to Cu2+. The four complexes 
interacted differently with the active site of bovine ~-trypsin as determined by X-ray 
crystallography. All complexes formed a salt bridge between the amidine moiety of 1.18 
and 1.19 to Asp189, Ser190 and Gly219. However, 1.19-Cu2+ was the only complex 
where an active site residue from the catalytic triad (His57) acted as a ligand to the metal 
ion. The crystal structure of (1.19)2-Fe3+, in the active site of bovine ~-trypsin, revealed 
two surprising alterations to its structure. One of the two benzamidine ligands of complex 
(1.19)2-Fe3+ was lost (probably to avoid unfavourable interactions with active site 
residues), and the Fe3+ ion was replaced by Mg2+. The new complex 1.19-Mg2+ was 
indirectly attached to two catalytic triad residues (Ser195 and His57) through a water 
molecule. Complex (1.18)2-Fe3+ contacted Gln192 via one of its carboxylate ligands, 
whereas 1.18-Cu2+ was shielded from any contact with active site residues other than those 
mediated by its ami dine group. For all cases except that of 1.19-Cu2+, the mode of binding 
was such that no ligand site of the metal ion was occupied by a catalytic triad residue. This 
differed to the ternary complex formed by 1. 13 a, Zn2+ and the enzyme, i.e. Ser195 and 
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His57 acted as ligands towards Zn2+. However, these binding modes revealed alternative 
means by which inhibition of the target enzyme can be achieved in a conceptually similar 
manner to that of l.13a, i.e. the presence of a metal ion increased the potency of an 
inhibitor. 
(a) 
1.18 
K j =28 /!M 
1.18-Cu2+ 
K j =4.2 /!M 
Cu2+ factor = 7 
(1.18)rFe3+ 
K j = 1.6 /!M 
Fe3+ factor = 18 
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(b) 
+eu2+ 
1.19 
Ki 12J!M 
HN 
H2~ 
q'~'Cu:.;' k1Me 
, , 
HO' 8'0 
o 
1.19-eu2+ 
Kj 2.8J!M 
ci+ factor 4 
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Scheme 1.6a and 1.6b. Complex fonnation between Cu2+ and the Schiff bases 1.18 
(Scheme 1.6a) and 1.19 (Scheme 1.6b) gave 1.18-Cu2+ and 1.19-Cu2+ respectively. 
Complex fonnation between Fe3+ and the Schiff bases 1.18 (Scheme 1.6a) and 1.19 
(Scheme 1.6b) gave (1.18h-Fe3+ and (1.19)2-Fe3+ respectively. (1.19h-Fe3+ was converted 
to 1.19-Mg2+ in the active site of bovine ~-trypsin. fuhibition data for all compounds/ 
complexes against the enzyme is presented. 
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Blum et at developed an "on-off' switch for senne protease inhibition?8 fu an 
uncomplexed form, none of the tridentate ligands 1.20-1.22 presented in Figure 1.8 
inhibited Kex2, a yeast serine protease. Kex2 is involved in the processing of peptide 
precursors into biologically active proteins that are secreted from the cel1.29 fuhibition of 
Kex2 is viewed as an excellent model system towards the inhibition of furin, a ubiquitous 
mammalian processing enzyme, as both enzymes have sequence homology and similar 
physiological roles. Potential antiviral therapies could arise from the selective inhibition of 
furin, as this enzyme inadvertently activates the envelope glycoproteins of many viruses to 
enable the uptake of viral particles by host cells.3o Upon addition of Cu2+ ions to separate 
samples of 1.20-1.22, the newly formed complexes displayed activity in the micromolar 
range against Kex2. fu contrast, attempts to elicit Kex2 inhibition by the complexation of 
1.20-1.22 with Zn2+ did not result in enhanced inhibitory activity. 
OMe 
I~ U ~ N~ Nl ~ N I~ 
/:N N ~ ~NH ~ 
~ N I~ 
1.20 ICso = 20 ~M 1.21 ICso = 75 f..tM ~N N~ 
1.22 ICso 10f..tM 
Figure 1.8. Kex2 inhibitors 1.20-1.22, and the inhibition data for each compound in the 
presence ofCu2+. 
Metal ions are not the only entities that can enhance serine protease inhibition. Williams, 
et apt synthesised a series of aryl benzamidines as proposed bovine ~-trypsin inhibitors. 
At pH 6.0, compound 1.23 demonstrated an enhancement of activity by a factor of 5.3 as a 
result of the formation of a ternary complex between inhibitor, sulfate (SOl-) ion and 
enzyme (Figure 1.9). At pH 7.5 this enhancement was considerably diminished. 
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At pH 6.0: 
Ki (NaCl) = 33 IlM 
Ki (Na2S04) = 6.2 IlM 
sol factor = 5.3 
At pH 7.5: 
Kj (NaCI) = 14 IlM 
Ki (Na2S04) = 10 J..lM 
sot factor = 1.4 
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Figure 1.9. Ternary complex fonned between 1.23, sol- and bovine ~-trypsin, m 
addition to the inhibition data at pH 6.0 and 7.5. 
Compounds that bind a metal ion to elicit a greater affmity for biological targets other than 
serine proteases have also been documented. The following examples illustrate that 
specific points in the HIV life cycle can be disrupted by metal-organic complexes. Xylyl-
bicyc1am 1.24 (Figure 1.10),32 upon the coordination of Zn(OAc )2, adopted a confonnation 
that elicited a strong interaction with the CXCR4 receptor, which is employed by HIV for 
membrane fusion and entry into the cel1.33 The CXCR4 antagonist activity of 1.24 toward 
HIV binding increases by 7-, 36-, and 50-fold upon incorporation of Cu2+, Zn2+, and Ni2+ 
respectively?4 Pseudopeptide 1.25 (Figure 1.10) displayed an 7-fold increase in the 
presence of Zn2+ in its ability to inhibit HIV -1 protease dimerisation.35 Prevention of 
dimerisation halts the processing of viral polyproteins. Several non-peptidic metal-organic 
complexes also inhibit HIV -1 protease. Examples include the porphyrin-Cu2+ complex 
1.26,36 the bathocuproine-Cu + complex 1.27,37 bis-(2-pyridylcarbonyl)-arnido-Cu2+ 
complex 1.28,38 and the benzarnide-Cu2+ complex 1.2939 (Figure 1.10). 
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1.24 
1.26 
ICsO 0.975 11M 
Kj 480 ~tM 
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r~\\~0~\~/~stfNH' y\b (' ~OH Ph 
HN O.J-NHZ r ACF3C02H 
~NH - OH Ph 
:1 OH -yO 
I 1 NHz i~ 1.25 
Kj (without Zn2"') 8 11M 
Kj (Zu2+) 1.2 11M 
Zn2+ factor 7 
1.27 
Kj= 111M 
~ 
OMeHN ~:;y MO ~ 
MeO 0--: 2+ 1 tc:. O--Cu---O ~ 1 I OMe ~ I 
OMe fNjNH OMe y 
1.29 
Kj 111M 
Figure 1.10. Anti-HIV agents 1.24-1.29. Inhibition data is included for 1.25-1.29. 
Examples 1.26-1.29 illustrate how a pre-fonned complex can be employed to elicit enzyme 
inhibition. Conversely, inhibitors have been designed to take advantage of the metal ions 
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already present in the active site, i.e. metalloenzyme-specific inhibition. The inhibition of 
BoNT/B-LC (botulinum neurotoxin serotype B, light chain) with BABIM (1.13a, see 
Figure 1.3) gave Kj = 1.6 ~.40 BoNTIB-LC is a metalloenzyme produced by the bacteria 
Clostridium botulinum that cleaves host neuropeptides, producing the paralytic symptoms 
of botulism.41 Subsequent analysis revealed that a ternary complex was initially formed 
between 1.13a, the enzyme and its catalytic Zn2+ ion, and the metal ion was then slowly 
displaced from the active site.42 Another Zn2+ metalloenzyme, bovine carbonic anhydrase, 
preassociated with the thioll.30 (Scheme 1.7) via co-ordination to Zn2+ in the active site.43 
Addition of an alkyl chloride (the optimal example 1.31 is displayed in Scheme 1.7) gave 
1.32, which inhibited bovine carbonic anhydrase with Ki 59 JlM. 
Bovine carbonic anhydrase 
1.30 
1.31 
Scheme 1.7: Inhibition of bovine carbonic anhydrase by formation of 1.32 in the active 
site. 
Three isozymes of carbonic anhydrase (CA I, CA II and CA IV) were inhibited by the 
Schiff base 1.33 (Figure 1.11).44 Increased inhibition was observed with C02+, Ni2+ and 
Cu2+, and the Cu2+ complex 1.34 is displayed in Figure 1.11. This is an example of a pre-
formed complex inhibiting a metalloenzyme, as opposed to the previous examples of 
metalloenzyme inhibitors that were purely organic compounds. 
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1.33 
Ki (CA I) 28 f.lM 
Ki (CA IT) 300 nM 
Kj(CAN) 3 f.lM 
S02NH2 
I~ 
6-;/ ;I~f 
. ~ ~ ~ Cl ¢ ~I 
S02NH2 
1.34 
K j (CA I) 210 nM 
Cu2+ factor 133 
K j (CA II) 13 nM 
Cu2+ factor 23 
K j (CAN) 83 ru\1 
Cu2+ factor 36 
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Figure 1.11. Inhibitory data for the Schiff base 1.33 and its Cu2+ complex 1.34 against CA 
I, CA II and CA IV 
Other zinc proteases targeted include the matrix metalloproteases (MMPs) and the 
bacterial proteases (BPs). 45 These enzymes are of medicinal interest due to involvement in 
cancer and arthritis (MMPs), or as targets for potential antibacterial agents (BPs). 
Inhibition of several representative MMP and BP examples, based on the inhibitor 
scaffolds 1.35a-b (Figure 1.12), was recorded into the low micromolar range. 
NHR1 
Ph I ~Y'0 ;-)l ~ N S SH 
° H 
1.35a R 1 = S02R2 
1.35b R 1 = CONHS02R 
2 
Figure 1.12. Structure ofMMP and BP inhibitor scaffolds 1.35a-b. 
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Inhibition of adenylyl cyclase (AC) isofonn V has been achieved with a series of inhibitors 
that complexed the two Mg2+ ions present in the active site via a hydroxamate moiety.46 
AC catalyses the conversion of adenosine triphosphate to the important cell signaling 
molecule cyclic adenosine monophosphate.47 Selective inhibition of the nine isofonns of 
AC would give therapeutic agents with differing effects on metabolic activity. Figure 1.13 
illustrates the optimal AC isofonn V inhibitors for two series of analogues. One series 
possessed an acyclic linker between the adenine moiety and the hydroxamate (optimal 
inhibitor 1.36), and the other series a cyclic linker (optimal inhibitor 1.37). 
o 
HOHN 1.37 
1.36 ICso 10.8/-lM 
ICso 7.6/-lM 
Figure 1.13. Structure and inhibition data for the adenylyl cyclase inhibitors 1.36 and 
1.37. 
Other biological targets studied include the prostate-specific antigen (PSA), whereby Zn2+ 
increased the affmity of cysteine-containing peptides for PSA.48 These peptides have 
potential for the identification of PSA variants and for the imaging and targeting of 
prostate tumours. A mutation to introduce a metal-binding cysteine into seven 
transmembrane receptor proteins has resulted in its activation by small hydrophobic 
chelators complexed with Zn2+, or by Zn2+ or Cu2+ ions themselves.49 
In summary, a wide variety of compounds have displayed a metal-mediated enhancement 
of activity toward certain biological targets. Serine proteases exhibit a tendency to be 
inhibited in this fashion. Inhibition of this class of enzymes can be effected by other 
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methods, and the following section addresses the concept of mechanism-based inhibition 
and its application to serine proteases. 
1.2.2 Mechanism-based enzyme inhibitors 
A diverse range of compounds, both natural and synthetic, have demonstrated inhibitory 
activity toward enzymes. Classification of these inhibitors results in two general 
categories that describe the mode of binding. The first group are termed reversible 
inhibitors, and these compounds merely reside in the active site of the enzyme, with no 
covalent linkage formed between the enzyme and inhibitor. ls The second group 
irreversibly inactivates the enzyme as a result of covalent derivatisation by a reactive 
inhibitor species. 15 A subset of the irreversible inhibitors are the mechanism-based or 
"suicide" inhibitors.5o These compounds are relatively unreactive molecules that possess 
structural similarity to the substrate, which endows specificity upon the inhibitor towards 
the target enzyme. Docking of the inhibitor into the enzyme active site releases the 
compounds latent reactivity upon initiation of the enzymes catalytic cycle. A covalent 
linkage is subsequently formed between an active site residue and the reactive inhibitor 
species, preventing further enzymatic activity, i.e. inhibition is effected by the modulation 
of the compounds chemical properties. A higher degree of enzyme specificity for a 
particular enzyme can be obtained by mechanism-based inhibitors over conventional active 
site inactivators. This observation is expected as the suicide inhibitors possess similarity to 
the substrate, in addition to activity being dependent on the catalytic mechanism of the 
target enzyme. 
The differences between the catalytic steps involved when an enzyme reacts with its 
normal substrate or a mechanism-based inhibitor are outlined below. For the reaction of an 
enzyme (E, Scheme 1.8) with its substrate (S),51 an enzyme-substrate complex (E:S) is 
formed. This is converted to the enzyme-product complex (E:P), with subsequent release 
of the product (P). All steps are reversible. 
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E+S E:S E:P ====~ E+P 
Scheme 1.8. Reaction of an enzyme (E) and its substrate (S) to give product (P). 
In contrast, reaction between an enzyme (E) and a mechanism-based inhibitor (I) initially 
fonns the enzyme-inhibitor complex (E:I, Scheme 1.9). The latent reactivity of the 
inhibitor is then released by enzyme catalysis to fonn the enzyme-activated inhibitor 
complex (E:I'). This complex cannot undergo the reverse reaction to refonn E:I, and 
instead either reaction k3 or k4 occurs. P is the product released by cleavage of E:I' 
(reaction k3), and E:r' is the enzyme-inhibitor adduct resulting from the fonnation of a 
covalent bond between the two species (reaction k4). 
E+I E:I ~ 
" 
E:I' E:I" 
k, j 
E+P 
Scheme 1.9. Reaction of an enzyme (E) and an inhibitor (1) to give the enzyme-inhibitor 
adduct E:I". 
The partition ratio, which is equal to k31k4, is the ratio of the number of latent inactivator 
molecules (E:I') converted to product (P) relative to the turnover of E:I' leading to enzyme 
inactivation. This ratio is a measure of the inhibitors efficiency towards enzyme 
deactivation. 
Mechanism-based inhibition has been applied to a wide range of biological targets, 
utilising a diverse array of inhibitor scaffolds.51 ,52 Inhibition of serine proteases has been 
achieved through the rational design and synthesis of mechanism-based inhibitors.53 In 
particular, a-chymotrypsin, the target enzyme ofthese laboratories, has been inactivated in 
a mechanism-based fashion by a diverse range of heterocyclic systems. Some 
representative examples include the succinimide 1.38, l3e coumarin 1.3913d and isocoumarin 
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1.40,54 pyrone 1.41,55 benzoxazinone 1.42,56 isatoic anhydride 1.43,57 and the halo enol 
lactones 1.4458 and 1.4559 (Figure 1.14). 
Ph 0 ~N-O-S02Me 
o 
1.38 
kobsJ[I] 9,000 M-1 s-1 
o 
~9 ~Cl 
Cl 
1.40 
kobsJ[I] 570 M-1 8-1 
Cl 
O~ cl~oN lAo~o 
1.39 
kinaclKi = 762,700 M-1 s-l 
Ph 
a~ 
1.41 
1.44 
Ki = 0.339 f.iM 1.45 
Figure 1.14. Structures of the mechanism-based a-chymotrypsin inhibitors 1.38-1.45. 
Inhibition data is given where appropriate. 
The reaction sequence determined for succinimide 1.38 upon its arrival in the active site of 
a-chymotrypsin13C serves as a representative example of mechanism-based enzyme 
inhibition. Nucleophilic attack by the hydroxyl group of Ser195 on 1.38 gave 1.46 
(Scheme 1.10), which instantaneously collapsed via a Lossen rearrangement to afford the 
enzyme-bound isocyanate 1.47. This highly reactive species was postulated to undergo 
three possible pathways: (i) hydrolysis of 1.47 to release the isocyanate derivative 1.48 into 
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the surrounding milieu; (ii) hydrolysis of the isocyanate functionality to afford the mono-
linked enzyme adduct 1.49; (iii) reaction of His57 with the isocyanate to give 1.50, 
whereby the inhibitor is covalently attached to the enzyme at two sites. 
S1 Serl95 ~6 
~{()-S02M' 
(!) 1.46 
S S o ~erl95 
(i) 
.. 
~ ~er195 
~o 1.47 
N=C=O 
\ ~h 0 
----lio- ~O 1.49 
lNH2 
(iii) 
S o ~erl95 
\ ~h 0 ~o D-m,57 
1.50 N~ 
H 0 
Scheme 1.10. Reaction of 1.38 in the active site of a-chymotrypsin. 
Compounds that possess latent reactivity have applications in medicine other than enzyme 
inhibition. Section 1.3 is a discussion of the alkylation of DNA by reactive species as a 
form of cancer chemotherapy. 
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1.3 ANTITUMOUR AGENTS THAT ALKYLATE DNA 
Cancer is a general tenn for more than 100 diseases characterised by the uncontrolled, 
abnonnal growth of cells in the body. 60 Cancer cells cause hann within an organism 
through the deprivation of nourishment and space to nonnal cells; fonnation of a mass 
(tumour) which can invade and destroy healthy tissue; and by the spread (metastasis) of 
cancerous cells to other parts of the body via the bloodstream or lymphatic system. 
Integral to the continued growth of a tumour is cell replication, which is itself dependent 
on the action of DNA replication enzymes.61 Essential to the process of DNA replication 
are the topoisomerase enzymes, which relieve the substantial conformational strain that 
accumulates within the genome during replication. Topoisomerase action occurs in two 
steps, with the first being introduction of strand breaks into the genetic material. 
Subsequent religation yields a less strained confonnation.62 The topoisomerases are 
separated into two classes, type I and type II, with classification dependent on the exact 
mode of action.63 These enzymes, particularly the type II class, are the target of many 
antitumour agents.64 DNA topoisomerase type II inhibitors have an unusual mode of 
action for an enzyme-targeted agent, as the enzymes nonnal catalytic function is not 
inhibited. Instead, the steady-state concentration of the complexes fonned between the 
enzyme and the cleaved DNA is increased, which results in a greater number of aberrations 
in the genetic material that are lethal to the cell.65 The levels of topoisomerase types I and 
II are generally elevated in rapidly dividing cells,66 so the effect of agents directed at these 
enzymes is typically more specific for tumour cells. The design of agents specific for 
DNA topoisomerase type II is an attractive therapeutic option for the treatment of cancer. 
One method by which the action of topoisomerase II can be disrupted is by alkylation of 
the genetic material. A biological alkylating agent is a compound which, under 
physiological conditions, can replace a hydrogen atom present on a biomolecule with an 
alkyl group. Many useful clinical agents for the chemotherapeutic treatment of cancer are 
compounds of this type.67 The chemical mechanisms by which these compounds alkylate 
DNA are diverse, and in general the most effective agents are those that are bifunctional 
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and can crosslink the genetic material, with the N7 position of guanine as the major 
nucleophilic site in DNA.68 Chlorambucil (1.51),69 an example of the nitrogen mustard 
class of alkylating agents, is shown in Scheme 1.11. Alkylation of the genetic material is 
reliant on the latent reactivity possessed by 1.51, which is released upon formation of the 
aziridinium ion 1.52. Subsequent nucleophilic attack by a DNA nucleophile affords adduct 
1.53, i. e. alkylation is dependent on the modulation of the chemical properties of 1.51. A 
second electrophilic alkyl halide on 1.53 allows for another alkylation event to occur by an 
analogous process, i. e. release of latent reactivity by formation of an aziridinium ion. This 
results in a crosslink in the genome which prevents complete DNA replication, and hence 
cell death occurs. 
DNA-NuH ( 
-cr ~N~ 
~ ~_ E (f)~ 
H02C Cl 1.52 
Scheme 1.11. Chlorambucil (1.51) and its reaction with a nucleophilic site in DNA 
(represented as DNA-NuH) to give adduct 1.53. 
Whilst compounds such as 1.51 are effective antitumour agents, one shortcoming 
displayed by the simple nitrogen mustards is a lack of selectivity for DNA. Increased 
affinity for the genetic material is desirable in the design of anticancer compounds, in order 
to reduce the likelihood that other biological entities present in the cell will interact with 
the therapeutic agent. As a result, deleterious side effects are lessened in the organism to 
which the agent is administered. The ability to insert between the pairs of complementary 
bases in the double helix is one method by which specificity for DNA can be endowed 
upon a putative antitumour agent. Compounds of this type require a hydrophobic planar 
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structure to interact favourably with the physical and chemical properties present between 
the base pairs. The desired specificity for DNA is displayed by a class of compounds 
lmown as intercalators, which possess the necessary planar aromatic structure. Three 
simple intercalators are presented in Figure 1.15 - acridine (1.54), acridine orange (1.55)70 
and ethidium bromide (1.56).71 Strong mutagenic and carcinogenic properties were 
displayed by 1.54-1.56 as a result of the high affinity for DNA possessed by these 
compounds. 
'/'1 NH2 
1.54 1.55 Ph 
1.56 
Figure 1.15. Structure of the intercalators acridine (1.54), acridine orange (1.55) and 
ethidium bromide (1.56). 
The interaction of ethidium bromide (1.56) with DNA is schematically represented in 
Figure 1.16. The intercalator, represented as a black rectangle, is interspersed throughout 
the genome. Formation of the intercalator-DNA complex requires separation of adjacent 
base pairs by approximately 3.4 A to allow the planar species to enter the genetic 
material.72 The unimpeded progress of the replication enzymes along the genome is 
essential for complete DNA replication, so any obstacle will be deleterious to this process. 
It has become clear that the primary mode of cytotoxicity of many clinically useful 
intercalating agents involves inhibition of the religation step of to poi some rase II.73 
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Figure 1.16. Interaction of ethidium bromide (1.56) with DNA. The double helix is 
represented in an unwound state for clarity. 
An enormous array of intercalating compounds with antitumour properties have been 
identified over the last few decades through isolation from natural sources or by synthetic 
means, with many reaching clinical trial. 74 The compounds displayed in Figure 1.17 are 
some representative examples of intercalators with interesting activities and/or structural 
motifs. 
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Figure 1.17. Structures of amsacrine (1.57), acridine-based bis- and tris-intercalators 
(1.58-1.59), a representative phenylquinoline-8-carboxamide (1.60), veiutamine (1.61), 
daunorubicin (1.62a), doxorubicin (1.62b), and unfused aromatic intercalators (1.63a-b, 
1.64). 
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Amsacrine (1.57) was the first synthetic DNA intercalating drug used clinically.75 The bis-
and tris-intercalators 1.5876 and 1.5977 were shown to insert into the double helix at more 
than one location per molecule. A series of phenylquinoline-8-carboxamides represented 
by 1.60 intercalated DNA if the phenyl ring was appended at the C2, C3 or C6 positions, 
but not if it was at positions C4 and C5.78 Veiutamine (1.61) is an example of a natural 
product extracted from a marine source (the sponge Zyzzyajitliginosa), and it was found to 
be a potent in vitro cytotoxin?9 The anthracycline class of antibiotics has yielded a range 
of potent compounds for the treatment of cancer, with daunorubicin (1.62a) and 
doxorubicin (1.62b) two classical examples.74b Studies to detennine the drug-DNA 
interaction has revealed that the aglycone chromophore possessed by compounds of type 
1.62 inserted into the double helix, while ring D and the amino sugar resided in the minor 
groove. 80 The unfused aromatics 1.63a-b81 and 1.6482 both interact with DNA in an 
intercalative fashion courtesy of the relatively planar structure of these agents. Compound 
1.64 also amplified the bleomycin-mediated degradation of DNA. 
The following section introduces the concept of "intercalating alkylators", i.e. compounds 
that possess an alkylating moiety fused to an intercalator to effect potent antitumour 
activity. 
1.3.1 Intercalators that alkylate DNA via a reactive functionality 
Many clinically useful alkylating agents display a moderate affinity towards tumour cells, 
however further improvements in specificity are considered desirable.74b An increased 
affinity for genetic material been effected by attachment of an intercalating ligand to an 
electrophile, the activity of which is reliant on its latent reactivity (ef 1.51). The 
intercalators preference for inserting between the base pairs of the double helix presents 
the electrophilic moiety to a reactive site in the DNA. An increase in selectivity for the 
genetic material would help to overcome the problems of excessive reactivity associated 
with many DNA alkylators, as a high proportion of the anticancer agent can degrade in 
vivo by hydrolysis or reaction with other biomolecules e.g. proteins?4b 
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The nitrogen mustard 1.65 (Figure 1.18), which displayed cytotoxicity towards the P388 
murine leukaemia cell line,83 illustrates the bifunctional nature of these "intercalating 
alkylators". An acridine ring system acted as the DNA-directing moiety to deliver the 
alkyl halide functionality (which was attached to the intercalator via an alkyl linker) into 
close proximity to the DNA. As a result, there is a greater likelihood that the alkyl 
chloride moieties would react with the genetic material than other biomolecules. 
Acridine = 
intercalator 
\ 
Cl ( 
o N~Cl 
HN~lN 
H '---------. 
1.65 t 
Nitrogen mustard 
alkylator 
Figure 1.lS. Structure of 1.65, with the intercalating and alkylating functionalities 
highlighted. 
An example of an intercalating alkylator with improved activity in comparison to its non-
intercalating counterpart was reported by Jones, et al.84 The pyrrolophenanthrene nucleus 
of 1.66 (Figure 1.19), which demonstrated intercalative activity, gave a lO-fold increase in 
potency against the HCT-116 colon cancer cell line over 1.67, which only had a phenyl 
ring attached to the nitrogen mustard. 
1.66 
~"-Cl 
Cl ICso =24nM 
ICso =2.5 nM 
Figure 1.19. Structure and anticancer cell line activity of the bifunctional alkylating 
agents 1.66 (intercalating) and 1.67 (non-intercalating). 
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Denny et al described a comparison between the effectiveness of an intercalating (acridine) 
or minor groove binding (quinoline) carrier to effect cytotoxicity in the P388 cellline.8s A 
range of compounds was synthesised, whereby the carrier was appended to an imidazole-, 
thioimidazole- or pyrrolizine-based alkylating unit. Subsequent analysis determined that 
thepyrrolizine-based unit was the most potent alkylator. The hydroxymethyl functionality 
highlighted in 1.68 (Figure 1.20) was resolved to be the point of attachment for 
pyrrolizines such as 1.68 to DNA. Analysis of the ICso data against the P388 cell line 
demonstrated that greater activity was elicited by the minor groove binder 1.68 (ICso = 
0.03 11M) than the intercalator 1.69 (ICso = 1.3 11M). Both compounds showed greater 
activity than the standard alkylating unit 1.70 (ICso >20 JlM). 
Hydroxymethyl 
fnnctionality......... ~ 
'I HO, HO 
Minor groove 
binding nnit 
If \ 
1.68 
ICso = 0.03 ~M 
Intercalating unit 
MeHNOCO ~OCONHM' MeS N 
~e 
1.70 
ICso >20/lM 
HO 
1.69 
IC50 = 1.3 ~ 
Figure 1.20. Structure and anticancer cell line activity of compounds 1.68 (minor groove 
binding alkylator), 1.69 (intercalating alkylator) and 1.70 (alkylator). 
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Another example of DNA alkylation mediated by a reactive hydroxymethyl group was 
reported by Demeunynck et al.86 A range of compounds was prepared with the 
hydroxymethyl group directly attached to the intercalator. This is in contrast to 1.69, 
where both an alkyl linker and a heterocycle separate the reactive functionality and 
intercalative moiety. Initial UV-visible spectroscopic analysis determined that a covalent 
bond was formed between 1.71 (Scheme 1.12) and calf-thymus DNA. Subsequent studies 
to elucidate the electrophilic nature of this class of compounds illustrated that the reaction 
proceeds by the mechanism illustrated in Scheme 1.12. The latent reactivity possessed by 
the protonated form of 1.71 was released upon formation of the quinone-imine-methide 
1. 72, and reaction of 1. 72 with a suitable nucleophile gave the adduct 1.73. 
HO 
1.71 
1.73 1.72 
NuH = MeOH, iPrOH, DNA 
Scheme 1.12. Reaction of 1.71 with various nucleophiles to form adduct 1.73. 
Selectivity for a specific nucleotide sequence was observed for the epoxide 1.7487 (Figure 
1.21). The (R)-epoxide alkylated at the 3' guanine of a GG sequence, whereas the (S)-
epoxide alkylated at the 5' guanine of that particular sequence. DNA affinity was 
conferred by the naphthyldiimide intercalator. This result illustrates that a degree of· 
sequence selectivity can be incorporated into the structure of an intercalating alkylator. 
Chapter One - Introduction 37 
O~O.~~ 0 
N r; ~ N\ 
0-0 
1.74 
Figure 1.21. Structure of the intercalating alkylator 1.74. The stereocentre is marked *. 
1.3.2 Threading intercalators 
One class of DNA intercalators is distinguished by the presence of non-intercalative 
functionalities at the distal ends of a planar aromatic structure. A novel mode of binding, 
known as "threading intercalation", occurs when the intercalator simultaneously directs the 
two substituents separately into each groove of the double helix. 88 The representative 
example nogalamycin (1.75)89 is illustrated in Figure 1.22, in addition to its schematic 
representation 1.76. Note the presence of the amino glucose (grey circle in 1.76) and 
nogalose (white oval in 1.76) sugar moieties attached to the intercalator. 
Amino \ \ 
glucose \ QR '-
\ 
\ - \ 
\ Me2N -, 
, 
, 
\ HO\\" 
'- Me " I \ , 
, " 
\ " \' 
o 
1.75 
-----------6 ----, 
Meo£O~ 
Me~ 
1.76 
OMe OMe 
Nogalose 
Figure 1.22. Structure ofnogalamycin (1.75) and its schematic representation 1.76. 
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Scheme 1.13 illustrates how threading intercalators such as nogalamycin interact with 
DNA. In step (i), the helix forms a temporary cavity by breaking hydrogen bonds between 
pairs of complementary bases. This enables the first non-intercalative moiety of 1.76 to 
"thread" through the base pairs and then occupy its preferred position in either the major or 
minor groove. The intercalator then sits between the base pairs of the distorted helix as a 
result of step (ii). In step (iii), the DNA reforms the hydrogen bonds that were disrupted 
temporarily to give a stable complex. Because the threading process in step (i) is relatively 
5' 3' 5' 3' 
(i) 
3' 5' 3' 5' 
(ii) 
5' 3' 5' 3' 
c 
(iii) 
3' 5' 3' 5' 
Scheme 1.13. Schematic model for the threading intercalation of nogalamycin 
(represented by 1.76) to DNA. 
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disfavoured, the binding constants for compounds of this type are expected to be lower 
than that of mono-substituted intercalators. Conversely, the dissociation rate (essentially 
step (i) in reverse) is also expected to be lower, so a greater retention time within DNA is 
expected for these compounds.72a 
Further examples of threading intercalators are displayed in Figure 1.23. The 
naphthalenediimide 1.77, with distal alkylamino substituents, bound polyGC sequences 20-
25 times more strongly than polyAT sequences.72a This result demonstrated that sequence 
specificity can be incorporated into threading intercalators. Compound 1.78 was 
synthesised by solid phase synthesis and utilised amino acid side chains to interact with the 
grooves of the double helix.88 A threading intercalator was created by appending 
cyclopropapyrroloindole (CPI) and triplex-forming oligonucleotide (TFO) moieties to an 
acridine nucleus to afford 1.79.90 The CPI unit binds to the minor groove of DNA, while 
the TFO resides in the major groove. A novel threading intercalator binding mode was 
exhibited by 1.80, and it bound to DNA in the manner represented by 1.81.91 
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Figure 1.23. Representative threading intercalators 1.77-1.80. 
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1.4 WORK DESCRIBED IN THIS THESIS 
The modulation of a compounds chemical or physical properties at the site of action can 
give rise to highly specific and potent interactions with a biological target. This thesis 
addresses the application of nitrogen-based heterocycles that possess latent reactivity 
towards two biological targets - the inhibition of a-chymotrypsin, and the development of 
putative anticancer compounds. 
Chapter Two describes the attempts made to elicit metal-enhanced enzyme inhibition 
against a-chymotrypsin. This enzyme is considered an exce1lent model system for serine 
protease inhibition due to its well defined active site structure and substrate specificity, in 
addition to being an important step in the development of inhibitors for chymotrypsin-like 
enzymes e.g. cathepsin G, mast cell chymase and human leukocyte elastase. The 
inhibitory activity of these compounds was proposed to be enhanced by the fonnation of a 
ternary complex between the enzyme, inhibitor and a metal ion. Incorporation of an 
aromatic functionality into the structure of the prepared inhibitors was considered critical 
for eliciting inhibition. The inhibition of a-chymotrypsin with or without the presence of 
Zn2+ was detenninedto elucidate whether the synthesised analogues inhibited the target 
enzyme in a metal-mediated fashion. 
Chapter Three describes the synthesis and assay of CS-(hydroxyalkyl)pyrroles as potential 
mechanism-based a-chymotrypsin inhibitors. Reaction of the CS-(hydroxyalkyl)pyrrole in 
the enzyme active site was proposed to unmask a reactive azafulvene species, which would 
subsequently fonn a covalent bond to the enzyme. Deactivation by a less electron-
withdrawing C2-acyl group was projected to increase the probability of azafulvene 
fonnation, relative to previously prepared inhibitors with an electron-withdrawing group 
on the pyrrole ring nitrogen, and hence result in a more reactive series of compounds. 
Emphasis was placed on the optimisation of inhibition by modification at positions C2 and 
CS. The application of solid phase organic synthesis toward the preparation of this class of 
compounds was also attempted. 
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Chapter Four describes the derivatisation of a senes of pyrrole-amino acid adducts 
prepared in Chapter Three under mild conditions to give a range of pyrrolizinones. This 
sequence of reactions was proposed to be a novel two-step method for initially derivatising 
the amino group of an amino acid, after which latent spectrophotometric properties were 
released upon pyrrolizinone fonnation. Investigations were perfonned to detennine 
whether the nature of the amino acid side chain adjacent to the pyrrolizinone ring system 
could be elucidated by UV spectroscopy or low resolution mass spectrometry. 
Chapter Five describes the attempted development of a novel series of compounds with 
potential antitumour activity. The proposed mechanism of action involves reaction of a 5-
(hydroxymethyl)pyrrole functionality with the nucleophilic sites present in DNA, in a 
manner analogous that that of the C5-(hydroxyalkyl)pyrrole a-chymotrypsin inhibitors 
described in Chapter Two. A proposed increase in affmity toward DNA was to be 
endowed upon the 5-(hydroxymethyl)pyrrole alkylators by the presence of an attached 
intercalative moiety. 
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2.1 INTRODUCTION 
There is an ongoing interest in these laboratories toward the development of heterocyclic-
based inhibitors of a-chymotrypsin. This enzyme is considered an excellent model system 
for developing novel classes of serine protease inhibitors due to its well-characterised 
active site structure! and substrate specificity.2 Additionally, inhibition of a-chymotrypsin 
is regarded as an important step toward the inhibition of enzymes with similar substrate 
specificity, such as cathepsin G, mast cell chymase and human leukocyte elastase.3 These 
enzymes have been implicated in a number of debilitating diseases in the human body4 (see 
Chapter One, Section 1.2 for further discussion of the disease states arising from serine 
protease over-activity). 
A novel mode of serine protease inhibition, reported by Katz et ai,5 was of interest in these 
laboratories as a new approach towards the inhibition of a-chymotrypsin. BABIM (1.l3a, 
Figure 2.1), a bis(benzimidazole )methane-based compound, was a moderate inhibitor of 
His57 
Ser195'1 ~ 
I (' 'NH 
HO ,N=.i , , 
, , 
, , 
, , 
'Zn2+ 
I , 
I , 
_------H2N~UMNH2 
o HN N N NH 
1~8 _--- H· H 
AspI89~' ---
o 1.13 a 
Trypsin 
Chymotrypsin 
18.8 
710 
2+ Ki (Zn ),I1M 
0.09 
120 
Zn2+ factor 
210 
6 
Figure 2.1. Ternary complex fonned between 1.l3a, Zn2+ and trypsin, as detennined by 
X-ray crystallography. The interaction between 1.l3a and the S1 sub site of trypsin is 
illustrated. Inhibition data for 1.l3a against trypsin and chymotrypsin is also displayed. 
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trypsin (Ki = 18.8 mM) in the presence of EDT A, a metal ion complexing agent. However, 
upon the addition of Zn2+ the activity of 1.13a against trypsin was increased by a "Zn2+ 
factor" of 210 to Ki = 90 nM. The ternary complex formed between 1.13a, Zn2+ and 
trypsin, displayed in Figure 2.1, was determined by X-ray crystallography, and it provided 
a basis for these observations. Binding of 1.13 a to the enzyme active site residues Ser195 
and His57, which are essential to the normal catalytic activity of the enzyme, was mediated 
by the metal ion. Therefore, complexation of Zn2+ by 1.13a resulted in a more optimal fit 
in the active site of trypsin than that of 1.13a alone, i.e. activity of the inhibitor is 
modulated by the presence of Zn2+. This mode of binding is an important application of 
the concepts discussed in Chapter One, i. e. modulating the chemical or physical properties 
of a molecule to elicit a specific interaction with a biological target. A series of inhibitors 
analogous to 1.13a were prepared and assayed for activity against a selection of serine 
proteases, and a wide range of inhibitor potencies and Zn2+ factors were observed (see 
Chapter One, Section 1.2.1 for further discussion). A common structural feature for 
compounds of type 1.13 was the presence of an amidine moiety at the C6 position. 
Formation of a salt bridge between the ami dine group and Asp189 at the base of the SI 
subsite enhanced the activity displayed by compounds of type 1.13 towards trypsin-like 
enzymes. (See Chapter One, Section 1.2 for a discussion of the SIP nomenclature 
developed by Schechter and Berger.6) The amidine functionality mimics the basic arginine 
or lysine residues which occupy the PI position of trypsins natural substrate,2b which 
revealed that the C6 group was integral for recognition ofthe inhibitor by trypsin. 
The mode of inhibition illustrated in Figure 2.1 stimulated research towards the inhibition 
of the target enzyme of these laboratories, a-chymotrypsin, in a manner analogous to that 
displayed by 1.13a against trypsin. Relatively moderate inhibition, and a small 
enhancement of activity when Zn2+ was present, was displayed by l.13a against a-
chymotrypsin (see data in Figure 2.1). The research discussed in this chapter focuses on 
two areas that would determine the extent to which this binding mechanism could be 
applied to other serine proteases. The first involved determination of whether a Zn2+_ 
mediated enhancement of inhibition, greater than that observed for l.13a, could be elicited 
against a-chymotrypsin. Secondly, the importance of the substituent at C6 would be 
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addressed. A hydrophobic substituent at C6 would endow greater affinity upon the 
putative inhibitor against a-chymotrypsin, in comparison to that observed for 1.13a, as this 
enzyme has a predilection for substrates and inhibitors with aromatic substituents.2a,7 This 
preference is a result of the Ser189 residue at the base of the non-polar Sl sub site in 
chymotrypsin-like enzymes (el Asp189 in trypsin).5 
Three proposed a-chymotrypsin inhibitors (2.1a-c, Figure 2.2), based on a benzimidazole 
ring system, were initially targeted for synthesis. Figure 2.2 displays a possible ternary 
complex between inhibitors of type 2.1, Zn2+ and the enzyme. The benzimidazole ring is 
substituted at C2 with a pyridin-2-ylmethyl moiety. As a result, compounds of type 2.1 
can act as a bidentate ligand that occupies two of the four Zn2+ co-ordination sites. 
Residues Ser195 and His57 of the catalytic triad coordinate the two remaining sites. 
Occupation of the Sl subsite with an aromatic moiety at the C6 position (i.e. R1) of the 
benzimidazole nucleus was proposed to elicit a favourable interaction between inhibitors 
of type 2.1 and the enzyme, with a concomitant increase in activity. Compound 2.1a has a 
2-phenylethyl group at R 1, whereas 2.1 b possesses a phenyl group at the same position. 
The presence of the ethylene linker in R1 of 2.1a was expected to increase its flexibility, 
potentially resulting in a more optimal fit in the Sl sub site than the phenyl group of2.1b. 
Ser195i 
HO, 
1 2.1aR =Ph(CH2h 
2.1b Rl =Ph 
2.1cRl =Me 
Trypsin Ki (EDTA) = > 1,000 ~M 
( 2+ Ki Zn ) = 136 ~M 
Zn2+ factor = >7 
Figure 2.2. Structure of the proposed a-chymotrypsin inhibitors 2.1 a-c, and the 
anticipated mode of binding in the active site. Inhibitor l.13d, and its activity against 
trypsin, is highlighted for comparison. 
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Hence, 2.la may be expected to elicit greater activity against a-chymotrypsin than 2.1b. 
Comparison of the activity displayed by benzimidazole 2.1c (R1 Me) to that of 2.la-b 
would determine the importance of the aromatic Rl groups possessed by 2.1a-b for 
inhibitory activity. The ability of the 2-(pyridin-2-ylmethyl)benzimidazole nucleus to 
effect Zn2+-enhanced inhibition was demonstrated by 1.13d (highlighted in Figure 2.2), as 
it displayed a greater than 7-fold enhancement for trypsin inhibition when Zn2+ was 
present. 5 
The position of the aromatic functionality possessed by compounds of type 2.1 must be 
considered. For example, 2.lc can exist as two tautomers, denoted as 2.1c(l) or 2.1c(2) in 
Figure 2.3, with the methyl group residing at either C6 or C5 respectively. Future 
representation of the proposed inhibitors will be that of 2.1c(1). This assumption was 
based on the tautomeric form of 1.13a, which resided in the active site of trypsin with the 
amidine group at C6 as determined by X-ray crystallography (see Figure 2.1). 
~J~ Me~Nl 
H 
H~/ £;eN l ~ I 10 ! 
Me 5 N 
3 
2.1c(1) 2.1c(2) 
Figure 2.3. Tautomeric forms of2.lc. 
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2.2 ATTEMPTED SYNTHESIS OF THE BENZIMIDAZOLES 2.1a-c 
A retrosynthetic analysis of the proposed benzimidazole-based inhibitors 2.1a-c suggested 
that the heterocyclic nucleus would be best obtained in the final synthetic step. 
Disconnection of 2.1a-c afforded the diamines 2.2a-c, which were to be reacted with 
appropriate derivatives (2.3a-c) that possess a pyridin-2-ylmethy1 moiety. The following 
section details the synthesis of diamines 2.2a-b, the attempted preparation of 2.1a-b, and 
the difficulties encountered upon synthesis of2.1c. 
1 2.1a R = Ph(CH2h 
2.1bR1 =Ph 
2.1cR1 =Me 
1 2.2aR =Ph(CH2h 
2.2b Rl =Ph 
2.2c Rl = Me 
Scheme 2.1. Retrosynthetic analysis ofthe benzimidazoles 2.1a-c. 
2.2.1. Synthesis of the diamine intermediate 2.2a 
+ 
1 2.3a R = C02H.HCl 
2.3bR1 =CN 
2.3cR1 = NH 
EtOJy 
.2HCl 
The synthesis of bibenzy1 diamine intermediate 2.2a is illustrated in Scheme 2.2. 
2-Nitroaniline (2.4) was iodinated with pyridine iodine monoch10ride8 to give 2.Sa in 97% 
yield, and subsequent acylation with acetyl chloride afforded 2.Sb in 91% yield. 
Treatment of 2.Sb with styrene under Heck ary1ation conditions using palladium acetate as 
the cross-coupling catalyst9 gave 2.6a in 51 % yield as pure E isomer. Assignment of 2.6a 
as the E isomer was based on the relatively large coupling constant (J = 16.6 Hz) given by 
an AB quartet for the alkene proton resonance at 8 7.09 ppm. This observation is in 
agreement with the larger coupling constants expected for vicinal protons in 1,2-
disubstituted E alkenes (commonly J = 14-16 Hz), in comparison to those obtained for 
vicinal protons in the corresponding Z alkenes (typically J = 6-8 HZ).10 Deacety1ation of 
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2.6a in 4: 1 ethanol/5 M aqueous sodium hydroxidell gave 2.6b quantitatively, and 
subsequent reduction with hydrogen over platinum oxide (Adams catalyst) afforded the 
desired diamine 2.2a in 96% yield. 
(i) 
2.4 C 2.5aRl=H (ii) 2.5b Rl =Ac 
(iii) 
C 2.6aRl=Ac (iv) 2.6b Rl =H 
2.2a 
Scheme 2.2. Reagents and conditions: (i) PyrICI, 30% AcOH(aq), r.t., 30 min (97%). (ii) 
AcCI, reflux, 15 min (91 %). (iii) Styrene, 10 mol % Pd(OAc)2, 20 mol % (o-tol)3P, Et3N, 
MeCN, reflux, 3 h (51 %). (iv) 4:1 EtOH/5 M NaOH(aq), reflux, 1 h (quantitative). (v) H2, 
Pt02, EtOH, r.t., 17 h (96%). 
2.2.2. Synthesis of the diamine intermediate 2.2b 
Preparation of the biphenyl diamine intermediate 2.2b is illustrated in Scheme 2.3. 4-
Nitro-I,l'-biphenyl (2.7) was reduced with hydrogen over 10% palladium on charcoal to 
afford the amine 2.8a in 96% yield, and subsequent acylation with acetyl chloride gave 
2.8b in quantitative yield. Nitration of 2.8b with nitric acid in acetic acid,12 followed by 
deacetylation in 4:1 ethanol/5 M aqueous sodium hydroxide, gave 2.9 in 76% yield over 
two steps. Reduction of 2.9 with hydrogen over Adams catalyst afforded the desired 
diamine 2.2b in 82% yield. 
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(i) 
2.7 
~NHRI _____ (i_ii)_,_(w_) ___ .~ 
~ Ph 
C 2.8aRl=H (ii) 2.8b Rl = Ac 2.9 j (v) 
~NH2 ~ Ph NH2 
2.2b 
Scheme 2.3. Reagents and conditions: (i) H2, 10% PdJC, EtOH, Lt., 17 h (96%). (ii) AcCI, 
reflux, 15 min (quantitative). (iii) RN03, AcOH, 70DC, 1 h. (iv) 4:1 EtOH/5 M NaOH(aq), 
reflux, 1 h (76% over two steps). (v) H2, Pt02, EtOH, Lt., 6 h (82%). 
2.2.3 Attempted synthesis ofbenzimidazoles 2.la-b 
The next stage involved determining the optimal conditions for preparation of the 
benzimidazo1es 2.la-c. Scheme 2.4 illustrates that separate reaction of 2.2a with 2.3a-c 
did not afford the expected product 2.la. 
2.2a 2.3a Rl = C02H.HCI 
or 
2.3bRl =CN 
or 
2.3cR1 = NH 
EtO~ 
.2HCI 
(i), (i~i)' (iii) or (iv) ~N ~~ 
----~----~. I ~ 
Ph h- N 
H 
2.la 
Scheme 2.4. Reagents and conditions: (i) 2.3a, PPA, 170-180DC, 5 h. (ii) 2.3a, 4 M HC1, 
120-l30DC, 6 h. (iii) 2.3b, PPA, 250DC, 4 h. (iv) 2.3c, AcOH, reflux, 15 h. 
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Reaction of the diamine 2.2a with 2-pyridylacetic acid hydrochloride (2.3a) in PPA at 170-
180°C13 gave an intractable mixture, and the presence of 2.la was not revealed by 1H 
NMR spectroscopy. Analysis by reverse-phase HPLC illustrated that a complex mixture 
of compounds was generated by the reaction of 2.2a with 2.3a in PPA (Figure 2.4). The 
reaction of 2.2a with 2.3a in refluxing 4 M hydrochloric acid14 again resulted in extensive 
byproduct formation as shown by 1H NMR spectroscopy. Reaction of 2.2a with 2-
pyridylacetonitrile (2.3b) in PP A at 250°C15 also gave an intractable mixture of 
compounds by 1H NMR spectroscopy. At this stage milder methods for the preparation of 
benzimidazoles were sought, and one such procedure involves reaction of an aromatic 
diamine with an imidate. 16 To this end, nitrile 2.3b was dissolved in 10: 1 benzene/ethanol 
at O°C, then saturated with hydrogen chloride gas, and the resulting suspension was stirred 
at r.t. for 16 h. After isolation, the imidate 2.3c was immediately reacted with 2.2a in 
refluxing acetic acid,17 but once again an intractable mixture of byproducts was produced. 
The 1H NMR spectrum of this mixture illustrated that little or no 2.la was formed, as it did 
BOO 
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300 
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1:2.54I1m,4."" 
-DrHu .... rdnIJl1 
DrHu ..... drun1 
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~NH, 
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2.2. 
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J) 5h. + ~ X, 
HO,C /< 
.HCI 
2.3. 
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H 
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Figure 2.4. HPLC trace of the mixture obtained from the reaction of the diamine 2.2a and 
2.3a in PP A at 170-180°C in the attempted formation of 2.la. 
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not contain the resonances expected for the downfield pyridyl protons (8 approximately 
8.8-8.3 ppm) or the methylene group (8 approximately 4.4 ppm). 
Diamine 2.2b was reacted with 2.3b in PP A at 250°C in an attempt to prepare 2.2b 
(Scheme 2.5), however IH NMR spectroscopy revealed that a wide range of byproducts 
had been formed. 
+ 
2.2b 
~~ NC~ 
2.3b 
(i) 
X 
. ~~ (Y~ Ph~N 
H 
2.1b 
Scheme 2.5. Reagents and conditions: (i) PPA, 250°C, 4 h. 
Reverse-phase HPLC analysis of the mixture generated by reaction of 2.2b and 2.3b 
(Figure 2.5) illustrated that less bypro ducts were formed than in the reaction of 2.2a and 
t: '54 nrn,~ nm 
-DCIl7.U. 
DCII7.'h PPA, 250°C, 4 h. £CN~ 700 ~NH2 + ~ X 700 Ph I ~ NH2 NC ~ Ph ~ N 
H 
'00 2.2b 2.3b '00 
2.lb 
500 500 
400 400 
mAU mAU 
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100 200 
100 u~ ~,~ 100 J .! I l\ 
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Minutes 
Figure 2.5: HPLC trace of the mixture obtained from the reaction of 2.2a and 2.3b in PP A 
at 250°C in the attempted preparation of2.1b. 
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2.3a (see Figure 2.4). However, the level of byproduct fonnation was sufficient to 
eliminate this methodology from any subsequent attempts toward the preparation of2.1b. 
The cause of excessive byproduct fonnation in reactions which utilised 2.2a or 2.2b was 
postulated to result from instability of the diamine starting materials under the relatively 
harsh reaction conditions utilised in the attempted preparation of 2.1a-b. Precedent exists 
for the degradation ofbibenzyl (2.10, Figure 2.6), the basic carbon backbone of 2.2a, to a 
range ofbyproducts. 18 The carbon-carbon bond strength of the adjacent methylene groups 
in 2.10 (marked by a dotted line in Figure 2.6) was calculated to be 235 kJ mOrl / 8e 
therefore bond cleavage requires comparatively little energy. It was envisaged that 2.2a, 
with its bibenzyl motif, would undergo cleavage under the harsh conditions used in the 
attempted preparation of 2.1a. Degradation would give the range of byproducts observed 
in both the IH NMR spectra and HPLC traces. The bond strength between the two phenyl 
rings of 2.2b would be considerably higher (calculated as 480 kJ mor l for its simple 
biphenyl analogue 2.11,18e Figure 2.6) than that between the adjacent methylene groups in 
2.2a. This accounted for the lower level of byproduct fonnation observed in the HPLC 
trace derived from the attempted synthesis of2.1b (see Figure 2.5). The following section 
235 kJmor1 
\ I~ 
, 
, 
~ // 
// 
2.10 
, 
~NH2 
~Ph NH2 
2.2a 
480kJmor i 
J ~ 
~ // , 
// 
2.11 
, 
(YNH2 
Ph~NH2 
2.2b 
Figure 2.6. Structures and calculated energies required for bond cleavage of bibenzyl 
(2.10) and biphenyl (2.11), the basic carbon backbones of 2.2a and 2.2b respectively. The 
points of cleavage are represented by dashed lines. 
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details the reaction of 2.2c (Rl = Me), under analogous conditions to those used in the 
attempted synthesis of 2.1 a-b, to test the proposition that this diamine was more stable than 
2.2a-b (Rl = aromatic). 
2.2.4 Synthesis and reactivity at the methylene bridge of benzimidazole 2.1c 
Separate reaction of 2.2c with 2.3a or 2.3b in PP A at 170-180°C afforded the desired 
benzimidazole 2.1c in yields of 50% (purified) and 78% (crude mass return) respectively 
(Scheme 2.6). Purification was not performed on the crude product obtained from the 
reaction of 2.2c and 2.3b, due to the sufficient amount of pure 2.1c isolated from the 
reaction of 2.2c and 2.3a. The numbering system for 2.1c is included in Scheme 2.6. 
Diamine 2.2c was also reacted with 2.3a in refluxing 4 M hydrochloric acid to give crude 
2.1c as the dihydrochloride salt with a quantitative return of mass. However, this 
compound degraded upon standing. Overall, 2.2c appeared to be a more stable reactant for 
benzimidazole preparation than its analogues 2.2a-b, which both possessed aromatic Rl 
groups. 
2.2c 2.3a Rl = C02H.HCl 
or 
2.3bR1 =CN 
(i), (ii) or (iii) 
6' 
4 ~~5' 5(Y~4' Me~N 3' 
7 H 
2.1c 
Scheme 2.6. Reagents and conditions: (i) 2.3a, PPA, 170-180°C, 5 h (50%). (ii) 2.3b, 
PPA, 170-180°C, 5 h (78% crude mass return). (iii) 2.3a, 4 M HCI, 120-130°C, 6 h 
(quantitative mass return). 
A noticeable change was observed in the IH NMR spectrum of 2.1c upon standing in 
CD30D. Figure 2.7a displays the IH NMR spectrum of 2.1c at 0 h, with the resonance at (5 
4.38 ppm assigned to the methylene group. However, after 16 h this resonance was no 
longer present (Figure 2. 7b). A 2H NNIR spectrum of the derivatised 2.1c in CH3CN, with 
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one drop of CDCb as a reference solvent, gave a weak resonance at 8 4.02 ppm, which was 
postulated to result from deuteration of the methylene group. 
(a) 
j):Nr-O 
M. "" ~ 
l.le 
CD;OD 
---r,-----r, ---,-, -,-, -'--;--'-'-'-'1 -'---;--'-'-'1 ----'-'----;--'-'1 --,-,--.-,--T·········,·····~',-------,-----r----.I --'-'---'--;'---"1 
1 6 5 , 3 pp!II 
(b) 
DeriV8tised 2,1e 
Cn,OD 
NoCHl 
I 
---,,-., ---.-, --" --'1 _·"---'-'--'--'1 -,--,---,-,--;---r--,--,-------,-,--,--.--,-, _., ····T···--,'----,,--,-, -,-, --'1 -.-,--.-.--
8 1 6 5 , 3 
Figure 2.7. IH NMR spectra of2.1c in CD30D after 0 h (a) and 16 h (b). 
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Analysis of derivatised 2.1c by electro spray ionisation LRMS gave molecular ions 
corresponding to the protonated equivalents of native 2.1c, mono- and dideuterated 2.1c, 
and the ketone 2.12 (Figure 2.8). These results revealed that the reactivity of the 
methylene bridge possessed by 2.1c allowed a combination of deuteration and oxidation to 
occur. 
(;N~ Me~N 0 
H 
2.12 
Figure 2.8. Ketone 2.12, derived from 2.1c. 
Due to the inability to effect formation of 2.1a-b, and the potential problems associated 
with the reactivity of the methylene bridge in compounds analogous to 2.1c, further 
synthetic work in this area was discontinued. An alternative preparative route to 
benzimidazoles with a slightly modified structure was undertaken. 
2.3 SYNTHESIS AND ASSAY OF BENZIMIDAZOLES 2.14a-c 
A milder synthetic method for the preparation of benzimidazoles was sought to overcome 
the difficulties encountered in the previous section towards the synthesis of 2.1a-b. The 
reported synthesis of a range of benzimidazoles was effected by the reaction of aromatic 
diamines with aryl aldehydes in nitrobenzene at 145°C for 18 h. 19 Nitrobenzene acted as 
both the solvent and an oxidant to complete benzimidazole formation. Application of the 
nitrobenzene-based benzimidazole preparation gave 2.14a-c by the synthetic route 
displayed in Scheme 2.7. Reaction of the diamines 2.2a-c with 2-pyridinecarboxaldehyde 
(2.13) in nitrobenzene at 150°C afforded 2.14a-c in yields of 43%, 57% and 46% 
respectively. The numbering system for compounds of type 2.14 is included in Scheme 
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2.7. TIlls synthetic methodology was considered advantageous since these compounds 
lacked the methylene bridge that was prone to the deuterationloxidation observed for 2.1c. 
An analogous compound (1.13e, highlighted in Scheme 2.7), with a pyridin-2-yl moiety at 
C2, displayed a 5-fold enhancement for trypsin inhibition when Zn2+ was present.5 
2.2a Rl Ph(CH2h 
2.2b R' Ph 
2.2cRI Me 
OHC-o 
2.13 
(i) 
4 6' 5(Y~~~15' Rl~J···\J 
7 H 3' 4' 
2.14a R' Ph(CH2h 
2.14b RI Ph 
2.14cRl Me 
H2NP:~{] 
NH H 
1.13e 
TrypsinKi (ETDA) 101 11M 
Ki (Zn2+) 20.9 11M 
Zn2+ factor 5 
Scheme 2.7. (i) PhN02, 150°C, 18 h (2.14a, 43%), (2.14b, 57%), (2.13c, 46%). 
2.3.1 Assay results for the a-chymotrypsin inhibitors 2.14a-c 
The benzimidazoles 2.14a-c were tested for inhibitory activity against a-chymotrypsin 
using the established method of Cannell et a/.2D This assay is reliant on a colourimetric 
technique, whereby enzymatic activity is measured by the cleavage of colourless N-
succinyl-L-phenylalanine-4-nitroanilide 2.15 to yellow-coloured 4-nitroaniline 2.16 
(Scheme 2.8). The level of 2.16 released is colourimetrically detected by the level of 
absorbed light at a wavelength of 405 nm. 
Chapter Two Development of Zinc-Mediated Benzimidazole-Based Inhibitors of a-Chymotrypsin 64 
N0 ° ~N02 __ a_-C_h_ym_o_tryp_s_in_-p-., rYyN02 
rrNyANAJ H2N~ 
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2.15 
Yellow 
2.16 
Scheme 2.8. Enzymatic breakdown of 2.15 to give the coloured product 2.16. 
Solutions of the benzimidazoles 2.14a-c were made up to 10 mM in distilled methanol and 
diluted by a factor of 10 sequentially six times, i.e. a range of seven concentrations (10 
mM, 1.0 mM, 0.1 mM, 10 /-tM, 1.0 /-tM, 0.1 /-tM, and 10 nM) at which inhibition was 
tested. Detenmnation of the inhibition elicited by the test compounds in the presence of 
is as follows. The inhibitor test solution, Tris-HCI buffer (PH 7.6), a solution of a-
chymotrypsin in Tris-HCI buffer (PH 7.6) and a solution of 1.0 mM zinc chloride in 
distilled water were added to the appropriate wells of a 96 well assay plate. The zinc 
chloride solution was added to determine the level of a-chymotrypsin inhibition elicited by 
2.14a-c via the proposed ternary complex between the enzyme, Zn2+ and inhibitor. After 
incubation at 37°C for 30 min, the substrate 2.15 in Tris-HCl buffer (PH 7.6) was added, 
and the assay well plates were returned to the incubator. Upon substrate addition, the final 
concentration of Zn2+ was 0.17 mM. The absorbance was read at 405 nm every hour until 
the maximum readings exceeded 1 absorbance unit. The calculated percent inhibition 
values are a measure of the enzyme activity relative to that when no enzyme was present 
(no substrate turnover, 100% "inhibition") and when no inhibitor was present (full 
substrate turnover, 0% inhibition). To this end, control samples, with Tris-HCI buffer (pH 
7.6) in place of the a-chymotrypsin solution, were included at all inhibitor concentrations 
to detenmne the level of absorbance when there was no turnover of 2.15. Maximum 
substrate turnover was calculated by the average absorbance across six wells where 
distilled methanol replaced inhibitor solution. Each inhibitor concentration was tested in 
triplicate and average absorbances were used to calculate the levels of inhibition. The 
potency of each compound was measured by its IC50 value - this is the concentration of 
inhibitor required for half-maximal inhibition of the target enzyme.21 The IC50 values were 
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calculated by plotting percent inhibition (y axis) against -loglO(inhibitor concentration) (x 
axis) in Microsoft Excel®. 
Activity of the test compounds in the presence of EDT A was performed in an analogous 
manner, except that the Zn2+ solution was replaced by 5.0 mM EDTA disodium dihydrate 
in distilled water. Upon substrate addition, the final concentration of EDTA was 0.83 
mM. Addition of the EDTA solution would determine the level of inhibition displayed by 
2.14a-c without the aid of any metal ions. Comparison of the activities elicited by 2.14a-c 
in Zn2+ or ETDA would resolve whether the activity of the proposed inhibitors against a-
chymotrypsin was enhanced due to the presence of metal ions. Results for the assay of 
2.14a-c against a-chymotrypsin are presented in Table 2.1. 
No. Rl IC50 (~M) 
Zn2+ EDTA 
2.14a Ph(CH2h 81 >17 
2.14b Ph >17 >17 
2.14c Me >167 681 
Table 2.1. IC50 values for 2.14a-c in the presence of Zn2+ or EDTA. 
Table 2.1 illustrates that 2.14a-c were moderate to weak inhibitors of a-chymotrypsin. An 
exact IC50 value was not obtained for 2.14a (in the presence of EDTA), 2.14b (in the 
presence of Zn2+ or EDTA), and 2.14c (in the presence of Zn2+), due to precipitation of the 
inhibitor in the assay wells. Typically this occurred at the two or three highest 
concentrations of inhibitor. Less than half-maximal enzyme inhibition was achieved at the 
inhibitor concentrations where precipitation did not occur, hence an IC50 value could not be 
calculated. Benzimidazole 2.14a displayed moderate inhibition of a-chymotrypsin, with 
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an IC50 value of 81 IlM in the presence of Zn2+. No quantifiable increase in inhibition 
attributable to enhanced Zn2+-mediated binding was determined for 2.14a, as an IC50 value 
could not be determined for the inhibitor when EDTA was present. Compound 2.14b was 
an extremely poor inhibitor, showing minimal effect on enzyme activity when precipitation 
of the inhibitor did not occur in the wells. Benzimidazole 2.14c was a poor inhibitor when 
EDTA was present in solution (IC50 = 681 IlM), and the opposite trend to that for 2.14a 
was displayed, whereby no IC50 value could be calculated for the solution containing Zn2+. 
The low inhibitory activity displayed by 2.14c was expected due to the absence of an 
aromatic Rl moiety at C6. 
A more detailed examination of the inhibition elicited by 2.14a against a-chymotrypsin is 
presented in Table 2.2. Overall, the data illustrates that no Zn2+-mediated enhancement of 
2.14a 
Conc. of2.14a in % inhibition (1) - (2) (%) 
assay well (M) Zn2+ present (1) EDTA present (2) 
1.67 x 10-3 * * 
# 
- - -
1.67 X 10-4 73 * 
# 
- -
1.67 X 10-5 0 6 -6 
1.67 x 10-6 5 12 -7 
1.67 x 10-7 0 4 -4 
1.67 x 10-8 11 1 10 
1.67 X 10-9 5 0 5 
.. 
* = precIpItatIon occurred In reactIOn wells during assay. 
# = (1) - (2) could not be calculated due to the occurrance of inhibitor precipitation during 
the assay. 
Table 2.2. Inhibition data for all concentrations at which 2.14a was assayed for inhibition 
of a-chymotrypsin in the presence of Zn2+ or EDT A. 
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inhibition was observed at any inhibitor concentration. This differed from the 
enhancement reported by Katz, et aZ5 whereby the addition of Zn2+ increased the potency 
of an inhibitor series towards selected serine proteases (see Chapter One, Section 1.2.1). A 
lack of enhancement for the inhibition of a-chymotrypsin by 2.14a in the presence of Zn2+ 
compared to when EDTA was present suggested that inhibition was not occurring in the 
fashion proposed in Figure 2.2. Instead, inhibition is likely the result of uncomplexed 
2.14a. 
2.4 SYNTHESIS AND ASSAY OF THE HYDROCHLORIDE SALT OF 2.14a 
The hydrochloride salt of 2.14a was prepared to determine whether an improvement in 
solubility, in comparison to the free base 2.14a, would allow for IC50 values to be 
calculated in the presence of Zn2+ and EDTA. As a result, any Zn2+ -dependent 
enhancement in the inhibition of a-chymotrypsin at higher concentrations of 2.14a would 
be revealed. To this end, 2.14a was dissolved in ethyl acetate, and hydrochloride gas 
passed through the solution until a solid formed. Removal of the solvent afforded the 
dihydrochloride salt of2.14a in 84% yield (see Experimental for details). This compound 
was assayed under the same conditions used for 2.14a-c. The assay result is displayed in 
Table 2.3, and the inhibitory activity ofthe free base of2.14 is included for comparison. 
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~N?-Q I '\ ~ /; Ph // N 
H 
2.14a 
No. ICso (f!M) 
Zn2+ EDTA 
2.14a 81 >17 
2.14a.2HCI 82 >17 
Table 2.3. ICso values for 2.14a.2HCI in the presence of Zn2+ or EDTA. The ICso values 
for 2.14a are shown for comparison. 
Preparation of the dihydrochloride salt of 2.14a gave no increase in activity against a-
chymotrypsin, or an improvement in its solubility properties. An almost identical 
inhibitory profile to that of the free base 2.14a was observed, with an ICso value of 82 f!M 
determined for the inhibitor in the presence of Zn2+, and no exact ICso value was calculated 
when EDTA was present due to the occurrence of precipitation in the assay wells. It was 
postulated that the dihydrochloride salt was immediately converted to its free base in the 
neutral pH environment of an assay well. Therefore, no change in the solubility of 2.14a 
was observed. The reported pKa values for a range of benzimidazoles (~5_7)22 and 
pyridine (5.36)23 are such that deprotonation of 2.14a dihydrochloride to the free base 
would occur in the neutral pH (7.6) present in the assay wells. 
Chapter Two - Development ofZine-Mediated Benzimidazole-Based Inhibitors of a-Chymotrypsin 69 
2.5 DETERMINATION OF THE ABILITY OF 2.14b TO ACT AS A LIGAND 
FOR TRANSITION METALS 
A potential factor that would contribute to the lack of Zn2+ -enhanced enzyme inhibition 
observed for 2.14a-c is that the 2-(pyridin-2-yl)benzimidazole-based scaffold was not able 
to form a complex with the metal ion. The ability of 2.14b to act as a ligand was 
determined by IH NMR spectroscopy. Initially, this compound was dissolved in CD30D, 
and the IH }'1MR spectrum that was recorded is displayed in Figure 2.9. 
D=N>-Q_H6' I "~~ Ph / N 
H 
2.14b 
H6' 
-
J 
I , i I j iii iii I i I I I j I I I I I 
8 7 6 5 4 3 ppm 
Figure 2.9. IH NMR spectrum of2.14b in CD30D. 
One equivalent of zinc diacetate (Zn(OAc)2) was added to the solution of2.14b in CD30D, 
and noticeable changes were observed in the chemical shifts of the IH NMR spectrum. 
Figure 2.10 illustrates that line broadening of the signals in the aromatic region (8 
approximately 7.2-8.6 ppm) occurred. Line broadening of this type is typically observed 
upon complexation due to non-rigidity and ligand exchange in the complex,24 and it has 
been observed for the Zn2+ complexes of organic molecules.25 Use of deuterated NMR 
solvents other than CD30D gave no improvement in the spectrum, as the level of line 
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broadening was approximately the same, or the complex was insoluble and no lH NMR 
spectrum could be obtained. The positions of signals for equivalent protons in the two 
spectra were noticeably different. In Figure 2.9, the resonance at b 8.72 ppm corresponded 
to H6' of the pyridyl ring, whereas in Figure 2.10 the most downfield signal resonated at b 
8.57 ppm, which was determined to be H6' in the COSY spectrum. A shift of this 
magnitude was expected as H6" of all the protons present in 2.14b, is closest to a nitrogen 
involved in the formation of a dative bond with the metal. 
2.14a-Zn(OAc}z 
iii i , , , , I 
9 7 
Iii 
6 
I 
, 
OAo 
ppm 
Figure 2.10. lH NMR spectrum of the complex formed between 2.14b and Zn(OAch in 
CD30D. 
Attempted formation of a crystal suitable for X-ray crystallography from 2.14b and 
Zn(OAc)2 was unsuccessful. Techniques used for crystal preparation included vapour 
diffusion (methanol/ether, DMSOlbenzene, methanol/water and methanol/acetonitrile), and 
evaporation of the solvent (methanol, methanol/water and methanol/acetonitrile) from 
2.14b. A further attempt toward crystal growth, by the evaporation of methanol from a 
solution of2.14b and Cu(N03h, was also ineffective. 
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2.5 CONCLUSION AND FUTURE WORK 
Potent Zn2+-enhanced inhibition of trypsin-like serine proteases has been reported by a 
series of benzimidazole-based compounds.5 This novel binding mode was applied to the 
development of novel a-chymotrypsin inhibitors. Initial efforts were focused on the 
synthesis of the proposed inhibitors 2.1a-b, which featured a 2-(pyridin-2-
ylmethyl)benzimidazole scaffold upon which aromatic recognition elements were attached 
at the C6 position (denoted R1). The aromatic groups were considered essential for 
recognition ofthe putative inhibitors by a-chymotrypsin, due to the hydrophobic Sl subsite 
possessed by this enzyme. However, preparation of the benzimidazoles 2.1a-b by a variety 
of methods was unsuccessful. The diamine precursors 2.2a-b were postulated to be 
unstable under the reaction conditions in which benzimidazole formation was attempted. 
Preparation of 2.1c, which differed from 2.1a-b by the presence of a methyl group at R1, 
demonstrated the stability of the diamine 2.2c (R1 = Me) in comparison to 2.2a-b (R1 = 
aromatic). However, the desired product 2.1c was prone to deuteration and oxidation at 
the methylene group. As a result, the structural integrity of inhibitors based on structure 
2.1 was compromised due to the potential for unwanted side reactions at this position. 
Subsequently, the synthesis of a slightly modified benzimidazole scaffold was undertaken, 
and these structures were based on a 2-(pyridin-2-yl)benzimidazole motif. This work 
identified a relatively mild synthetic step for the synthesis of the benzimidazoles 2.14a-c, 
which did not lead to the excessive formation of byproducts observed in the attempted 
synthesis of 2.1a-b. Benzimidazoles 2.14a-b were moderate to weak inhibitors of a-
chymotrypsin, despite the presence of aromatic moieties at R 1 that were expected to act as 
suitable recognition elements for the enzyme. Compound 2.14c, with a methyl R1 group, 
was a poor inhibitor as expected due to the lack of an aromatic functionality at this 
position. No Zn2+-enhanced inhibition of a-chymotrypsin was exhibited by 2.14a-c due to 
the poor solubility profile displayed by these compounds in the assay conditions used. A 
closer examination of the inhibition elicited by 2.14a gave no evidence of enhanced a-
chymotrypsin inhibition in the presence of Zn2+ at any inhibitor concentration. An 
attempted improvement of the solubility displayed by 2.14a involved the formation of its 
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dihydrochloride salt, but no change in the inhibitory activity or solubility profile was 
observed. Overall, a Zn2+-enhanced mode of inhibition toward a-chymotrypsin was not 
elicited by the 2-(pyridin-2-yl)benzimidazole scaffold. However, it is uncertain whether 
this was a result of the scaffold used, inappropriate groups at Rl, or the properties of the 
enzyme active site itself. 
The proposed binding mode of 2.14a-c required that the 2-(pyridin-2-yl)benzimidazole 
scaffold acted as a ligand to Zn2+. Addition of Zn(OAc)2 to 2.14b in CD30D caused line 
broadening and signal shifts to occur in the IH NMR spectrum, illustrating that complex 
formation was taking place. However, no crystal suitable for X-ray crystallography was 
obtained with either Zn2+ or Cu2+ as the metal centre. 
Future work in this area could involve appending more polar groups to certain positions of 
the benzimidazole scaffold to improve its solubility, e.g. hydroxyl groups on the pyridyl 
nng. Additionally, a thorough investiga~ion of the optimal group at Rl for eliciting 
inhibition of a-chymotrypsin could be undertaken. 
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3.1 INTRODUCTION 
The inhibition of a-chymotrypsin, a member of the serine protease family of enzymes, l is 
regarded as an important step in the development of inhibitors that target chymotrypsin-
like enzymes.2 Examples of this subclass of serine proteases include cathepsin G, mast cell 
chymase and human leukocyte elastase, and over-activity of these enzymes is implicated in 
a number of debilitating diseases in the human body.3 (See Chapter One, Section 1.2 for 
further discussion of the disease states arising from serine protease over-activity.) a-
Chymotrypsin is considered an excellent model system for serine protease inhibition due to 
its well-defined active site structure4 and substrate specificity.5 Previous work in these 
laboratories6 revealed a series of N-substituted 2-(hydroxymethyl)pyrroles based on the 
general structure 3.1 (Figure 3.1) as a new class of a-chymotrypsin inhibitors. Compounds 
of type 3.1 were distinguished by the presence of an electron-withdrawing group (EWG) 
attached to the pyrrole ring mtrogen, and a hydroxymethyl group at the C2 position. 
Optimal inhibition for the range of analogues assayed was displayed by 3.1a, and its pro-
ROJ{) 
N 
3.1 
I 
EWG 
Figure 3.1. General structure 3.1 of the N-substituted 2-(hydroxymethyl)pyrrole-based a-
chymotrypsin inhibitors. The optimal inhibitor 3.1a is shown, and its binding in the 
enzyme active site is correlated to that of the natural substrate (cleavage point indicated by 
a bold arrow). 
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posed interaction with the active site of a-chymotrypsin is illustrated in Figure 3.1. The 
hydrophobic phenylsulfonyl EWG of 3.1a was projected to mimic the aromatic Pi group 
adjacent to the scissile peptide bond in natural substrates of a-chymotrypsin.5c (See 
Chapter One, Section 1.2 for a discussion of the SIP nomenclature developed by Schechter 
and Berger.7) The pyrrole ring was proposed to occupy the space where the Pi' residue 
normally resides in the enzyme active site. Hence, these peptidomimetics were postulated 
to be dipeptide analogues of an a-chymotrypsin substrate. 
2-(Hydroxymethyl)pyrroles based on structure 3.1 were designed to act as mechanism-
based inhibitors of a-chymotrypsin based on extensive chemical precedence. In particular, 
Scheme 3.1 outlines the possible pathways for nucleophilic attack upon the N-substituted 
2-(hydroxymethyl)pyrrole 3.1 and its unsubstituted analogue 3.3. The presence of an 
EWG, such as triflyl or mesyl, on 3.1 has been shown by deuterium labelling experiments 
to favour displacement of the hydroxyl group by an SN2 mechanism to give 3.5a (pathway 
b), rather than via the azafulvene intermediate 3.2 (pathway a).8 Unsubstituted 2-
(hydroxymethyl)pyrroles such as 3.3 readily formed azafulvene 3.4, and subsequent 
nucleophilic attack resulted in compounds oftype 3.5b.9 
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Scheme 3.1. Reaction of the 2-(hydroxymethyl)pyrroles 3.1 and 3.3 with nucleophiles to 
give 3.5a-b. 
Further analysis of N-substituted 2-(hydroxymethyl)pyrroles revealed that potassium 
hydroxide-catalysed transfer of the N-acyl EWG of 3.6 gave the 2-( O-acylhydroxy-
methyl)pyrrole 3.710 (Scheme 3.2). The presence of an excellent leaving group allowed 
azafulvene formation to occur, and consequent nucleophilic attack by (+)-sec-butylamine 
afforded 3.8. This system was proposed to model the mechanism-based inhibition of 
serine proteases, with the hydroxide mimicking the Ser195 residue and the external 
nucleophile mimicking the final step of covalent attachment to the enzyme. 
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Scheme 3.2. Reaction sequence detennined for 3.6, which ultimately gave 3.8. 
The experimental evidence presented here led to the development of a general mechanism 
of enzyme inhibition for 2-(hydroxymethyl)pyrroles of type 3.1. Enzyme catalysed 
removal ofthe EWG from 3.1 releases the latent reactivity ofthis molecule (Scheme 3.3). 
Azafulvene 3.4 is then fonned, and subsequent reaction with an active site nucleophile 
affords the enzyme-inhibitor adduct 3.9. 
HO~ 
N 
3.1 
I 
EWG 
Enz-XJ) 
N 
H 
3.9 
Enzyme catalysis '" HO~ 
N 
I 
H 
3.3 
j 
[ : 
3.4 
Scheme 3.3. Mechanism-based inhibition of serine proteases by 3.1. 
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A recent report from these laboratories determined that the mode of binding displayed by 
the representative 2-(hydroxymethyl)pyrrole 3.1a to a-chymotrypsin was in fact non-
covalent in nature. l1 Incubation of 3.1a with a-chymotrypsin revealed signals in the 
LCMS spectrum at 25,236 g mor l (corresponding to native enzyme) and 25,473 g mOrl. 
The difference of 237 g mor l corresponded to the molecular mass of intact 3.1a. 
Incorporation of labelling at the hydroxymethyl carbon of 3.1 a, followed by incubation 
with a-chymotrypsin, gave a resonance of 8 56 ppm in the l3C NMR spectrum, the same 
chemical shift observed for labelled 3.1a in the absence of enzyme. The lack of covalent 
binding displayed by 3.1a towards a-chymotrypsin stimulated an investigation towards the 
discovery of alternative pyrrole-based structures as potential mechanism-based a-
chymotrypsin inhibitors. Introduction of an EWG at the C2 position for a series ofpyrrole-
based inhibitors was considered a means to promote covalent bond formation between the 
enzyme and inhibitor, as opposed to attachment of the EWG to the nitrogen as in 
compounds of type 3.1. It was reasoned that the pyrrole ring system would be deactivated 
to a lesser extent, and as a result azafulvene formation and covalent derivatisation of the 
enzyme would be more likely to occur. Figure 3.2 illustrates the general structure of the 
proposed inhibitors (3.10), compared to that ofthe natural substrate, in addition to the in-
Figure 3.2. Schematic representation of the substrate (bottom) bound to the active site of 
a-chymotrypsin, correlated to the structure of the C2-acyl-C5-(hydroxyalkyl)pyrrole 3.10. 
The point of cleavage of the natural substrate is indicated by a bold arrow. 
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teraction of both structures with the active site of a-chymotrypsin. An acyl group is 
attached to the C2 position, and its electron withdrawing properties are lessened by the 
occurrence of electron delocalisation in the amide bond. Note that 3.10 mimics a more 
favourable substrate conformation compared to that mimicked by 3.1a in Figure 3.1. 
Covalent linkage of 3.10 to a-chymotrypsin would be favoured by formation of the 
azafulvene 3.11 (Scheme 3.4), which would then react with an active site residue to give 
the enzyme-inhibitor adduct 3.12. The mechanistic sequence displayed here differs to that 
for 3.1 (see Scheme 3.3), as formation of the azafulvene 3.10 is not dependant on release of 
an EWG. Elaboration of 3.10 at positions Rl and R2 would allow compounds of this type 
to more closely mimic the natural substrate, which would potentially elicit a more potent 
inhibitory response to that of the N-substituted inhibitors. A series of such compounds was 
prepared and assayed against a-chymotrypsin. The solid phase synthesis of a 
representative C2-acyl-5-(hydroxymethyl)pyrrole-based a-chymotrypsin inhibitor was also 
investigated. 
Scheme 3.4. Mechanism-based inhibition of senne proteases by the C2-acyl-C5-
(hydroxyalkyl)pyrrole 3.10. 
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3.2 PREPARATION AND ASSAY OF C2-ACYL-C5-(HYDROXYALKYL)-
PYRROLES TO DETERlVIINE THE OPTIMAL GROUP AT Rl FOR a-
CHYMOTRYPSIN INHIBITION 
The initial focus of this research was to understand the importance ofRI in compounds of 
type 3.10 (see Figure 3.2) with respect to a-chymotrypsin inhibition. Three compounds 
were targeted for synthesis - the 5-(hydroxymethyl)pyrrole 3.13a and the C5-
(hydroxyalkyl)pyrroles 3.14a-b (Figure 3.3). Compound 3.13a has a hydroxymethyl group 
at the C5 position to allow for comparison of its inhibitory properties and those of the N-
substituted 2-(hydroxymethyl)pyrroles synthesised in the previous study.6 The I-hydroxy-
3-phenylpropyl side chain of 3.14a was chosen to mimic the aromatic recognition element 
at PI ofthe natural substrate of a-chymotrypsin (see Figure 3.2). The I-hydroxyethyl side 
chain of 3.14b was chosen to be of intermediary size and hydrophobicity between those 
given by the small hydroxymethyl group of 3.13a and the bulky aromatic group of 3.14a. 
Determination of the inhibitory activity for 3.13a and 3.14a-b would give insight into the 
importance of side chain size and hydrophobicity at the C5 position. The phenylalanine 
derivative was chosen to be appended at the C2 position as in our proposed inhibitor-
enzyme interaction the aromatic side chain would fit into the S2' subsite of a-
chymotrypsin, which can accommodate large, hydrophobic moieties.12 The following 
section details the synthetic methodology utilised in the preparation of 3.13a and 3.14a-b, 
in addition to the assay results for all three compounds. 
3.13a 1 3.14a R = (CH2)2Ph 
3.14bRl =Me 
Figure 3.3. Synthetic targets 3.13a and 3.14a-b. 
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3.2.1 Preparation of peptidomimetics 3.13a and 3.14a-b 
Scheme 3.5 details the synthesis of compounds 3.13a and 3.14a-b. The pyrrole ester 
3.1513 was formylated under Vilismeier-Haack conditions14 to give 3.16a and its 4-formyl 
isomer 3.17a in 61 % and 25% yields respectively. Hydrolysis of the ester 3.16a15 with 
potassium hydroxide afforded the acid 3.16b in a yield of60%. Acid 3.16b was coupled to 
L-phenylalanine methyl ester hydrochloride under standard EDCIIHOBT conditions16 to 
give 3.18a in 71 % yjeld, and subsequent reduction of the 5-formylpyyrole 3.18a with zinc 
borohydrideB afforded the tripeptide analogue 3.13a in a moderate yield of 57%. The C5-
(hydroxyalkyl)pyrroles 3.14a-b were obtained by an analogous synthetic route. Pyrrole 
ester 3.15 was acylated separately by hydrocinnamoyl chloride and acetyl chloride17 to 
give 3.19a-b in 35% and 37% yields respectively. The pyrrole esters 3.19a-b were 
sUbjected to hydrolysis by potassium hydroxide to afford the acids 3.20a-b in yields of 
86% and 93% respectively. A 2:1 water/tetrahydrofuran solvent system was necessary for 
hydrolysis of 3.19a-b due to the insufficient solubility of these starting materials in the 
100% water system used for hydrolysis of 3.16a. The acids 3.20a-b were separately 
coupled to L-phenylalanine methyl ester hydrochloride under EDCIIHOBT conditions to 
afford 3.21a-b in 70% and 91 % yields respectively. Compound 3.21a was reduced by zinc 
borohydride to give the extended peptide analogue 3.14a in a relatively low yield of 21 % 
as an inseparable 1:1 mixture of diastereoisomers by 1H and 13C NMR spectroscopy. 
Additionally, the over-reduced byproduct 3.14c was obtained after flash chromatography 
in an approximately 1:1 mixture with unreacted 3.21a by 1H NNIR spectroscopy. 
Reduction of 3.21b with lithium borohydride afforded 3.14b in 46% yield, but this 
compound proved difficult to purify and was ultimately unstable by 1H NMR 
spectroscopy, as a complicated mixture of bypro ducts had formed. 
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(ii) 
(i) j 
n ORC N C02R1 
R 
1 
C 3.16aR =Et 3.16b Rl =R 
3.18a 
(iv) 
(v) 
ORCh 
+ ~ ~ 
N C02Et 
R 
3.17a 
(vi) 
1 2 3.19a R = Ph(CR2h, R = Et 
[ 
3.19bRl =Me,R2=Et 
1 2 3.20a R = Ph(CR2h, R = R 
3.20b Rl = Me, R2 = R 
(iii) 
3.21a Rl = Ph(CR2h 
3.21bRl =Me 
(iv) or] (vii) 
3.14a Rl = Ph(CR2h, R2 = OR 
3.14b Rl = Me, R2 = OR 
3.14c Rl = Ph(CR2h, R2 = R 
Scheme 3.5: Reagents and conditions: (i) POCh, DMF, 1,2-DCE, reflux, 15 min, then 
CH3C02Na.3H20, reflux, 15 min (3.16a, 61 %), (3.17a, 25%). (ii) KOH, H20, 40-50°C, 2 
h (60%). (v) L-PheOMe.HCl, EDCI, HOBT, DIEA, CH2Cb, r.t., 16 h (3.18a, 71%), 
(3.21a, 70%), (3.21b, 91%). (iv) Zn(B&)2, Et20, O°C, 1 h (3.13a, 57%), (3.14a, 21%), 
(3.14c). (v) ZnCb, 1,2-DCE, 50°C, 1 hand Ph(CH2)2COCl (3.19a, 35%) or AcCl (3.19b, 
37%). (vi) KOH, 2:1 H2O/THF, 40-50°C, 2 h (3.20a, 86%), (3.20b, 93%). (vii) LiB&, 
Et20, -78°C, 1 h, then r.t., 1 h (3.14b, 46%). 
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The over-reduction of 3.14a was proposed to occur via the mechanism outlined in Scheme 
3.6. Hydride-induced formation of the azafulvene 3.22, which subsequently reacted with a 
hydride nucleophile, gave 3.14c upon workup. 
f Orrr HO 0 Y \ ~~co2Me U NI- : 1:/ ::. 
(. ~ 0 ~Ph 
Ph ) 3.14a 
e H 
Scheme 3.6. Proposed mechanism for the over-reduction of3.14a to give 3.14c. 
Compound 3.14b was also prepared by the methodology presented in Scheme 3.7. To this 
end, the fonnyl group of pyrrole 3.16a underwent reaction with methyllithium to give 
3.23a in 95% yield. Ethyl ester hydrolysis with sodium hydroxide gave the acid 3.23b in a 
low yield of 17%, which was subsequently coupled to L-phenylalanine methyl ester under 
standard EDCIIHOBT conditions to afford 3.14b in 54% yield. This product again proved 
OHC~COzEt --- HO«C02R1 __ (ii_i)_> HOM~yC02Me 
H Me H Me H 0 "Ph 
3.16a C 3.23a Rl = Et 3.14b 
(ii) 
3.23bR1 =H 
Scheme 3.7: Reagents and conditions: (i) MeLi, THF, -25°C, 5 h (95%). (ii) NaOH, 1:1 
THFlHzO, 40-50°C, 24 h (17%). (iii) L-PheOMe.HCI, EDCl, HOBT, DlEA, CHzCh, r.t., 
16 h(54%). 
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to be unstable by the development of a complicated mixture, as determined by lH and 13C 
NMR spectroscopy. 
3.2.2 Assay results for peptidomimetics 3.13a and 3.14a 
The inhibition results displayed in Table 3.1 for 3.13a and 3.14a against a-chymotrypsin 
were generated by a simple screening assay described previously.6 (For a discussion of 
this assay technique, see Chapter Two, Section 2.3 - for the assays performed in this 
chapter, the ZnCb/EDTA solutions were replaced with distilled water.) Compound 3.14a 
was assayed as the 1: 1 mixture of diastereoisomers, and 3.14b was too unstable to be 
assayed. Inhibition was measured at concentrations of 1250 Ilg mL-l, 125 Ilg mL-l and 
12.5 Ilg mL-t, made up separately for both 3.13a and 3.14a. The calculated percent 
inhibition values are a measure of the enzyme activity relative to that when no enzyme was 
present (no substrate turnover, 100% "inhibition") and when no inhibitor was present (full 
substrate turnover, 0% inhibition). 
HO 5 J/~.2 ~ CO Me Y~~(I( y 2 
Rl H 0 = 
"Ph 
No. Rl % Inhibition (Ilg mL-l) 
1250 125 12.5 
3.13a H 75 35 45 
3.14a Ph(CH2)2 75 35 15 
Table 3.1. Inhibition of a-chymotrypsin by 3.13a and 3.14a. 
No significant difference in inhibitor potency was observed between 3.13a and 3.14a, 
despite the presence of the bulky aromatic group present at Rl of 3.14a which was 
anticipated to occupy the primary specificity pocket Sl (see Figure 3.2). The minimal 
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difference in activity observed between 3.13a and 3.14a suggested that these inhibitors do 
not interact with the enzyme active site in the manner proposed in Scheme 3.4. Inhibition 
of a-chymotrypsin can be elicited by a wide range of compounds, with the stipulation that 
an aromatic group is present. 18 It was decided from this outcome that the 5-
(hydroxymethyl)pyrrole moiety was a sufficient scaffold upon which to focus further 
structure-activity studies, specifically on modifications at the C2 position. Additionally, 
determination of how 3.13a binds to the active site of a-chymotrypsin would allow for 
comparison of its mode of inhibition to that of the N-substituted 5-(hydroxymethyl)pyrrole 
3.1a. 
3.3 WORK TOWARDS DETERMINATION OF THE BINDING MODE 
DISPLAYED BY 3.133 TO a-CHYMOTRYPSIN 
Mass spectrometry was performed on a-chymotrypsin, incubated with 3.13a at 37°C for 3 
hours in 50 mM Tris-HCI (PH 7.6), to determine whether or not the inhibitor was 
covalently attached to the enzyme. The mass spectrum obtained from incubation of the 
enzyme without 3.13a is displayed in Figure 3.4. The four main signals could have 
resulted from how the enzyme responded to mass spectrometry, or the presence of a-
chymotrypsin isoforms, or partially cleaved forms of the native enzyme. At least one of 
these forms was active, as the inhibitor assay demonstrated that hydrolysis of the substrate 
occurred, which made it a suitable enzyme sample for the mass spectrometry study 
performed here. 
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25192.0 
C 
11.0 
o 
Figure 3.4. Mass spectrum of a-chymotrypsin incubated in Tris-HCI at 37°C for 3 h. 
88 
A separate incubation was performed under the same conditions outlined before, except for 
the addition of one equivalent of inhibitor 3.13a. Figure 3.5 illustrates that an essentially 
identical spectrum was obtained to that given by the enzyme alone (Figure 3.4). The only 
noticeable differences are slight variations in the peak heights of the four major signals, 
e.g. in Figure 3.4 peak A was the base peak, whereas in Figure 3.5 peak B was the signal of 
greatest intensity. No increase in mass of 285.3 g mor l was observed for any of the four 
main signals, which was the increase expected if 3.13a was covalently bound to an active 
site nuc1eophile as a result of the azafulvene-type mechanism proposed in Scheme 3.4. 
Therefore, inhibitor 3.13a must act as a non-covalent, reversible inhibitor in a manner 
similar to that determined for 3.1a (see Introduction to this chapter). 
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A 
25195.0 
B 
25411.0 HOJ~ I ~yC02Me '~/i( _ 
C 
2G715.0 
o 'Ph 
3,13a 
mass 
Figure 3.5. Mass spectrum of a-chymotrypsin and 3.13a incubated in Tris-HCI at 37°C 
for 3 h. 
3.4 PREPARATION AND ASSAY OF C2-ACYL-5-(HYDROXYMETHYL)-
PYRROLES TO DETERMINE THE OPTIMAL GROUP AT R2 FOR a-
CHYMOTRYPSIN INHIBITION 
ill light of the fmding that 3.13a did not appear to be covalently bound to a-chymotrypsin, 
further work was undertaken to increase the range of peptidomimetics of type 3.13a for 
assay against a-chymotrypsin. This would result in a greater understanding of the 
structure-activity relationships for C2-acyl-5-(hydroxymethyl)pyrroles as reversible a-
chymotrypsin inhibitors. All structural modifications in this section of work were 
restricted to the amino acid group at the C2 position. Replacement of the aromatic 
phenylalanine residue of 3.13a with leucine and proline allowed evaluation of the 
inhibition elicited by an aliphatic (3.13b, Figure 3.6) or a cyclic, non-aromatic side chain 
(3.24), compared to that of 3.13a. Additionally, an inhibitor was synthesised with a 
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dipeptide functionality at the C2 position (3.25). The L-phenylalanyl-L-Ieucine dipeptide 
portion of 3.25 was chosen as previous studies19 have shown that a leucine residue 
contiguous to a phenylalanine elicited greater inhibition of a-chymotrypsin, in comparison 
to inhibitors that only possessed a phenylalanine residue. 
HO 
o 
"'--Ph 
3.13a 
no~r{ 
H 0 C02Me 
3.25 
3.24 
Figure 3.6. Structural modifications to the a-chymotrypsin inhibitor 3.13a at C2 afforded 
the synthetic targets 3.13b, 3.24 and 3.25 
3.4.1 Preparation of peptidomimetics 3.13b, 3.24 and 3.25 
Preparation of 3.13b and 3.24 was performed as described for the synthesis of 3.13a. To 
this end, 3.16b was coupled under standard EDCUHOBT conditions to L-Ieucine methyl 
ester hydrochloride and L-proline methyl ester hydrochloride to give 3.18b and 3.26 in 
yields of 61 % and 74% respectively (Scheme 3.8). Separate reduction of 3.20b and 3.26 
with zinc borohydride afforded the tripeptide mimics 3.13b and 3.24 in 42% and 24% 
yields respectively. The yield of 3.13b was improved to 66% with the use of lithium 
borohydride as the reducing agent in place of zinc borohydride. Scheme 3.8 also presents 
the separate EDCIJHOBT -mediated couplings between 3.16b and glycine ethyl ester 
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hydrochloride,20 glycine benzyl ester hydrochloride, L-phenylalanine ethyl ester 
hydrochloride, L-Ieucine ethyl ester hydrochloride, L-valine methyl ester hydrochloride and 
L-alanine methyl ester hydrochloride to give 3.18c-h in yields of 70%, 56%, 58%, 38%, 
53% and 43% respectively. Acid 3.16b and glycine methyl ester hydrochloride were 
coupled using BOp21 to afford 3.18i in 44% yield, as this amino acid derivative did not 
couple to 3.16b under standard EDCIIHOBT conditions. Intermediates 3.18a-i were used 
in the development of a novel N-derivatising agent for amino acids (see Chapter Four for 
further discussion). 
n OHC N C02H 
H 
(i) or (ii) 
. n ~ COR2 -------, 
OHC'" "~/ i( y 2 
H 0 Rl 
3.16b 3.18b-i (iii) or (iv) 
(i) j 
n NQ OHC'" "~/ i( 
H 0 C02Me 
3.26 
(Hi) j Rl R2 3.18b CH2CHMe2 Me 
3.18c (ref 20) H Et 
3.18d H Bn 
HO~q 
H 0 C02Me 
3.18e CH2Ph Et 
3.18f CH2CHMe2 Et 
3.18g CHMe2 Me 
3.18h Me Me 
3.24 3.18i H Me 
Scheme 3.8. Reagents and conditions: (i) EDCI, HOBT, DIEA, CH2Ch, Lt., 16 hand 
either L-LeuOMe.HCI (3.18b, 61%), GlyOEt.HCI (3.18c, 70%),20 GlyOBn.HCI (3.18d, 
56%), L-PheOEt.HCI (3.18e, 58%), L-LeuOEt.HCI (3.18f, 38%), L-VaIOMe.HCI (3.18g, 
53%) or L-AlaOMe.HCI (3.18h, 43%) or L-ProOMe.HCI (3.26, 74%). (ii) GlyOMe.HCI, 
BOP, DIEA, CH2Ch, Lt., 16 h (3.18i, 44%). (iii) Zn(BH4b ether, O°C, 1 h (3.13b, 42%), 
(3.24,24%). (iv) LiBH4, ether, -78°C, 1 h (3.13b, 66%). 
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Preparation of the tetrapeptide analogue 3.25 began with the esterification of L-
phenylalanyl-L-Ieucine hydrate (3.27c, Scheme 3.9) by diazomethane, after which the 
resultant methyl ester 3.28c was coupled to 3.16b in the presence of BOP to afford 3.29c in 
52% yield over two steps. Reduction with lithium borohydride then gave 3.25 in 68% 
yield. The dipeptide-pyrrole adducts 3.29a-b were synthesised by an analogous route to 
that of 3.29c for use in Chapter Four. To this end, the dipeptides L-phenylalanylglycine 
3.27a and L-Ieucylglycine 3.27b (Scheme 3.9) were esterified with oxalyl 
chloride/catalytic DMF in refluxing methanol to give the methyl ester hydrochlorides 
3.28a-b in 89% and quantitative yields respectively. Separate reaction of 3.28a-b with 
3.16b via BOP-mediated couplings gave 3.29a-b in yields of 49% and 45% respectively. 
(i) or 
o R2 
H2N~N~C02R3 
Rl H 
3.27a-b R3 = H 
3.27c R = H.H20 
[
3 
C) 
11 3.28a-b R3 = Me.HCI 
3.28cR3 =Me 
Rl 
3.27aJ3.28a/3.29a CH2Ph 
3.27b/3.28b/3.29b CH2CHMe2 
3.27c/3.28c/3.29c CH2Ph 
(iii) 
(iv) 
R2 
H 
H 
CH2CHMe2 
Scheme 3.9: Reagents and conditions: (i) (COCI)2, DMF(cat.), MeOH, reflux, 3 h (3.28a, 
89%), (3.28b, quantitative yield). (ii) CH2N2, THF, r.t., 15 h (3.28c). (iii) 3.16b, BOP, 
DIEA, CH2Cb, r.t., 16 h (3.29a, 49%), (3.29b, 45%), (3.29c, 52% over two steps). (iv) 
LiBH4, THF, -78°C, 1 h, then r.t., 1 h (68%). 
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3.4.2 Assay results for peptidomimetics 3.13b, 3.24 and 3.25 
Assay results for compounds 3.13b, 3.24 and 3.25 against a-chymotrypsin are displayed in 
Table 3.2. The assay conditions used to determine the inhibitory activity of 3.13b, 3.24 
and 3.25 were identical to that used for 3.13a and 3.14a. The results for 3.13a (which 
initially appeared in Table 3.1) are included for comparison. 
No. Rl 
3.13a NH-L-PheOMe 
3.13b NH-L-LeuOMe 
3.24 N-L-ProOMe 
HO n Rl ~'~/I( 
H 0 
% Inhibition ()lg mL-1) 
1250 125 
75 35 
10 5 
45 25 
3.25~ NH -L-Phe-L-LeuOMe 100 20 
~ ICso = 108 )lM. 
Table 3.2. Inhibition of a-chymotrypsin by 3.13a-b, 3.24 and 3.25. 
12.5 
45 
20 
5 
15 
Comparison of the assay results for compounds that possessed a 5-(hydroxymethyl)pyrrole 
moiety (3.13a-b, 3.24 and 3.25) demonstrated that those with a phenylalanine residue at 
the C2 position (3.13a and 3.25) were the most potent. The increased activity of 3.13a and 
3.25 was consistent with a-chymotrypsins preference for aromatic-cOIitaining substrates 
and inhibitors. A proline residue (as in 3.24) gave increased potency relative to the acyclic 
aliphatic leucine residue in 3.13b. However, both compounds were noticeably less active 
than 3.13a and 3.25. Inhibitor 3.25 gave the greatest activity against a-chymotrypsin of 
the compounds assayed, and a more in-depth study led to the determination of an ICso 
value of 1 08 ~M. This result revealed that 3.25 was an effective inhibitor of a-
chymotrypsin. 
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3.5 ATTEMPTED SYNTHESIS OF AN a-CHYMOTRYPSIN INHIBITOR 
WITH A 4-(HYDROXYMETHYL)PYRROLE FUNCTIONALITY 
An investigation of alternative pyrrole-based scaffolds to that of 3.13a-b, 3.14a, 3.24 and 
3.25 was undertaken to determine whether greater inhibition could be elicited, in addition 
to a covalent binding mode for the inhibitor to a-chymotrypsin. Synthesis of an alternative 
4-(hydroxymethyl)pyrrole scaffold was targeted to elucidate whether transfer of the 
hydroxymethyl group from the C5 position to C4 would give the desired effects. To this 
end, the 4-formyl pyrrole e~ter 3.17b22 was hydrolysed with potassium hydroxide to give 
the acid 3.17c in 77% yield (Scheme 3.10), which was subsequently coupled to L-
phenylalanine methyl ester under standard EDCIIHOBT conditions to afford 3.30 in 66% 
yield. Reduction with lithium borohydride gave the 4-(hydroxymethyl)pyrrole 3.31 in a 
low yield of 28%. However, this compound degraded to a complicated mixture of 
byproducts within 1-2 days· as demonstrated by IH NMR spectroscopy, before 
measurement of its activity as an a-chymotrypsin inhibitor could be performed. Further 
work towards the synthesis of 4-(hydroxymethyl)pyrrole-based a-chymotrypsin inhibitors 
was abandoned at this point. 
(ii) (iii) 
.. 
3.30 3.31 
Scheme 3.10. Reagents and conditions: (i) KOH, H20, 40-50°C, 2 h (77%). (ii) L-
PheOMe.HCl, EDCI, HOBT, DIEA, CH2Ch, r.t., 16 h (66%). (iii) LiBH4, Et20, -78°C, 1 
h, then r.t., 1 h (28%). 
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3.6 ATTEMPTED SOLID PHASE SYNTHESIS OF 5-(HYDROXYMETHYL)-
PYRROLE-BASED a-CHYMOTRYPSIN INHIBITORS 
The solid phase synthesis of an a-chymotrypsin inhibitor senes with a 5-
(hydroxymethy1)pyrro1e moiety would allow for a broader examination of structure-
activity relationships at the C2 position. Combinatorial synthesis is a powerful method for 
screening large collections of compounds against a biological target.23 Synthesis of 3.13a 
by solid phase chemistry was investigated as a model system for the development of a 
diversity-orientated synthetic route for this class of compounds. 
3.6.1 Attempted reduction of 3.33, a solid phase precursor to 3.13a 
The initial attempt towards development of a solid-phase based synthetic route to 3.13a 
was based on one critical step. Reduction of a 5-formy1pyrro1e moiety, linked via its C2-
acyl group to a resin-bound ammo acid, would afford the desired 5-
(hydroxymethyl)pyrro1e functionality. This reduction step is analogous to that illustrated 
in Scheme 3.5, whereby 3.18a was reacted with zinc borohydride to give 3.13a. To this 
end, deprotection of N-(9-fluoreny1methoxycarbony1)-L-pheny1a1any1 Wang resin (3.32a, 
Scheme 3.11) with 1:4 piperidine/dich1oromethane gave the free amine 3.32b, and reaction 
with the pyrro1e acid 3.16b under BOP-mediated coupling conditions afforded 3.33. 
Reaction of 3.33 with sodium borohydride in DMF24 was performed in an effort to obtain 
the proposed resin-bound 5-(hydroxymethy1)pyrro1e 3.34, after which the free acid 
analogue of 3.13a (3.35) would be released by cleavage from the resin with 1: 1 
TFAIdichloromethane. The lH NMR spectrum of the cleaved material indicated that 
extensive degradation had occurred and the expected product 3.35 was not present. 
Exposure of the 5-(hydroxymethy1)pyrro1e 3.13a, obtained by the solution phase synthetic 
route outlined in Scheme 3.5, to 1:1 TFAIdich1oromethane at r.t. for 1 h resulted in 
extensive degradation of 3.13a as determined by lH NNIR spectroscopy. Conversely, the 
same conditions did not cause degradation of 3.18a, the solution phase precursor to 3.13a, 
which conversely possessed a 5-formy1pyrro1e moiety. These results indicated that the 5-
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(hydroxymethyl)pyrrole functionality was not compatible with a cleavage procedure that 
involved the use of a strong acid. An alternative synthetic strategy needed to be developed 
that avoided formation of the 5-(hydroxymethyl)pyrrole moiety on the solid phase. 
0 
RIHN~( 
: 0-
""'Ph 
3.32a Rl = FMOC 
(i)L 
3.32b Rl=H 
~H HO N (Ny C02H 
H 0 -
""'Ph 
3.35 
I 
Y 
HO~~yC02M' 
H 0 -
""'Ph 
3.13a 
~H 0 (ii) 
OHC N (N00-" 
H 0 -
""'Ph 
3.33 
(iii) j 
(iv) ~H 0 ~ HO 1N \ Ny(O_ " H 0 -
""'Ph 
3.34 
Scheme 3.11. Reagents and conditions: (i) 1:4 piperidine/dichloromethane, r.t., 30 min. 
(ii) 3.16b, BOP, DIEA, CH2Cb, r.t., 48 h. (iii) NaBH4, DMF, r.t., 24 h. (iv) 1:1 
TFAlCH2Cb, r.t., 2 h. 
3.6.2 Attempted preparation of 3.18a from its solid phase synthesis precursor 3.33 
Scheme 3.12 outlines the attempted preparation of 3.18a, the immediate precursor to the 
representative 5-(hydroxymethyl)pyrrole a-chymotrypsin inhibitor 3.13a (see Scheme 
3.5). Preparation of 3.18a was considered a model system for development of a synthetic 
route whereby the 5-formylpyrrole precursors would be synthesised on the solid phase, 
with the desired 5-(hydroxymethyl)pyrroles afforded by subsequent solution phase 
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reduction. Fonnation of 3.18a required the cleavage of 3.33 and subsequent esterification 
of the carboxylic acid. Cleavage and esterification of a solid phase-linked carboxylic acid 
to afford the corresponding methyl ester has been combined into a "one-pot" methodology 
by Scheeren et al. 25 Application of the reported conditions to 3.33, where the resin was 
suspended in refluxing 30:6:1 benzene/methanol/triethylamine in the presence of catalytic 
potassium cyanide, gave a mixture of compounds by 1 H NMR spectroscopy, with no 
indication of the desired intennediate 3.18a. Direct cleavage of 3.33 was effected with 1: 1 
trifluoroacetic acidldichloromethane to give the free acid 3.36. However, 3.36 was obtain-
3.33 
(ii) 
n H HO"--./ "~/ i(Ny C02Me 
H 0 -
3.13a 
• I 
3.18a 
"""Ph 
n ~ COH 
OHC" "~/ If Y 2 
H 0 = 
"""Ph 
3.36 
+ 
n OHC N C02H 
H 
3.16b 
Scheme 3.12. Reagents and conditions: (i) 30:6:1 C6HdMeOHlEt3N, KCN(cat.), reflux, 48 
h. (ii) 1:1 TFAlCH2Clz, r.t., 2 h. (iii) CH2N2, THF, r.t., 15 h. 
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ed in an inseparable 1: 1 mixture with unreacted 3.16b, despite extensive washing of the 
resin after the coupling step that resulted in 3.33 (see Scheme 3.11). Improved isolation of 
the desired compound was attempted by the esterification of 3.36 with diazomethane to 
afford 3.18a. Separation of 3.18a from the methyl ester equivalent of 3.16b was proposed 
to occur more readily than the separation of the acids 3.36 and 3.16b, due to esters 
possessing more favourable solubility properties than acids for separation by flash 
chromatography. However, lH NMR analysis indicated that the pyrrole ring nitrogen was 
methylated by the electrophile under these conditions. This is in agreement with a 
previous report that noted the facile methylation of the pyrrole ring nitrogen with 
diazomethane.26 Further work towards the solid phase-based synthesis of 3.13a was 
abandoned at this point. 
3.6.3 Attempted solution phase synthesis of peptidomimetic 3.35 
Synthesis of the free acid 3.35 was also attempted by solution phase chemistry to 
determine whether it was a more potent inhibitor of a-chymotrypsin than its methyl ester 
derivative 3.13a. To this end, 3.18a was hydrolysed with potassium carbonate in refluxing 
10:1 methanol/water27 to give 3.36 in 82% yield (Scheme 3.13). Reduction of 3.36 with 
lithium borohydride in THF proved problematic, as the portionwise addition of 15 
equivalents of the reducing agent resulted in only a 1: 1 ratio of starting material to 3.35 by 
lH NMR spectroscopy. Reaction of 3.36 with sodium borohydride in 6: 1 iso-
propanol/water at r.t. afforded 3.35 in 44% yield. However, 3.35 was determined to be un-
n ~ caRl 
OHC" "~/ if y 2 
H a = 
"'-...Ph (i)L 3.18a Rl = Me 
3.36R l =H 
3.35 
Scheme 3.13. Reagents and conditions: (i) K2C03, 10:1 MeOHIH20, reflux, 18 h (82%). 
(ii) NaBH4, 6:1 i-PrOHlH20, r.t., 18 h (44%). 
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stable due to the gradual development of a complicated mixture of bypro ducts, as observed 
by IH NMR spectroscopy and electro spray LRMS. 
3.7 CONCLUSION AND FUTURE WORK 
A range of peptidomimetic mechanism-based inhibitors of a-chymotrypsin (3.13a-b, 
3.14a, 3.24 and 3.25) was prepared and tested for inhibitory activity towards the target 
enzyme. These pyrrole-based compounds are distinguished by the presence of 
hydroxymethyl or hydroxyalkyl functionalities at the C5 position, in addition to a C2 acyl 
group. Irreversible inhibition was proposed to occur by formation of a reactive azafulvene 
upon entry into the enzymes active site, with subsequent formation of a covalent bond 
between the inhibitor and eniyme arising from nucleophilic attack by an active site 
residue. Preliminary results illustrated that the hydroxymethyl moiety at the C5 position of 
3.13a was sufficient for eliciting inhibition. Increased hydrophobicity and steric bulk at 
C5, in the form of the 3-phenyl-l-hydroxypropyl functionality present on 3.14a, did not 
increase inhibitory activity. Analysis by mass spectrometry indicated that 3.13a was not 
covalently attached to a-chymotrypsin, which suggested that this compound was in fact a 
reversible inhibitor. The importance of the aromatic group present at C2 of 3.13a/3.14a 
for eliciting inhibition was illustrated by the lowered activity of compounds 3.13b and 
3.24, which instead had non-aromatic leucine and proline residues at C2 respectively. 
Optimal inhibition of a-chymotrypsin was elicited by 3.25, which had a phenyl alanyl-
leucine dipeptide at C2, and an IC50 of 108 flM was determined for this compound. 
Synthesis of compounds that possessed either a 5-(1-hydroxyethyl)pyrrole group (3.14b) 
or a 4-(hydroxymethyl)pyrrole functionality (3.31) gave unstable materials that could not 
be tested for inhibitory activity against a-chymotrypsin. 
The attempted solid phase synthesis of 3.13a demonstrated that the 5-
(hydroxymethyl)pyrrole functionality was unstable to the acidic cleavage conditions used 
in the attempted release of 3.35, a precursor to 3.13a, from the solid support. Cleavage of 
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the resin-bound 5-formyl intermediate 3.33 gave the free acid 3.36 as a 1:1 mixture with 
unreacted 3.16b, and attempts to purify this mixture were unsuccessful. The solution 
phase-based synthesis of 3.35 (the free acid analogue of 3.13a), demonstrated that a 
compound of its structure, which possessed both hydroxyl and carboxylic acid 
functionalities, was unstable. 
Future work could involve further elaboration of the functionality at the C2 position to 
determine if greater inhibition could be elicited. Additionally, esterification of the 
hydroxymethyl group at C5 could give more peptide-like structures and further 
enhancement of inhibition. 
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4.1 INTRODUCTION 
Ultraviolet-visible (UV-vis) spectroscopy is a powerful analytical technique with a wide 
variety of applications in chemistry, physics and biology. 1 Quantitative UV -vis 
spectroscopy is typically concerned with the determination of an analytes concentration,2 
whereas qualitative UV-vis analysis identifies a molecule of interest by recognition of its 
characteristic spectrum.3 Amino acids, the building blocks from which proteins and 
polypeptides are derived, can be detected by UV-vis spectroscopy,4 and even the nature of 
the variable group at the a-carbon (denoted as R 1, see Scheme 4.1) can be determined. 
However, direct detection of an amino acid by UV -vis spectroscopy is problematic. The 
functional groups common to all amino acids (i.e. the amine and carboxylic acid moieties) 
exhibit little or no absorption ofUV-vis light above 210 nm, which is the wavelength range 
characteristically used in UV-vis spectroscopy. Some influence is exerted on UV-vis 
absorption by R 1, but it is dependent on the chemical nature of this group. Amino acids 
with an aliphatic Rl group do not absorb light in the UV region above 220 nm (with the 
exception of cysteine), whereas the aromatic residues phenylalanine, tyrosine, tryptophan 
and histidine typically absorb between 250-300 nm.s The lack of activity means 
alternative methods such as chemical derivatisation are necessary for the reliable 
characterisation of amino acids by UV-vis spectroscopy. Ninhydrin (4.1, Scheme 4.1) is 
the most commonly used colourimetric assay for amino acids.4b Reaction of 4.1 with an 
amino acid (represented by 4.2) forms the coloured compound 4.3 ("Ruhemann's purple") 
o 
~\<OH + ~(OH 
o 
4.1 
o 0 
o=tN=\O 
0 8 0 
4.3 
Scheme 4.1. Schematic representation of the reaction between ninhydrin (4.1) and an 
amino acid (4.2) to give Ruhemann's purple (4.3). 
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through a complex series of intennediates.6 Adduct 4.3 has an absorbance maximum 
("-max) at approximately 570 nm, and its intrinsic colour is not constant. This allows for 
amino acid diagnosis from the colour yield of 4.3 relative to that of leucine (arbitrarily 
assigned as 1.00). For example, tryptophan gives a low colour yield of 0.94, whereas the 
yield obtained from lysine (1.10) is more intense than that ofleucine. 
Fluorimetry is another technique that allows for the detection of amino acids by direct 
chemical modification. While several fluorometric agents exist for this purpose, the 
example of fluorescamine4b (4.4, Scheme 4.2) illustrates the general principles. Reaction 
of 4.4 with the representative amino acid 4.2 gives the highly fluorescent pyrrolinone 4.5, 
which is detected fluorometrically. In a manner analogous to ninhydrin, amino acid 
assignment is based on the colour yield of 4.5, relative to that derived from the reaction of 
4.4 and norleucine (or glycine amide for the basic amino acids). 
o 
4.4 
Ph 
+ 
CHR1C02H I 
N 
H02C / HO /, 
o Ph 
4.5 
Scheme 4.2. Schematic representation of the reaction between fluorescamine (4.4) and an 
amino acid (4.2) to give 4.5. 
The development of detection methods for amines on a solid phase support has allowed for 
reaction efficiency to be monitored. Fonnation of a peptide bond between a resin-bound 
amine and the carboxylic acid functionality of an N-protected amino acid is one reaction 
process that has undergone close scrutiny.7 The coupling step needs to be reliable, fast, 
and proceed to almost quantitative yield, and dependable monitoring systems are required 
to detennine the outcome of a reaction. Many of these detection systems operate by the 
exposure of unreacted resin-bound amino groups by reaction of the amine and a reporter 
molecule, which affords a brightly coloured complex. Examples of the direct modification 
and visualisation of resin-bound amines include the ninhydrin-based Kaiser test,8 the p-
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nitrophenyl ester NF31,1 and malachite green isothiocyanate9 for primary amines, and 
chioranillacetaidehyde10 for secondary amines. 
The derivatisation of a resin-bound amino group, and subsequent diagnosis of its presence, 
has been divided into separate steps by Reich et aZ. ll Reaction of 
nitrophenylisothiocyanate-O-trityl (NPIT, 4.6, Scheme 4.3) with a resin-bound amine (4.7) 
affords adduct 4.8. Exposure to TF A releases the latent reactivity of 4.8 to give the red 
coloured derivatised amine 4.9 and the dimethoxytrityl cation 4.10. Cation 4.10 has an 
extinction coefficient (6) of 76,000 M-1 cm-1 at 498 nm, which allows for the quantitative 
measurement of the amount of free amine present on the solid support. Qualitative 
detection of the amino groups is based on visual detection of 4.9. The methodology 
presented in Scheme 4.3 is considered an application of modulated chemical reactivity (see 
Chapter One, Section 1.1 for discussion of this concept), whereby 4.10 was released on 
demand from a species (4.8) which possessed latent reactivity. 
02N~ 
DMTrO~NCS + 
4.6 4.7 
Coupling I S 0:nN ~ 
,... DMTrO ~ NJlN4 
4.8 
10% TF AlCH,C1, j 
H ~1 
02N~ S 
HO~NjlN4 
H i 1 
4.9 + 
MeO 
4.10 
Scheme 4.3. Reaction ofNPIT (4.6) with a resin-bound amine (4.7). 
OMe 
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Despite these known techniques, there remains a need for new improved methods that 
reveal the presence of functional groups, such as the amine functionality of an amino acid, 
in a simple and reliable way.? Previous work in these laboratories12 serendipitously 
discovered a cyclisation reaction that occurred when an essentially colourless 2,5-
disubstituted pyrrole, linked by its 2-acyl substituent to an O-protected amino acid, was 
reacted with hydrocinnamoyl chloride to produce a brightly coloured pyrrolizinone. We 
postulate that this may form the basis of a novel method for determining the presence of 
amino acids. Scheme 4.4 illustrates the two-step synthetic methodology that results in a 
derivatised amino acid with interesting spectrophotometric properties. Reaction of 3.16b 
with L-phenylalanine methyl ester hydrochloride under standard EDCIIHOBT conditions 
gave the N-derivatised amino acid 3.18a in 91 % yield. Subsequent reaction of 3.18a with 
hydrocinnamoyl chloride, in the presence of DIEA and a catalytic amount of DMAP, 
afforded pyrrolizinone 4.lla in 58% yield, rather than the desired intermediate 4.12. It 
was hoped that 4.12 would give rise to 4.13, a putative a-chymotrypsin inhibitor. Scheme 
4.4 also displays the structure of the a-chymotrypsin inhibitor 3.13a, prepared in Chapter 
Three, for comparison to 4.13. 
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n OHC N C02H (i) 
H 
3.16b 3.13a 
(ii) 
4.11a 
~\ H (N~C02Me OHC ;l 0 .:. 
) 0 "Ph 
Ph 4.12 
3.13a 
Scheme 4.4. Reagents and conditions: (i) EDCI, HOBT, DIEA, CH2Cb, r.t., 16 h (91 %). 
(ii) Ph(CH2)zCOCI, DIEA, DMAP, CH2Cb, r.t., 24 h (58%).12 
The scope of this synthetic sequence was demonstrated by the preparation of two further 
examples.12 The 5-formylpyrroles 3.18b-c, derived from the separate reaction of 3.16b 
with the O-protected amino acids L-Ieucine methyl ester hydrochloride and glycine ethyl 
ester hydrochloride, afforded 4.11b-c in 55% and 58% yields respectively upon reaction 
with hydrocinnamoyl chloride (Scheme 4.5). 
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)[-~ ~ CO R2 _(i_) .... 
OHC N/ i( Y 2 
H 0 lil 
3.18b-c 0N '\ ~~_: C02R2 \ R l R2 o lil --------b--------+----o 3.18b/4.11b CH2CHMe2 Me Ph 3.18C/4.11c H Et 
4.11b-c 
Scheme 4.5. Reagents and conditions: (i) Ph(CH2)2COCI, DIEA, DMAP, CH2Ch, r.t., 24 
h (4.11b, 55%), (4.11c, 58%).12 
A comparison can be drawn between the reaction of ninhydrin (4.1, Scheme 4.1) and 
fluorescamine (4.4, Scheme 4.2) with amino acids, and preparation of the pyrrolizinones 
4.11a-c (Schemes 4.4 and 4.5). In all cases, the amine functionality of an amino acid is 
derivatised by chemical modification to afford products with interesting 
spectrophotometric properties. However, both 4.1 and 4.4 react with amino acids in a one 
step process, after which visualisation is performed. Preparation of the pyrrolizinones 
4.11a-c differed in that chemical modification of the amino acid was separated into two 
steps before the bright colouring was revealed. The amine functionality was initially 
"capped" with the pyrrole acid 3.16b to give 3.18a-c, which possess the ability to be 
coloured and hence visualised on demand. Upon reaction with hydrocinnamoyl chloride 
the spectrophotometric ally active moiety was released. This methodology is considered an 
example of the modulation of chemical reactivity (see Chapter One, Section 1.1 for 
discussion of this concept), as striking spectrophotometric properties are liberated upon 
release of the latent reactivity possessed by the pyrrole-amino acid adducts. 
This mechanism of action has relevance to the detection of amino groups in solid phase 
chemistry. To this end, additional work in these laboratories13 demonstrated that the 
synthetic methodology utilised in Schemes 4.4 and 4.5 to effect pyrrolizinone formation 
was applicable to resin-bound amino acids (Scheme 4.6). Deprotection of N-(9-
fluorenylmethoxycarbonyl)glycine Wang resin (4.14a) with 1:4 piperidine/dichloro-
methane gave the free amine 4.14b. The pyrrole acid 3.16b was coupled to 4.14b by 
standard EDCI/HOBT methodology to afford the colourless beads 4.15. Reaction with 
hydrocinnamoyl chloride gave the brightly coloured beads 4.16, i.e. the presence of the 
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resin-bound amino groups (4.14b) was revealed by colour formation after two separate 
synthetic steps. 
o 
RIHNJO-Q 
C 4.14a RI = FMOC (i) 4.14bR I = H 
(ii) 
n ~ 0 OHC/>'(n ·JO-Q 
H 0 
4.15 
(ii i) 
Scheme 4.6: Reagents and conditions: (i) 1:4 piperidine/ClhCb, r.t. , 30 min . (ii) 3.t6b, 
EDCl, HOST, OlEA, CH2Cb, r.t., 2 h. (iii) Ph(CH2)2COCl, OlEA, DMAP, CH2Cb, r.t. , 5 
h.13 
The following aspects were investigated in this chapter. First, a range of pyrrolizinones 
were prepared to elucidate whether any ditlerences, dictated by the variations introduced at 
the R I and O-pmtecting (R2) groups, were observable for the Amnx and E values in the UV-
vis spectra of the synthesised analogues. This would demonstrate whether derivatisation of 
the IV-terminal of amino acids by pyrrolizinone formation is a viable method for amino 
acid determination by UV -vis spectroscopy cf ninhydrin (4.1). Also, Beers Law would 
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allow ammo acid concentration to be determined, if the E value was known. 
Inconsistencies were observed for the Amax values of 4.11 a-c when methanol was used 
during preliminary UV-vis spectroscopy,12 therefore additional work involved determining 
a solvent suitable for analysis of the pyrrolizinones. Finally, the fragments generated from 
the pyrrolizinones during mass spectrometry were analysed to elucidate whether Rl could 
be determined by a diagnostic product ion. 
4.2 SYNTHESIS OF PYRROLIZINONES WITH VARIABLE GROUPS AT Rl 
ANDR2 
A range of the pyrrolizinone-amino acid adducts based on the general structure 4.11 
(Figure 4.1), with variability at Rl and R2, were synthesised for UV-vis and mass 
spectrometry analysis. Additionally, two dipeptidic examples based on general structure 
4.17 were synthesised to determine the effect of an additional glycine residue on the UV-
vis and mass spectra ofthe resulting pyrrolizinone-dipeptide adducts. 
Figure 4.1. General structure of the synthetic targets 4.11 and 4.17. 
4.2.1 Synthesis of the pyrrolizinones 4.11 d-i and 4.17 a-b 
Compounds 3.18d-i were separately reacted with hydrocinnamoyl chloride to give the 
pyrrolizinones 4.11d-i in yields of 42%, 35%, 31%, 44%, 21 % and 43% respectively 
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(Scheme 4.7). It is important to note that strictly anhydrous reaction conditions were 
needed for pyrrolizinone formation to occur. 
R' R2 
~~ COR2 (, ) 'R~~~CO'R' 3.IBd/4.lld H Rn OHC J\ Y 2 \ J\ ~ 3. I Be/4. I Ie CH 2Ph Et 
H 0 R' o R' 3.IBf/4.11f CH 2CHi\lc2 Et 
0 3.18g14.llg CHMe, Me 3.IBd·i Ph 
4.lld-i 3.IBh/4.llh Me Me 
3.1Bi/4.11 i H Me 
Scheme 4.7. Reagents and conditions: (i) Ph(CH2hCOCl, DIEA, DMAP, CH 2CI2, r.t. , 24 
h (4.11d, 42%), (4.11e, 35%), (4.11f, 31%), (4.11g, 44%), (4.11h, 21%), (4.11i , 43%). 
A single crystal X-ray structure of 4.11 h (F igure 4.2) was determined for comparison to 
reported crystal structures of pyrrolizin-3-ones, and to characterise the extended 
conjugated backbone of this molecule. This compound crystallised, with an orthorhombic 
space group 1222, from an ethyl acetate/petroleum ether solvent system by the technique of 
vapour diffusion (see Appendix for crystal structure details). 
C(T) 
C(I2) 
0(19) 
\ C(IO) 
C(16) • C(ll) C(l) 
C(I3) C(5) C(19) 
C(11) 
C(2) C(3) N(l7) 0(20) 
C(9) 0(3) C(l8) C(I4) 
C(I6) 
C(22) 
Figure 4.2. X-ray crystal structure of 4.11 h with crystallographic numbering system. 
Analysis of the crystal structure of 4.11 h illustrated that it possessed the structural 
characteristics observed in previous reports. 12.14 The bicyclic ring system is essentially 
planar, and the amide bonds lengths are noticeably different to those of a normal cyclic 
tertiary amide. ls Compound 4.11h has a C(3)-N(4) bond length of 1.413(3) A, which is 
longer than the C-N bond length (1.335(9) A) of a nonnal cyclic tertiary amide. [n 
contrast, the C(3 )-O( 3) bond, at I .214(3) A, is somewhat shorter than that of a c=o bond 
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in a nonnal cyclic tertiary amide (typically 1.234(11) A). This observation is consistent 
with the reduced amide bond delocalisation previously reported for pyrrolizin-3-ones. 12,14 
The altered bond lengths of the pyrrole substructure of 4.11h compared to pyrrole16 itself 
further supported the idea of reduced delocalisation in the pyrrolizin-3-one ring system 
compared to pyrrole itself. 
Scheme 4.8 outlines the synthetic route towards pyrrolizinone-dipeptide adducts of type 
4.17. Reaction of 3.29a-b with hydrocinnamoyl chloride afforded the dipeptide 
pyrrolizinones 4.17a-b in yields of 34% and 33% respectively (Scheme 4.9). 
n H 0 
OHC' "~/ yN~N/'-...C02Me 
H 0 Rl H 
3.29a-b 
(i) iC\ H 0 
- __ " (NJ /'-... \ N ~ N C02Me 
o Rl H 
o 
Ph 4.17a-b 
3.29a/4.17a CH2Ph 
3.29b/4.17b CH2CHMe2 
Scheme 4.8: Reagents and conditions: (i) Ph(CH2)2COCl, DIEA, DMAP, CH2Cb, r.t., 24 
h (4.17a, 34%), (4.17b, 33%). 
4.3 INITIAL UV-VIS SPECTROSCOPIC ANALYSIS OF THE 
PYRROLIZINONE 4.11e USING METHANOL AS SOLVENT 
The initial goal of the spectroscopic studies reported in this chapter was to give a deeper 
understanding of the UV -vis spectrophotometric properties possessed by pyrrolizinones of 
type 4.1114.17. Specifically, the influence that Rl and R2 had upon the Amax and E values in 
the UV -vis spectra recorded for compounds of type 4.11/4.17 was to be detennined. Any 
conspicuous trends would fonn the basis of a technique that would allow elucidation of the 
Rl and R2 groups by N-derivatisation of an amino acid, with subsequent analysis by UV-
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vis spectroscopy. Also, once the 8 value is known, the concentration of an amino acid in a 
mixture could be quantified by Beers Law. Pyrrolizinones 4.11a-c were subjected to UV-
vis spectroscopic analysis in the previous study,12 however noticeable differences were 
observed in the Amax values obtained for these compounds. These differences were 
dependent upon the solvent used for UV -vis spectroscopy. The spectrum for 4.11a, 
obtained in chloroform, possessed two maxima at 301 and 438 nm (Table 4.1). In contrast, 
4.11b and 4.11c were analysed in methanol, and both pyrrolizinones had three Amax values. 
No. Rl RL Solvent Amax (nm) [8 (M-1 cm-1)] 
4.11a CH2Ph OMe CHCb 301 [12,300],438 [4,100] 
4.11b CH2CHMe2 OMe MeOH 223 [11,500],339 [9,100], 436 [900] 
4.11c H OEt MeOH 242 [11,300], 338 [25,400],423 [200] 
Table 4.1. UV-vis spectroscopic data for the pyrrolizinones 4.11a_c. 12 
A time-course study was implemented to determine what effect the use of a nucleophilic 
solvent such as methanol had upon a representative pyrrolizinone during UV -vis 
spectroscopy. To this end, 4.11e was dissolved in methanol and allowed to stand at r.t. 
under an ambient atmosphere. UV-vis spectra of this solution were taken at 10 min 
intervals. At 0 min a spectrum was obtained with two Amax at approximately 330 and 430 
nm (Figure 4.3a). After 30 min the shape of the absorbance plot had changed markedly 
(Figure 4.3a). The Amax at approximately 430 nm had disappeared, and the Amax at 
approximately 330 nm was replaced by an extremely distorted signal between 310-360 nm. 
This result revealed that pyrrolizinones such as 4.11e were unstable in methanol, and 
therefore it is an unsuitable solvent for UV-vis spectroscopy. 
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Figure 4.3. UV-vis spectra of 4.11e after 0 min (a) and 30 min (b). 
The reactivity of the pyrrolizinone ring system upon exposure to nuc1eophiles has been 
demonstrated previously.12 Pyrrolizones 4.11a-c were reacted with 15 equivalents of 
sodium methoxide in methanol to give the colourless pyrrole acrylic esters 4.18a-c within 
1 min, in yields of 85%, 82% and 80% respectively (Scheme 4.9). This sequence provides 
a method for "decolourising" the amino acid, hence the spectrophotometric properties of 
the pyrrolizinone can be subsequently removed at a desired stage. 
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4.11a-c 
(i) 
Ph 
4.11a/4.18a CH2Ph Me 
4.11b/4.18b CH2CHMe2 Me 
4.11c/4.18c H Et 
Scheme 4.9: Reagents and conditions: (i) MeONa, MeOH, r.t., 1 min (4.18a, 82%), 
(4.18b, 80%), (4.18c, 85%).12 
An identical process, i.e. ring opening of the pyrrolizinone at C3, must have occurred when 
4.11e was allowed to stand in methanol for 30 min. To avoid pyrrolizinone degradation 
during UV-vis spectroscopy, it was deemed prudent to exchange methanol for the 
relatively inert solvent acetonitrile. 
4.4 UV-VIS SPECTROSCOPIC ANALYSIS OF THE PYRROLES 3.18e AND 
3.18i, AND THE PYRROLIZINONES 4.11a-i AND 4.17a-b 
Determining the influence ofRl and R2 on the UV-vis spectra recorded for compounds of 
type 4.1114.17 in acetonitrile was then undertaken. However, preliminary UV -vis 
spectroscopy was performed on the pyrroles 3.18e and 3.18i in order to determine the 
activity exhibited by the pyrrole-based precursors. This was carried out to establish to 
what extent the activity demonstrated by the pyrrolizinones was dependent on the pyrrole-
amino acid substructure. Compound 3.18e was chosen as an example of a precursor with a 
UV active aromatic group at R\ and 3.18i as one with a non-aromatic side chain. Figure 
4.4 displays the UV-vis spectrum for 3.18e, which was found to have a Amax of291 nm (8 = 
28,610 M-1 cm-1). 
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Figure 4.4. UV-vis spectrum for 3.18e. 
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The Amax of 289 run observed for 3.18i (Figure 4.5) was almost identical to that obtained 
for 3.18e, but the E value calculated for 3.18i was much lower (16,780 M-I cm-I). These 
results indicated that compounds oftype 3.18 have Amax of approximately 290 run, but the E 
value appeared to be dependent on the nature of the side chain. The almost identical Amax 
values for 3.18e and 3.18i was attributed to the conjugated nature of the 2,5-disubstituted 
pyrrole ring system possessed by both compounds. 
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Figure 4.5. UV-vis spectrum for 3.18i. 
UV-vis spectroscopic analysis of the pyrrolizinones 4.lla-i and 4.17a-b was subsequently 
performed to determine what influence R 1 and R2 had upon the Amax and E values. 
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Accurate comparisons between 4.11a-i and 4.17a-b required analysis of the previously 
synthesised compounds 4.11a-c. 12 The spectral plot of 4.11d, displayed in Figure 4.6, is 
typical for all pyrrolizinones. 
1.8 A~ ~ COBn ''t,/ y "-./ 2 \ 0 o 
Ph 
4.11d 
250 300 350 400 450 500 550 600 
Wavelength (nm) 
Figure 4.6. UV -vis spectrum for 4.11d. 
Table 4.2 presents the UV-vis spectroscopic data for compounds 4.11a-i and 4.17a-b in 
freshly distilled acetonitrile. Data for 3.18e and 3.18i, the synthetic precursors to 4.11e 
and 4.11i respectively, is also displayed for comparison. 
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No. Rl 
4.11a# CH2Ph 
4.11b# CH2CHMe2 
4.11c# H 
4.11d H 
4.11e CH2Ph 
(3.18e) CH2Ph 
4.11f CH2CHMe2 
4.11g CHMe2 
4.11h Me 
4.11i H 
(3.18i) H 
4.17a CH2Ph 
4.17b CH2CHMe2 
-
- PrevIOusly synthesIsed 
* = Not applicable 
R,( Amax (nm) [8 (M-I cm-I)] Ratio 8(-300 nmy 
8(-430nm) 
OMe 299 [6380],434 [1950] 3.27 
OMe 300 [5010],434 [1550] 3.23 
OEt 299 [8200],433 [2150] 3.81 
OBn 299 [5610],431 [1530] 3.67 
OEt 299 [8500], 432 [1920] 4.45 
OEt 291 [28610] na* 
OEt 298 [7450], 429 [1580] 4.71 
OMe 300 [7580], 434 [1780] 4.25 
OMe 299 [8950],434 [2190] 4.09 
OMe 297 [7190], 433 [1860] 3.86 
OMe 289 [16780] na* 
NHCH2C02Me 299 [5500],432 [1570] 3.50 
NHCH2C02Me 298 [7100], 435 [1840] 3.86 
LL 
Table 4.2. UV -vis spectral data for pyrrolizinones 4.11a-i and 4.17a-b in acetonitrile. 
Data for 3.18e and 3.18i is included underneath the respective pyrrolizinone analogues 
4.11e and 4.11i for comparison. 
The distinctive shape of the spectral plots for pyrrolizinones of type 4.11/4.17 (see Figure 
4.6) arose from splitting of the single Amax possessed by pyrroles of type 3.18 at 
approximately 290 nm. As expected, the more extensive conjugation of the pyrrolizinone 
ring system, compared to the pyrrole-based structures, resulted in the two Amax possessed 
by compounds of type 4.11/4.17 absorbing at wavelengths longer than 290 nm.17 The 
spectra of 4.11a-i and 4.17a-b were then compared to determine whether the variable RI 
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and R2 groups had any effect on the Amax or E values. All of the pyrrolizinones have Amax at 
approximately 300 and 430 nm, eliminating Amax as a method of identifying Rl or R2. 
Comparison of the E values for 4.11a-i and 4.17a-b at either approximately 300 or 430 nm 
also revealed they were not dependent on the presence of a specific Rl or R2 group. 
Further analysis of the data in Table 4.2 was performed in order to ascertain any influence 
on the E values that resulted from the nature ofRl or R2. A ratio was calculated by division 
of the E value at approximately 300 nm by the E value at approximately 430 nm (i.e. E(-300 
nm/E(-430 nm)), and the ratios for 4.11a-i and 4.17a-b appear in the right-hand column of 
Table 4.2. However, there was no correlation between the ratio and the nature of the group 
at Rl or R2. For example, comparison of the ratios obtained for compounds that possessed 
an identical Rl group gave noticeably different values. For example, 4.11c, 4.11d and 
4.11i (Rl = H) gave relatively similar values of 3.81, 3.67 and 3.86 respectively, whereas 
4.11b, 4.1H and 4.17b (Rl = CH2CHMe2) gave disparate ratios of 3.23, 4.71 and 3.86 
respectively. In contrast, a comparison of two dissimilar Rl groups gave little variation in 
the calculated ratios, e.g. 4.11a (Rl = CH2Ph) had a ratio of 3.27, which was almost 
identical to the ratio of 3.23 for 4.llb (Rl = CH2CHMe2). The R2 group also had little 
influence over the value for E(-300 nm/E(-430 nm). Pyrrolizinones with identical R2 
functionalities gave dissimilar ratios, e.g. the low value of 3.27 obtained for 4.11a (R2 = 
OMe) versus the high ratio of 4.25 obtained for 4.11g (R2 = OMe). In contrast, similar R2 
groups gave almost identical ratios, e.g. the values of 3.27 and 3.23 given by 4.11a (R2 = 
OMe) and 4.11b (R2 = OMe) respectively. Overall, the lack of recurring trends for Rl and 
R2, by inspection of the Amax, E or E(-300 nm/E(-43 0 nm) values, meant that UV -vis spectroscopy 
did not allow for the identification of what functionality was present at these positions. 
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However, then derivatisation of an amino acid to give a compound of type 4.11 becomes a 
method for quantifying the amount of an unknown amino acid by the use of Beers Law 
(Figure 4.7), and the reference data in Table 4.2, to calculate pyrrolizinone concentration. 
A= Ecl 
Figure 4.7. Beers Law (A = absorbance, E = extinction coefficient, c = concentration, 1= 
sample path length). 
4.5 MASS SPECTROMETRY FRAGMENTATION ANALYSIS OF THE 
PYRROLIZINONES 4.11a-i AND 4.17a-b 
The LRMS spectra of 4.11a-i and 4.17a-b were analysed to determine whether a product 
ion was generated during mass spectrometry whose mlz ratio was dictated by RI. This 
would form the basis of a technique whereby a particular amino acid might be diagnosed 
by derivatisation and subsequent mass spectrometry. Two features were revealed, the first 
of which was the presence of four product ions in all spectra. The most noticeable was the 
base peak at mlz 236.1, which is formed by fragmentation of the molecular ion (M+,) ofthe 
representative pyrrolizinone 4.11 to give product ion 4.19 (Figure 4.8). The molecular 
formula of 4.19 (ClsHlON02,) was confirmed by analysis of the HRMS data. Another ubi-
_ 4.19 __ 
(236.1) 
W\ i~ COR2 \ N r: Y , -1 , __ , 0, R /, , ( " 0 : \,~~\ : 4.11 (M+') 
4.20 
(91.1) 
Figure 4.8. Fragmentation of the pyrrolizinones represented 4.11 afforded the product 
ions 4.19 and 4.20. 
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quitous fragment had mlz of 91.1, which corresponded to the benzyl product ion 4.20 
(HRMS data confinned a molecular fonnula of C7H7'). The abundance of 4.20 in the 
spectra of 4.11a-i and 4.17a-b ranged between 5-29%, relative to 4.19, and its fonnation is 
favoured due to resonance stabilisation. 18 Two other ubiquitous fragments had mlz of 
153.1 (8-17% abundance relative to 4.19) and 180.1 (5-14% abundance relative to 4.19). 
However, analysis of the HRMS data for these two product ions did not lead to any 
definitive structural assignment. 
The second and most important feature of the fragmentation patterns was a product ion that 
revealed the nature of R 1. Analysis of the LRMS data indicated that cleavage of the bond 
between the a-carbon of the amino acid contiguous to the pyrrolizinone ring system, and 
the carbonyl carbon of the ester or amide functionality, produced a product ion that 
revealed the structure of R 1• Cleavage at this point is typical of the amino acids.19 The 
postulated mechanism of cleavage for compounds of type 4.11 is illustrated in Scheme 
4.10. Removal of one electron from the amide nitrogen of 4.11 results in conversion to the 
molecular ion, which undergoes a-cleavagel9 to give the product ions 4.21 and 4.22. 
0\ H 0 Ionisation I N ("" II -----..... - N J~R2 \ ::'1 o R 
o 
Ph 4.11 (M+') 
Fragmentation j 
+ 
o 
.ll 2 R 
4.22 
Scheme 4.10. Postulated fragmentation mechanism for the molecular ion 4.11 (M+), to 
give the product ions 4.21 and 4.22. 
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Table 4.3 summarises the infonnation given by examination of the fragmentation patterns 
observed in the LRMS spectra of 4.11a-i and 4.17a-b. All compounds were subjected to 
electron impact ionisation mass spectrometry. 
f{r\ H \ N ~~ o Rl 
o 
Ph 4.21 
No. Rl mlzof mlz of ion 4.21 M+ - (mlz ~. - (mlz 4.21) 
M+' (% intensity) 4.21) corresponds to loss of: 
4.11a# CH2Ph 414.2 355.1 (6) 59.1 -C02Me 
4.11b# CH2CHMe2 380.2 321.2 (31) 59.0 -C02Me 
4.11c# H 338.1 265.1 (7) 73.0 -C02Et 
4.11d H 400.1 265.1 (8) l35.0 -C02CH2Ph 
4.11e CH2Ph 428.2 355.1 (7) 73.1 -C02Et 
4.11f CH2CHMe2 394.2 321.2 (76) 73.0 -C02Et 
4.11g CHMe2 366.2 307.1 (46) 59.1 -C02Me 
4.11h Me 338.1 279.1 (40) 59.0 -C02Me 
4.1H H 324.1 265.1 (8) 59.0 -C02Me 
4.17a CH2Ph 471.2 355.2 (42) 116.0 -CONHCH2C02Me 
4.17b CH2CHMe2 437.2 321.2 (81) 116.0 -CONHCH2C02Me 
If_ ill 
- PrevIously syntheSIsed 
Table 4.3. LRMS data for pyrrolizinones 4.11a-i and 4.17a-b, which afforded the product 
ion represented by 4.21. 
Fragmentation of the pyrrolizinones 4.11a-i and 4.17a-b to give a product ion of type 4.21 
appeared to be a reliable phenomenon for these compounds. The mass of 4.21 was 
dependent on the Rl group. Almost all of the natural amino acids have a unique mass, 
which is dictated by RI. The only exceptions where identical masses are given by different 
amino acids are glutamine and the free base oflysine, glutamic acid and protonated lysine, 
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and the constitutional isomers leucine and isoleucine. Hence, an amino acid can be 
characterised by the presence of a diagnostic product ion such as 4.21 in a mass spectrum. 
Derivatisation of ammo acids and subsequent analysis by mass spectrometry has 
previously allowed assignment ofthe Rl group by the mlz ratios of distinctive product ions. 
Examples include the N-trifluoroacetyl amino acid n-butyl esters represented by 4.2320 
(Figure 4.9), trimethylsilyl derivatives such as 4.24,21 oxazolones and closely related cyclic 
stmctures19 (based on 4.25), and the phenylthiohydantoin-based compounds represented by 
4.26.22 Products of type 4.26 were generated by automated degradation of a protein with 
phenylisothiocyanate (Edman's reagent), and the polypeptide sequence was subsequently 
determined by chemical ionisation LRMS analysis of the resulting adducts.22 Precedence 
also exists for elucidation of the Rl group by mass spectrometry after the derivatisation of 
amino acids with dansyl chloride, fluorescamine (see Scheme 4.2), and a range of N-acyl 
groupS.19 All of the methods discussed here function by the direct chemical modification 
of an amino acid (or its ester equivalent), followed by mass spectrometric analysis. The 
method presented in this chapter differs in that the amino acid is derivatised in two steps, 
with the second step unmasking the pyrrolizinone when desired. This product undergoes 
fragmentation during mass spectrometry to give a product ion (4.21), whose mlz ratio is 
dictated by the RI group. 
H 
F3CI(Ny co2nBu 
o fil 
4.23 4.24 
Figure 4.9. Derivatised amino acids 4.23-4.26. 
4.25 
S,}-NPh 
HN~o 
Rl 
4.26 
The nature of the Rl group appeared to influence the abundance of the product ion relative 
to the base peak (see Table 4.3). Particularly strong intensities (between 31-76%) were 
observed for the product ion 4.21 derived from compounds 4.11b and 4.11f-h (Rl = alkyl). 
This discovery was surprising, as amino acids that possess an alkyl group of two or more 
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carbons tend to undergo fragmentation in a way that results in cleavage of the Rl group 
from the a-carbon. 19 Compounds with either Rl = H (4.11c, 4.11d and 4.11i) or Rl = 
CH2Ph (4.11a and 4.11e) had a lower abundance of the product ion (between 6-8%). A 
low signal intensity for the product ion derived from 4.11a and 4.11e was expected, as 
amino acids with a side chain of type CH2Ar tend to eject the highly stable species 
·CH2Ar. 19 The pyrrolizinone dipeptides 4.17a-b gave product ions with relatively strong 
intensities (42% and 81 % respectively), and for the compound where Rl is an alkyl group 
(4.17b) a higher intensity of 4.21 was observed than that for 4.17a (Rl CH2Ph). 
Comparison of the dipeptide pyrrolizinones 4.17a-b to their corresponding monopeptide 
analogues illustrated that the adjacent glycine residue generally increased the abundance of 
4.21. Fragmentation of 4.17a (R1 = CH2Ph) gave a product ion with an abundance of 42%, 
which was much higher than that derived from its methyl ester (4.11a, 6%) or ethyl ester 
(4.11e, 7%) analogues. A similar trend was noticed for 4.17b (R1 CH2CHMe2), which 
gave a product ion with an abundance (81 %) that was greater than that derived from its 
methyl ester analogue 4.11b (31 %), although the ethyl ester analogue 4.11f gave a product 
ion with a similar intensity (76%). 
Interestingly, the 5-formylpyrroles 3.18a-i and 3.29a-b also displayed a fragmentation 
process analogous to that observed for 4.11a-i and 4.17a-b. Scheme 4.11 illustrates that a-
cleavage of the molecular ion generated from compounds of type 3.18/3.29 gave the 
product ion 4.27. 
~\ ~\ COR2 OHC N (+.y, 2 
H 0 if' 
--------~. ~ ~ ORC/' '~/ i( + ~ 
H 0 itl 
3.18/3.29 (M+') 4.27 
Scheme 4.11. Fragmentation mechanism for the molecular ion (~) of type 3.18/3.29 to 
give the product ion 4.27. The point of cleavage is marked by a dashed line. 
Analysis of the fragmentation patterns in the LRMS spectra for 3.18a-i and 3.29a-b gave 
the data summarised in Table 4.4. All compounds were subjected to electron impact 
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ionisation mass spectrometry, with the exception of 3.29b, which was analysed by 
electro spray ionisation mass spectrometry 
No. Rl mlzof 
M+ 
3.18a * CH2Ph 300.1 
3.18b# CH2CHMe2 266.1 
3.18c# H 224.1 
3.18d H 286.1 
3.18e CH2Ph 314.1 
3.18f CH2CHMe2 280.1 
3.18g CHMe2 252.1 
3.18b Me 224.1 
3.18i H 210.1 
3.29a CH2Ph 357.1 
3.29bl1 CH2CHMe2 346.1 t 
Jl\R 
ORC" "~/ I(~~ 
R 0 Rl 
4.27 
mlz of ion 4.27 M+ - (mlz 
(% intensity) 4.27) 
241.1 (5) 59.0 
207.1 (38) 59.0 
151.1 (25) 73.0 
151.1 (18) 135.0 
241.1 (6) 73.0 
207.1 (47) 73.0 
193.1 (44) 59.0 
165.0 (98) 59.1 
151.1 (25) 59.0 
241.1 (25) 116.0 
207.1 (12) 139.0 
M+ - (mlz 4.27) 
corresponds to loss of: 
-C02Me 
-C02Me 
-C02Et 
-C02CH2Ph 
-C02Et 
-C02Et 
-C02Me 
-C02Me 
-C02Me 
-CONHCH2C02Me 
-CONHCH2C02Me - Na+ 
* = Synthesised by the author, but mass spectrometry results were obtamed from the 
frevious studyl2 
= Previously synthesisedl2 
11 = Analysed by electrospray ionisation LRMS 
t=~+Na 
Table 4.4. LRMS data for pyrroles 3.18a-i and 3.29a-b, which afforded the product ion 
represented by 4.27. 
The LRMS data for the pyrroles 3.18a-i and 3.29a-b displayed some of the trends observed 
for the pyrrolizinones 4.11a-i and 4.17a-b. Most importantly, the mass of product ion 4.27 
was dictated by R l, which suggested that the amino acid side chain can be determined by 
mass spectrometry at either step of the derivatisation technique presented in this chapter. 
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The abundance of 4.27 appeared to be dependent on the nature of R 1. Derivatives with an 
alkyl Rl group (3.18b and 3.18f-h) had a greater intensity recorded for 4.27 (38%, 47%, 
44% and 98% respectively), in comparison to those with Rl = CH2Ph (3.18a, 3.18e and 
3.29a, 5%, 6% and 25% respectively). Compounds where Rl = H (3.18c-d and 3.18i) gave 
product ion intensities of 25%, 18% and 25% respectively, which were noticeably higher 
than those recorded for the product ion 4.21 derived from the corresponding pyrrolizinones 
4.11c-d and 4.11i (7%, 8% and 8% respectively). This suggested that the first 
derivatisation step, whereby the pyrrole derivative 3.16b was coupled to the N-terminus of 
a glycine derivative, gave an adduct that afforded greater levels of the diagnostic product 
ion in comparison to the resultant pyrrolizinones. The relatively low abundance of product 
ion derived from 3.29b (12%) resulted from the use of electrospray ionisation, a "soft" 
ionisation technique that leads to lessened fragmentation of the parent ion. 18 This result 
indicated that electron impact ionisation was more effective than electrospray ionisation 
for production of the fragments of interest, 4.21 and 4.27. Finally, the presence of an 
additional glycine residue at the R2 position of the pyrrole-dipeptide adduct 3.29a (Rl = 
CH2Ph) resulted in a greater abundance of 4.27 (25%), compared to that derived from the 
methyl ester (3.18a, 5%) and ethyl ester (3.18b, 6%) analogues. This was in agreement 
with what was observed for the corresponding pyrrolizinone-dipeptide adduct 4.17a. 
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4.6 CONCLUSION AND FUTURE WORK 
Previous work in these laboratories developed a procedure for the two-step derivatisation 
of amino acids,12 which began by the attachment of a pyrrole derivative to the amino 
group. Subsequent reaction afforded the pyrrolizinones 4.11a-c, which displayed a bright 
colouring and interesting UV spectroscopic behaviour. This two-step procedure was 
proposed to be a novel .derivatisation method, whereby the amino functionality was 
initially "capped" by reaction with the pyrrole acid 3.16b, and the latent reactivity of the 
attached pyrrole derivative was released under mild reaction conditions to reveal the 
presence of an amino group by pyrrolizinone formation. 
Expansion of the range of amino acids reacted under these conditions, which afforded the 
pyrrolizinones 4.11d-i and 4.17a-b, demonstrated that the introduction of variable groups 
at R1 and R2 gave no observable differences in the UV spectra. However, this 
derivatisation method could be used to quantify the amount of an amino acid by the use of 
Beers Law. The use of methanol was not compatible with the UV-vis spectroscopic 
analysis of compounds of type 4.1114.17 due to degradation of the pyrrolizinone ring 
structure, and acetonitrile was found to be a more suitable solvent. 
Analysis of the fragmentation patterns in the LRMS spectra of 4.11a-i and 4.17a-b 
revealed that a product ion (4.21), which resulted from cleavage between the a-carbon of 
the amino acid and the adjacent carbonyl carbon, was present in all spectra. The mass of 
4.21 was dependent on RI. Additionally, the nature ofRl dictated the abundance of 4.21 -
if it was an alkyl group the intensity was higher than if RI or CH2Ph. A glycine 
residue adjacent to the amino acid contiguous to the pyrrolizinone ring system increased 
the signal intensity of 4.21 in comparison to the monopeptide analogues with identical Rl 
groups. Analysis of the fragmentation patterns for 3.18a-i and 3.29a-b, the synthetic 
precursors to the pyrrolizinones, indicated that the a-cleavage observed for the 
pyrrolizinones was also a facile process for the pyrrole-amino acid adducts. Both the mass 
and abundance of the product ion 4.27 was dictated by RI, with signal intensity increased 
by the presence of an alkyl side chain group relative to those with RI = CH2Ph. 
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Fragmentation of the pyrrole-glycine adducts 3.18c-d and 3.18i gave an abundance of the 
diagnostic product ion that was noticeably higher than what resulted from the analogous 
pyrrolizinones 4.11c-d and 4.11i. This suggested that derivatisation of glycine with the 
pyrrole 3.16b gave greater levels of the diagnostic product ion. The signal intensity of 
4.27, derived from the pyrrole-dipeptide adduct 3.29b, was lower than expected due to a 
reduced level of fragmentation which resulted from the use of electro spray ionisation 
LRMS. The technique of electron impact ionisation was therefore deemed more suitable 
for the elucidation of R\ as this method is known to cause a greater level of parent ion 
fragmentation, and consequently more of the product ion would be observed. 
Future work could involve the determination of other ftmctional groups that have the 
ability to be derivatised and subsequently revealed by this methodology. Any difference in 
the behaviour of these novel pyrrolizinones under both UV spectroscopy and mass 
spectrometry, in comparison to that of the amino acid-based pyrrolizinones, would be 
determined. An investigation towards the potential of Beers Law as a means for 
determining what group was adjacent to the pyrrolizinone could also be undertaken. The 
application of this two-step derivatisation method to the sequencing of peptides could also 
be investigated. 
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CHAPTER FIVE 
DEVELOPMENT OF 
5-(HYDROXYMETHYL)PYRROLE-
BASED DNAALKYLATING AGENTS 
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5.1 INTRODUCTION 
Cancer is a disease characterised by the uncontrolled growth and division of cells within 
the body. 1 Treatment of a patient suffering from cancer is often dependent on the 
adnlinistration of therapeutic agents which inhibit the growth of tumour cells, resulting in 
destruction of the tumour by the body's immune system. One class of antitumour agent 
relies on alkylation of the genetic material for activity, whereby a covalent bond is formed 
between the compound and a nucleophilic site within the DNA. A wide range of reactive 
functionalities can alkyl ate DNA, and in particular the nitrogen mustards such as 
chlorambucil (1.51, Figure 5.1) have become the most common alkylating agents.2 DNA 
alkylation has also been effected by hydroxymethylpyrrole-based compounds. The bis-
alcohols 5.1/ 5.24 and 1.695 were determined to alkyl ate DNA. Greater affinity for the 
genetic material was endowed upon 5.2 and 1.69 by the attachment of minor groove 
binding and intercalating moieties respectively. 
~Cl 
~N~ 
R02C Cl 
1.51 
R0?!JRO 
/ \ 
. N Ph 
5.1 
RO 
OR 
R ~H :/1 H rON N ~ ~ M'zN~N~ ~~ \ 3 OR HN 
0 IC¢OI o Me 5.2 1.69 / I Minor groove 
binding unit Intercalating unit 
Figure 5.1. Structure of the representative nitrogen mustard chlorambucil (1.51), and the 
hydroxymethylpyrrole-based DNA alkylators 5.1, 5.2 and 1.69. 
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A mechanism for DNA alkylation by pyrrole-derived cross-linking agents has been 
proposed6 (Scheme 5.1). The pyrrolizine 5.3, which was reported to cross-link short 
oligonucleotides,7 is converted to the reactive azafulvene 5.4, which is subsequently 
attacked by a DNA nucleophile to give adduct 5.5. This reaction sequence occurs again to 
give the cross-linked adduct 5.7. 
OCONHCHMe2 OCONHCHMe2 
CI 
(' 
1 \ J OCONHCHMe2 
N2) 
1(f)/-
:)\ 
• CI HNu-DNA ~ N) 
CI CI 
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5.3 5.4 
J 
DNA-~ C OCONHCHMe2 
X-DNA Nu-DNA 
CI .. CI 
CI CI 
5.6 5.5 
J 
DNA 
" Nu 
Nu....--DNA 
CI ~ N 
CI ~ 
5.7 
Scheme 5.1. Cross-linking of DNA by 5.3. The nucleophilic sites in DNA are represented 
asDNA-NuH. 
Other pyrrolic compounds display potential as antitumour agents. The moderate anticancer 
cell line activity of twelve 5-(hydroxymethyl)pyrrole-based metabolites, isolated from the 
Atlantic sponge Mycale micracanthoxea, was reported by Ortega, et al.8 The 
representative examples 5.8a (mycalazol 5) and 5.8b (mycalazol 11) are displayed in 
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Figure 5.2. Compounds of type 5.8 possess an acyl side chain, of variable length and 
unsaturation, at the C2 position. A previous report9 from these laboratories detailed a 
synthetic route that afforded this class of compounds by reaction of a stannylpyrrole and 
fatty acid chlorides under Stille coupling conditions. While compounds of type 5.8 
displayed moderate activity against the P388 murine leukaemia cell line, this study did 
illustrate the potential application of the 5-(hydroxymethyl)pyrrole moiety toward the 
development of compounds with anticancer activity. 
5.8a 
5.8b 
Figure 5.2. Structure of mycalazol5 (5.8a) and mycalazolll (5.8b). 
The 5-(hydroxymethyl)pyrrole functionality was utilised in Chapter Three as a reactive 
moiety to which an enzyme active site residue becomes covalently attached. Concurrent to 
that study was the development of 5-(hydroxymethyl)pyrroles, based on the general 
structure 5.9 (Figure 5.3), as DNA alkylating agents. Whilst the 5-(hydroxymethyl)pyrrole 
moiety possessed by compounds of type 5.8 is retained in the structure of 5.9, the aliphatic 
chain of 5.8 has been replaced by an intercalating moiety, appended to C2 via an alkyl 
linker. 
5-(Hydroxymethyl)-
pyrrole 5.9 
\.~--~---~) Y 
Intercalator 
Figure 5.3. General structure 5.9 of the proposed DNA alkylating agents. 
Compounds of type 5.9 possess three important structural elements. The first is an 
intercalator, a planar aromatic moiety that is able to insert between pairs of complementary 
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bases in the DNA double helix (see Chapter One, Section 1.3 for further discussion). This 
would introduce the property of DNA affinity into compounds of type 5.9. Figure 5.4 
illustrates the proposed interaction of 5.9 with the genetic material, with the intercalator 
inserted between the base pairs. The second element is an alkyl linker, which endows 
flexibility upon 5.9, allowing positioning of the 5-(hydroxymethyl)pyrrole moiety into 
close proximity to DNA nucleophiles. The activity displayed by compounds of type 5.9 
towards cancer cells was proposed to be dependent on the alkylation of DNA by the 5-
(hydroxymethyl)pyrrole functionality. 
5' 3' 
HO 
NuH 
HN,1-
X 
3' 5' 
Figure 5.4. Schematic representation of the interaction of 5.9 with DNA (NuH = reactive 
site on DNA). The double helix is represented in an unwound state for clarity. 
DNA alkylation by compounds of type 5.9 is proposed to occur by the mechanism 
illustrated in Scheme 5.2. This process is analogous to those postulated for the 5-
(hydroxymethyl)pyrrole-based a-chymotrypsin inhibitors (see Chapter Three, Section 3.1), 
and the pyrrole-derived cross-linking agents (see Scheme 5.1). To this end, azafulvene 
5.10 is generated from the 5-(hydroxymethyl)pyrrole 5.9, and subsequent attack by a DNA 
nucleophile affords adduct 5.11. 
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5.11 
Scheme 5.2. Proposed reaction of 5.9 with a nucleophile present within DNA (represented 
as DNA-NuH) to afford adduct 5.11. 
This chapter initially describes the synthesis towards compounds of type 5.9, with 
structural variations restricted to the intercalating moiety. The prepared compounds were 
then assayed for activity against the P388 cancer cell line to give a preliminary 
understanding of the structure-activity relationships for this class of compound. 
Additionally, compounds of type 5.9 were assayed against representative microbes and 
viruses to determine the activity of this class of compounds against these important 
pharmaceutical targets. 
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5.2 MODEL SYNTHETIC STUDIES TOWARDS 5-(HYDROXYMETHYL)-
PYRROLE-BASED DNA ALKYLATORS 
A model synthetic study, with the general structure 5.12 (Scheme 5.3) the initial target, 
was undertaken to determine the optimal route to compounds of type 5.9. A naphthyl 
moiety was chosen to act as an intercalator surrogate due to the availability of suitable 
naphthalene derivatives. The retrosynthetic analysis outlined in Scheme 5.3 illustrates that 
compounds of type 5.12 would be best obtained by reduction of 5.13. Disconnection of 
5.13 gives the pyrrole acid 3.16b and 5.14, which is the linker-carbocycle adduct derived 
from a naphthyl starting material (5.15). 
HO~Xtr.Y~ 
H 0 Vv 
5.12 
Scheme 5.3. Retrosynthetic analysis for 5.12. 
n X y 
> OHC/ "~/ Y 'M: ~ 
H 0 
5.13 
3.16b 5.14 
5.15 
Preparation of the key intermediate represented by 5.14 was initially undertaken. This 
target required a nucleophilic moiety for subsequent coupling to 3.16a (see Scheme 5.3). 
The aromatic compound chosen to act as an intercalator surrogate was naphthalen-l-
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ylamine (5.16, Scheme 5.4). Reaction of 5.16 with SUCCllliC anhydride in refluxing 
toluenelo gave the acid 5.17a in 91 % yield. Attempted reduction of 5.17a to the alcohol 
5.18 with LAH gave a complex mixture of products by lH NMR spectroscopy and TLC. 
Derivatisation of the carboxylic acid of 5.17a was considered a means to generate a moiety 
more suited for reduction. To this end, esterification of 5.17a with diazomethane afforded 
5.17b in 70% yield. However, reduction of 5.17b with LAH, or the milder reducing agent 
DIBALH, again gave a mixture of products by lH NMR spectroscopy and TLC. 
Alternatively, 5.17a was converted to its acid chloride 5.17c by reaction with oxalyl 
chlorideIDMF. Reduction of 5.17c with either LAH or DIBALH gave a mixture of 
products by lH NMR spectroscopy. At this stage, work towards the reduction of 5.17a-c to 
the alcohol 5.18 was abandoned. 
(i) 
>< .. .. 
5.16 C 5.17aRl=OH:= (ii) 5.17b Rl = OMe (iii) 
5.17cR1 = CI 
5.18 
Scheme 5.4. Reagents and conditions: (i) Succinic anhydride, PhMe, reflux, 15 min 
(91 %). (ii) CH2N2, THF, r.t., 15 h (70%). (iii) (COClh DMF(cat.), CH2Cb, r.t., 1 h (not 
isolated). 
Preparation of the key intermediate 5.18 was achieved as illustrated in Scheme 5.5. Amine 
5.16 was reacted with succinic anhydride in refluxing toluene, then treated with sodium 
acetate in acetic anhydridel1 to afford the succinimide 5.19 in 86% yield over two steps. 
Reduction and ring-opening of 5.19 with sodium borohydride in 6: 1 iso-propanollwater12 
gave 5.18 in 71 % yield. A BOP-Cl-mediated coupling13 of 3.16b and 5.18 afforded 5.20, 
and reduction of the coupled product with lithium borohydride gave 5.21 in 18% yield over 
two steps. 
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Scheme 5.5. Reagents and conditions: (i) Succinic anhydride, PhMe, reflux, 15 min. (ii) 
CH3C02Na, AC20, 70-80°C, 4.5 h (86% over two steps). (iii) NaBH4, 6:1 iPrOH!H20, r.t., 
17 h (71 %). (iv) 3.16b, BOP-CI, Et3N, CH2Ch, r.t., 64 h. (v) LiBH4, THF, -78°C, 1 h, then 
r.t., 1 h (18% over two steps). 
5.3 ATTEMPTED SYNTHESIS OF A 5-(HYDROXYlVIETHYL)PYRROLE-
BASED DNA ALKYLATOR WITH AN ANTHRACENE INTERCALATIVE 
MOIETY 
Preparation of the naphthyl-based compound 5.21 yielded a general synthetic method for 
the introduction of a range of aromatic moieties into compounds of type 5.9. Hence, the 
structure-activity relationships for this class of compounds could be investigated. 
Generally, a fused tricyclic structure is required for intercalation14 (although some 
exceptions exist, see Chapter One, Section 1.3 for further discussion). Therefore, an 
anthracene ring system was chosen to be the first example of a "true" intercalator 
incorporated into compounds of type 5.9. The synthetic target 5.22 is illustrated in Figure 
5.5, in addition to bisantrene (5.23), an example of a clinically trialed anticancer agent 
based on an anthracene ring system.15 
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Figure 5.5. Structures of the synthetic target 5.22 and bisantrene (5.23). The anthracene 
ring system is highlighted in both compounds. 
The synthesis of 5.22 (Scheme 5.6) was attempted in a manner analogous to that of 5.21. 
Anthracen-2-ylamine (5.24) was reacted with succinic anhydride, followed by treatment 
with sodium acetate/acetic anhydride, to afford the succinimide 5.25 in 89% yield over two 
steps. Reduction/ring opening of 5.25 with sodium borohydride gave alcohol 5.26 with a 
quantitative return of material, and this crude product was coupled to the pyrrole acid 
3.16a by BOP-CI methodology. However, the IH NMR spectrum obtained after workup 
revealed a weak resonance at 0 4.28 ppm, corresponding to C02Cfu (marked * in Scheme 
5.6), hence 5.27 was a minor product. The low yield of coupled product resulted from the 
insolubility of 5.26 in dichloromethane. Prior studies revealed a polar solvent such as 
DMF did not effect the coupling of 3.16a to 5.18a to afford 5.20 (see Scheme 5.5), and as 
such further attempts towards the synthesis of 5.22 were abandoned. 
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Scheme 5.6. Reagents and conditions: (i) Succinic anhydride, PhMe, reflux, 1 h. (ii) 
CH3C02Na, AC20, 70-80°C, 4.5 h (89% over two steps). (iii) NaBH4, 6:1 iprOH1H20, r.t., 
17 h (quantitative crude yield). (iv) 3.16b, BOP-Cl, Et3N, CH2Clz, r.t., 64 h. 
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5.4 ATTEMPTED SYNTHESIS OF A 5-(HYDROXYMETHYL)PYRROLE-
BASED DNA ALKYLATOR WITH A HETEROCYCLIC INTERCALATOR 
A heterocyclic intercalator, in place of the carbocyclic moiety possessed by 5.26, was 
proposed to overcome the low yield encountered in the coupling step between 3.16a to 
5.26 due to an improved solubility profile. The following section details the work towards 
the synthesis of a compound of type 5.9 that possessed such a moiety. 
5.4.1 Model synthetic studies with 8-aminoquinolene as an intercalator surrogate 
Quinolin-8-ylamine (5.28, Scheme 5.11) was used as a model heterocycle to determine 
whether the synthetic route developed for the naphthyl-based analogue 5.21 was applicable 
to an example with a heterocyclic moiety. To this end, 5.28 was reacted with succinic an-
5.28 
HO n O~ ~ "~/); CONH N 
5.31 
-:?' I' 
~ ~ 
5.29 
(iii) 
5.30 
Scheme 5.7. Reagents and conditions: (i) Succinic anhydride, PhMe, reflux, 15 min. (ii) 
CH3C02Na, AC20, 70-80°C, 4.5 h (79% over two steps). (iii) NaBH4, 6:1 iPrOHlH20, r.t., 
17 h. (iv) 3.16b, BOP-CI, Et3N, CH2Ch, r.t., 64 h. (v) LiBH4, THF, -78°C, 1 h, then r.t., 1 
h (11 % over three steps). 
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hydride, then treated with sodium acetate/acetic anhydride, to afford the succinimide 5.29 
in 79% yield over two steps. Reduction of 5.29 with sodium borohydride gave the alcohol 
5.30, which was subsequently coupled to 3.16b by BOP-CI methodology. The coupled 
product was reduced with lithium borohydride to give the desired product 5.31 in 11 % 
yield over three steps. 
5.4.2 Attempted synthesis of a 5-(hydroxymethyl)pyrrole-based DNA alkylator with 
an acridine intercalative moiety 
Preparation of the putative intercalating alkylator 5.32 (Figure 5.6), which incorporated an 
acridine ring system into its structure, was subsequently undertaken. Many antitumour 
agents intercalate as a result of an acridine group, and the example of amsacrine (1.57)16 is 
displayed in Figure 5.6 (see Chapter One, Section 1.3 for further examples of compounds 
with acridine moieties). 
HO n o~l ~"~/y NH 
H 0 ~ ~ 
I~ 
5.32 
'Acridine/ 
ring system 
1.57 
Figure 5.6. Structures of the synthetic target 5.32 and amsacrine (1.57). The acridine ring 
system is highlighted in both compounds. 
The synthetic route to 5.32 is illustrated in Scheme 5.8. Acridin-9-ylamine (5.33) was 
treated with succinic anhydride in refluxing DMF in place of toluene, due to the 
insolubility of 5.33 in non-polar solvents. Treatment of the intermediate acid with sodium 
acetate/acetic anhydride afforded the succinimide 5.34 in 35% yield over two steps. 
Reduction and ring opening of the succinimide gave the alcohol 5.35 in 89% crude yield, 
which was subsequently reacted with pyrrole acid 3.16b under BOP-CI coupling 
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conditions. The coupled product was reduced with lithium borohydride to afford 5.32 in a 
very low yield «5%) and an impure state despite several attempts to effect purification by 
chromatography and recrystallisation. HRMS analysis confirmed the presence of 5.32 by 
the accurate mass obtained for protonated product (C23H22N304 404.1600 g mor!, 
calculated mass 404.1610 g mof l ). 
(i), (ii) 
5.33 
(iv), (v) 
.>< 
5.32 
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5.34 
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~ V~T4 N 
5.35 
Scheme 5.8. Reagents and conditions: (i) Succinic anhydride, DMF, reflux, 30 min. (ii) 
CH3C02Na, Ac20, 70-80°C, 4.5 h (35% over two steps). (iii) NaBH4, 6:1 iPrOH!H20, r.t., 
17 h (89% crude). (iv) 3.16b, BOP-CI, Et3N, CH2Ch, r.t., 64 h. (v) LiBH4' THF, -78°C, 1 
h, then r.t., 1 h. 
The mixture containing 5.32 was analysed by reverse-phase HPLC (Figure 5.7). 
Expansion of the trace between 7.9-10.7 min revealed four compounds of similar polarity. 
Other peaks in the spectrum are solvent and impurity peaks found in all HPLC traces that 
utilise this particular solvent system (see Experimental for details). The mass spectrum 
obtained from analysis of the mixture by electrospray ionisation LRMS contained ions 
corresponding to protonated 5.32 (C23H22N304 404.2 g mor l ) and protonated 5-
fonnylpyrrole precursor (C23H20N304 = 402.2 g mor l ). Ions were also observed that were 
two mass units lower than that expected for 5.35, and one mass unit lower than that 
expected for 3.16b, which suggested that these compounds were present, and 
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rearrangements were occumng during mass spectrometry to gIVe the observed ions. 
Because of the low yields and extreme difficulties encountered with purification, the 
synthesis of 5.32 was abandoned. 
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Figure 5.7. HPLC trace of 5.32, with the region between 7.9-10.7 min expanded to 
illustrate the impure nature of the sample. 
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5.5 ATTEMPTED SYNTHESIS OF A 5-(HYDROXYMETHYL)PYRROLE-
BASED DNA ALKYLATOR CAPABLE OF ACTING AS A THREADING 
INTERCALATOR 
Threading intercalation is a binding mode whereby an intercalative moiety directs two 
substituents into each groove of the double helix simultaneously17 (see Chapter 1, Section 
1.3.2 for further discussion). The synthetic target 5.36 (Figure 5.8) was proposed to 
interact with DNA in this manner. Two distal 5-(hydroxymethyl)pyrrole-linker groups are 
appended to an acridine core, i. e. the reactive functionalities could potentially alkylate 
DNA at two separate sites per molecule of 5.36. Figure 5.8 also illustrates the 
representative threading intercalator 1. 78, 17 and the structural similarities between 5.36 and 
1. 78 are highlighted. 
Intercalating 
unit "-
O~~~ 0 
HO n o~ j~o n OH 
'--./ "~/ I( N N i( "~/ ~ 
H 0 H H 0 H 
1.78 
Intercalating 
unit 
Groove binding 
substituents 
5.36 
Figure 5.8. Synthetic target 5.36, and the representative threading intercalator 1.78. The 
acridine and groove binding structural features are highlighted in both compounds. 
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To this end, 3,6-diaminoacridine (5.37, Scheme 5.9) was reacted with succinic anhydride 
in refluxing pyridine,18 then treated with sodium acetate/acetic anhydride, to afford the 
succinimide 5.38 in a low yield of 5% over two steps. Reduction of 5.38 with sodium 
borohydride gave crude alcohol 5.39 (determined by IH J'lNIR spectroscopy) with a mass 
return of 84%. The attempted BOP-Cl-mediated coupling of 3.16b to 5.39 gave an 
intractable mixture. Analysis by electro spray ionisation LRMS revealed an ion at 624.0 g 
mor\ corresponding to the mass ofprotonated 5.40, however the IH NlVIR spectrum of the 
mixture indicated that 5.40 was a minor product. The synthesis of 5.36 was abandoned at 
this stage due to the low yields encountered in the preparation of key intermediates (cf 
synthesis of 5.22 and 5.32). 
(i), (ii) 
5.37 
(iii) j 
o ~ 0 
>K HO~ ~"T~ ~OH (iv) '---______ ------, ~ N ~ ~ 5.39 
O~~~ 0 
'/\ 0 I ~ 0/\ OHC~ ~N --" N --" N~ y~CHO 
H 0 H H 0 H 
5.40 
t 
o ~ 0 
HO n O~ ~,,~ ~O ~OH ~"~/y N N N i(N 
H 0 H H 0 H 
5.36 
Scheme 5.9. Reagents and conditions: (i) Succinic anhydride, pyridine, reflux, 2 h. (ii) 
CH3C02Na, AC20, 70-80°C, 4.5 h (5% over two steps). (iii) NaBH4, 6:1 iprOH!H20, r.t., 
17 h (84% crude). (iv) 3.16b, BOP-CI, Et3N, CH2Ch, r.t., 64 h. 
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5.6 SYNTHESIS OF A 5-(HYDROXYMETHYL)PYRROLE SUBSTRUCTURE 
ANALOGUE 
The postulated mechanism of DNA alkylation by compounds of type 5.9 in Scheme 5.2 is 
mediated by the latent reactivity of the 5-(hydroxymethyl)pyrrole functionality. The 
biological activity of the 5-(hydroxymethyl)pyrrole substructure analogue 5.41 was to be 
compared against that elicited by 5.21 and 5.31 to determine the importance of this 
substructure for activity. Any additional activity displayed by 5.21 and 5.31 would result 
from interaction of the linker-aromatic structure possessed by these compounds with the 
genetic material. To this end, the 5-formylpyrrole 3.16a (Scheme 5.10) was reduced with 
lithium borohydride to give 5.41, in 76% yield, for use in the assays. 
3.16a 
(i) n ----»-~ HOJ'T~ 
N C02Et 
H 
5.41 
Compare activity of 5.41 to: 
HO fl O~ ~ "~/ i( NH 
H 0 ~ 
5.21 VU 
o 
HO fl O~ ~ "~/ r ooNH N
-:?' I " 
5.31 ~ 0 
Scheme 5.10. Reagents and conditions: (i) LiBH4, THF, -78°C, 1 h, then Lt., 1 h (76%). 
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5.7 BIOLOGICAL ASSAYS 
The following subsections give background infonnation to the antitumour, antiviral and 
antimicrobial assays, in addition to the activities of six compounds (see Table 5.1) in each 
assay. Naphthylen-1-ylamine (5.16) and quinolin-2-ylamine (5.28) were submitted for 
comparison of their activities to that of the 5-(hydroxymethyl)pyrrole-based compounds 
that possessed these ring systems (5.21 and 5.31 respectively). A representative tricyclic 
aromatic starting material (5.37) was submitted for comparison of its biological activity to 
that of the bicyclic starting materials 5.16 and 5.28. Submission of the 5-
(hydroxymethyl)pyrrole substructure analogue 5.41 allowed elucidation of this moieties 
biological activity. Additionally, the binding constant of 5.31 to DNA was detennined. 
5.7.1 Antitumour assay 
The antitumour assay is the most sensitive assay for cytotoxicity. Results from the P388 
assay are given as an 1Dso value, which expresses the sample concentration required to 
reduce the growth of P388 murine leukaemia cells by 50%, in comparison to the control 
cells.19 The IDso value is detennined using the absorbance values (detected at 540 nm) 
obtained when the yellow dye MTT tetrazolium (5.42, Scheme 5.11) is reduced in the 
mitochondria of viable leukaemia cells to the purple coloured MTT fonnazan (5.43). 
Reduction 
5.42 
Scheme 5.11. Reduction of yellow MTT tetrazolium 5.42 to purple MTT fonnazan 5.43 
by viable leukaemia cells. 
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Increased cytotoxicity is revealed by a lower ID50 value. The ID50 value is expressed as Ilg 
mrl, and results that contain a > sign indicate that the sample was not concentrated 
enough for an ID50 value to be determined. 
Table 5.1 displays the activity determined for 5.16, 5.21, 5.28, 5.31, 5.37 and 5.41. The 
standard method of expressing the ID50 values (column 4) has also been calculated to give 
ID50 values as molar concentrations (column 5). This was done to more accurately 
compare the activities of the compounds assayed against the P388 cancer cel1line. 
No. Solvent Sample concentration ID50 ID50 
system * (mg mL-1t (Ilg mL-1) (11M) 
co A 10 87 611 4- 4-
5.16 
-J) 0 HO '/ \ 0 B 20 165 468 N l(~NH 
H 0 Co 
5.21 i 4- h 
A 10 13 88 
5.28 
A 10 111 314 
B 1 2.0 9.4 
5.37 
A 10 >125 >739 
H 
5.41 
*A 3: 1 MeOHIDMF 
Table 5.1. Activity of5.16, 5.21, 5.28, 5.31, 5.37 and 5.41 against the P388 cell line. 
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A 23% increase in activity was observed for the 5-(hydroxymethyl)pyrrole 5.21 (ID50 = 
468 J..lM), compared to its naphthyl starting material 5.16 (ID50 = 611 J..lM). In contrast, 
quinolin-8-amine 5.28 (ID50 = 88 J..lM) was 3.5-fold more active than the 5-
(hydroxymethyl)pyrrole 5.31 (ID50 = 314 J..lM), derived in five steps from 5.28. The 5-
(hydroxymethyl)pyrrole substructure analogue 5.41 displayed no activity. All compounds 
were appreciably less active than 5.37. The increased ability of 5.37 to restrict cell 
proliferation, compared to 5.16, 5.21, 5.28, 5.31 and 5.41, must result from the tricyclic 
ring system of 5.37 binding tightly to the genetic material by intercalation. 
5.7.2 Antiviral assay 
The membrane enveloped RNA virus Polio type 1 (Pfizer vaccine strain, PV 1) and the 
non-membrane enveloped DNA virus Herpes simplex type 1 (ATC VR 733, HSV 1) were 
the test viruses used in this assay. African green monkey kidney cells (BSC-l), grown on 
the surface of plastic wells, were used as host cells for the test viruses. 
A scale is used to record the antiviral and cytotoxic zones of inhibition which surrounds 
the discs onto which the sample of interest was loaded: 
ND No discemable antiviral or cytotoxic effects 
± Minor effects located under the disc 
+ Antiviral or cytotoxic zone 1-2 mm excess radius from the disc (25%) 
2+ Antiviral or cytotoxic zone 2-4 mm excess radius from the disc (50%) 
3+ Antiviral or cytotoxic zone 4-6 mm excess radius from the disc (75%) 
4+ Antiviral or cytotoxic zone over the whole well (100%) 
+* Light toxicity throughout the whole well 
? Unable to determine level of antiviral activity due to strong cytotoxicity. 
Needs to be re-assayed at lower concentration. 
?* No antiviral activity as the virus is growing right up to the cytotoxic zone 
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Interpretation of the results can be difficult where both cytotoxic and antiviral effects are 
present because strong cytotoxicity will mask any antiviral activity within the cell. The 
results for 5.16,5.21,5.28,5.31,5.37 and 5.41 are displayed in Table 5.2. 
No. PV1 HSV1 
Antiviral Cytotoxic Antiviral Cytotoxic 
effects effects effects effects 
& 7 4+ 7 4+ / / 
5.16+ 
Ho~o~l ND ND ND JID N NH 
H 0 60 
5.21# I / / 
NH2 
6:) 7* 2+ 7* 2+ / / 
5.28+ 
Ho~o~l 
r, 0 60 7 4+ 7* 3+ 
'" '" 5.31+ I / / 
on 7* + 7* 2+ H2N / N'" / NH2 
5.37+ 
HO~ 
ND N C02Et H ND ND ND 
5.41+ 
.. 
+ ACtIVIty tested III the solvent system and sample concentratIOn specIfied III Table 5.1. 
# Activity tested in solvent system A at 10 mg mL-1. 
Table 5.2. Activity of 5.16, 5.21, 5.28, 5.31, 5.37 and 5.41 against the Polio type 1 virus 
(PV 1) and Herpes simplex type 1 virus (HSV 1). 
The antiviral activity of 5.16 could not be determined because of a strong cytotoxic effect 
(denoted as 7) towards the kidney cells used as viral hosts in the assay. Amines 5.28 and 
5.37 displayed no antiviral effects beyond the cytotoxic region (denoted as 7*). The 
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antiviral activity of 5.31 against PV 1 could not be detennined due to strong cytotoxicity. 
No antiviral effects were displayed by 5.31 against HSV 1 beyond the cytotoxic region. 
No antiviral or cytotoxic activity was observed for 5.21 and 5.41. 
5.7.3 Antimicrobial assay 
A zone of growth inhibition is used to test for antimicrobial activity. The samples of 
interest are adsorbed onto separate paper discs, allowed to dry and placed on a seeded agar 
plate of the organism of interest. The zone of growth inhibition around the disc is 
measured (mm) after an incubation period. Six test organisms were used in the assay 
(names in parentheses are the abbreviations used in Table 5.3): 
Bacteria: Escherichia coli (E coli), Bacillus subtilis (B sub)*, Pseudomonas aeruginosa (P 
aer) 
Fungi: Candida albicans (C alb), Trichophyton mentagrophytes (T ment)*, Cladosporium 
resinae (C res) 
* most sensitive organisms. 
Table 5.3 presents the activity of 5.16, 5.21, 5.28, 5.31, 5.37 and 5.41 against the six 
microbial species. The activity of these compounds is compared to that generated by discs 
containing 10 Ilg of gentamycin (an antibacterial agent selective for the Gram negative 
species coli and P. aeruginosa), 30 Ilg of chloramphenicol (an antibacterial agent 
selective for the Gram positive species B. subtilis), and 20 Ilg of nystatin (an antifungal 
agent). 
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No. Bacteria Fungi 
E coli Bsub Paer Calb Tment Cres 
00 4 3 1 10 22 10 ~ ~
5.16+ 
HO~O~ -~ - - - - -N NH 
H 0 60 
5.21# I ~ ~ 
NH2 
CO 3 10 - 15 10 15 ~ ~
5.28+ 
HO~O~ 1 ~ 0 60 - - - - -
"'" " 5.31+ I ~ ~ 
an H2N ~ N'" ~ NH2 2 10 1 1 6 3 
5.37+ 
HO~ N C02E! - - - - 3 -
H 
5.41+ 
Gentamycin 10 10 
Chloramphenicol 13 
Nystatin 10 7 12 
+ Activity tested in the solvent system and sample concentration specified in Table 5.1. 
# Activity tested in solvent system A at 10 mg mL-1. 
~ No activity observed. 
Table 5.3. Activity of 5.16, 5.21, 5.28, 5.31, 5.37 and 5.41 against selected microbial 
species. 
None of the 5-(hydroxymethyl)pyrrole-based compounds (5.21, 5.31 or 5.41) displayed 
antibacterial activity, which suggests that compounds based on this structural motif are not 
effective bacterial growth inhibitors. The aromatic amines 5.16, 5.28 and 5.37 displayed 
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mild activity against E. coli and P. aeruginosa, but it was noticeably less than that elicited 
by gentamycin. Activity similar to that recorded for chloramphenicol against B. subtilis 
was displayed by the heterocyclic amines 5.28 and 5.37, whereas the carbocyclic amine 
5.16 was less active. The 5-(hydroxymethyl)pyrrole 5.21 was totally inactive against all 
fungal species. The other pyrrolic compounds, 5.31 and 5.41, were less active against T. 
mentagrophytes than nystatin, and they did not inhibit c. albicans and C. resinae growth. 
Amines 5.16, 5.28 and 5.37 were active against all fungal species, with 5.37 being 
noticeably weaker than 5.16 and 5.28. Amine 5.28 displayed similar activity to nystatin 
against the three fungal species. Interestingly, the carbocyc1e 5.16 was comparable to 
nystatin for C. albicans and C. resinae growth inhibition, whereas its inhibition of T. 
mentagrophytes growth was three times higher than nystatin. Overall, compounds 5.21, 
5.31 and 5.41 were poor antimicrobial agents. 
5.7.4 Determination of the binding constant of 5.31 to DNA 
The relatively low activity displayed by 5.31 against the P388 cell line (see Table 5.1) 
could have resulted from a low affinity for DNA. Baguley et apo reported a method for 
determining the DNA binding activity of a compound, relative to ethidium bromide (1.56, 
Figure 5.9), by measurement of the competition for DNA binding sites. Compound 5.31 
was submitted for analysis,~ and it had a 3,000-fold lower affinity for poly[dA-dT] (4.6 x 
103 M-1) and poly[dG-dC] (3.0 x 103 M-1) than 1.56 (1.1 x 107 M-1), i.e. 5.31 had a 
relatively low affinity for DNA. The equations in reference 20 were used by the 
experimentalist~ to calculate the binding constants for 5.31, however the endpoint of the 
assay (20% displacement of 1.56 by 5.31) was different to that typically used (50% 
displacement) due to the low solubility of 5.31 in the assay.21 The binding mode of 5.31 to 
DNA is not determined in this assay, as both groove binding agents and intercalators 
compete with 1.56.22 A separate assay which determines whether intercalation is occurring 
by the unwinding ofDNA5 could not be performed due to the poor solubility of 5.31 in the 
11 The author would like to thank Professor Bruce Baguley at the Auckland Cancer Society Research Centre 
for performing the assays, and calculating the binding constants. 
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assay.21 However, 5.31 is unlikely to bind DNA as a result of intercalation, due to the lack 
of a tricyclic aromatic ring system. 
HO ft O~ ~ "~/ r 60NH N 
5.31 
I ~ " 
// // 
K (poly[dA-dTJ) = 4.6 x 103 M-1 
K (poly[dG-dCJ) = 3.0 x 103 M-1 
Ph 
1.56 
K (poly[dA-dT] or poly[dG-dCJ) = 1.1 x 107 M- 1 
Figure 5.9. DNA binding assay results for 5.31 and the classical intercalator 1.56. 
5.8 DETERMINATION OF THE ABILITY OF 5.31 TO ALKYLATE AN 
AROMATIC AMINE 
The alkylating activity displayed by compounds of type 5.9 was reliant on the formation of 
a covalent bond to DNA. The mild activity of 5.21 and 5.31 against the P388 cell line 
could have resulted from the inability of the 5-(hydroxymethyl)pyrrole functionality to 
alkylate the genetic material. A model system was devised to elucidate whether 5.31 could 
alkylate aniline (5.44, Scheme 5.12) to give adduct 5.45. This system was postulated to 
mimic the reaction between DNA nucleophiles and compounds of type 5.9 (see Scheme 
5.2). Two equivalents of 5.44 were added to one equivalent of 5.31 in acetonitrile, and 
incubated at 37°C for 48 h. The first equivalent of 5.44 was added to induce azafulvene 
formation by deprotonation of the pyrrole ring nitrogen (see Scheme 5.2). Nucleophilic 
attack by the second equivalent of 5.44 upon the azafulvene would result in adduct 5.45. 
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+ 
5.44 
HO n O~ ~'~/y NH 
H 0 ttl 
-:;/ I '" 
5.31 ~,....-::. 
HJ)y 0 N / \ 0 II ~ ~NH V HO CON I '" 
5.45 ~,....-::. 
Scheme 5.12. Reaction of aniline (5.44) and 5.31 to afford 5.45. 
The HPLC traces for separate samples of5.31 and 5.44 are displayed in Figure 5.10. The 
peaks below 5 min, and between 33-34 min , were artefacts of the solvent system used for 
HPLC analysis (see Experimental for details) . 
_ :~:~~:;'In~" "'01 ."eel"''" ........ 1 
- OC"' ~I' 
DC ... " . .... DCM ' 41c 
.. , 
HO~O~ ~ 0 60 
-;? " 
"" I h 
"" 
7" 
... 
5.31 (red trace) 
ONH2 
5--'-' (black tmce) 
lOG 
, .. 
· 00 
) ~t 
0 0 <1 ~ S O 7~ 100 125 15 0 IHt .1:00 22 .$ 25 0 l1! ;wJ1J Jl~ 1~ O 315 .too 
M61ut • • 
Figure 5.10. HPLC analysis of separate samples of 5.31 (red trace) and 5.44 (black trace). 
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Progress of the reaction between 5.31 and 5.44 was monitored by reverse-phase HPLC 
analysis after ° h (blue trace), 24 h (green trace) and 48 h (pink trace) (Figure 5.11). A 
large peak eluted at approximately 12 min in all three HPLC analyses (cftrace for 5.31 in 
Figure 5.10, major peak elutes at approximately 12 min). After 24 h, this large peak was 
collected and analysed by mass spectrometry. The base peak in the spectrum had a mass 
of 354.1 g mor l , corresponding to protonated 5.31. Analysis by mass spectrometry of the 
minor peaks at approximately 13 and 17.5 min revealed that they were unknown 
byproducts, i.e. adduct 5.45 was not being formed . 
5000 •• "bllm .... " •• 1 
- OC .. ''1''.I ••• '' .... . . " 
OC .. ,y".' .... "III" • • • " 
" .. 
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"" 
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" " " 
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- OC .... pyrul •• ' '' .. In . . .. " 
.,_" .. "' ...... 101 
OCMIIY" ' o .o .... ,lno · l o" !U'IOQ 
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"" ."ul • • 
Figure 5.11. Traces from the HPLC analysis of the reaction between 5.44 and 5.31 after ° 
h (blue), 24 h (green) and 48 h (pink). 
These findings suggested that 5-(hydroxymethyl)pyrroles of type 5.9 are not reactive 
enough, under mild conditions, to undergo nucleophilic substitution of the hydroxyl group 
by an aromatic amine. As a result, this scaffold may not effect DNA alkylation. 
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5.9 CONCLUSION AND FUTURE WORK 
The 5-(hydroxymethyl)pyrrole scaffold was used as the basis from which a new class of 
putative DNA alkylating agents, of type 5.9, were developed. Model synthetic studies 
yielded 5.21 and 5.31, which possess bicyclic naphthyl and quinolyl ring systems 
respectively as intercalator surrogates. However, the attempted preparation of 5.22 and 
5.32, which. incorporate anthryl and acridinyl intercalating moieties respectively, was 
unsuccessful due to low yields and difficult purification. Preparation of 5.36, a proposed 
DNA alkylator whose projected mode of binding to the genetic material was by threading 
intercalation, was also unsuccessfuL 
The biological activity of the pyrroles 5.21 and 5.31, the aromatic amine starting materials 
5.16 and 5.28 (used in the preparation of 5.21 and 5.31 respectively), a representative 
tricyclic structure 5.37, and the pyrrole substructure analogue 5.41 was tested. Amine 5.16 
was slightly less active against the P388 murine leukaemia cell line than 5.21, whereas 
amine 5.28 was 3.5-fold more effective than 5.31. Diamine 5.37 was noticeably more 
active than all the other compounds in the cancer cell line assay. Compound 5.41 was 
inactive against the cancer cell line. None of the compounds demonstrated antiviral 
activity. Compound 5.21 showed no antimicrobial activity, whereas 5.31 and 5.41 
displayed only minimal antifungal activity. The aromatic amines 5.16, 5.28 and 5.37 all 
showed antimicrobial activity to some degree. Pyrrole 5.31 displayed a low affinity for 
oligonucleotides, in comparison to the classical intercalator ethidium bromide, in a DNA 
binding assay. A model system, whereby 5.31 was incubated with aniline, was designed to 
mimic the reaction of a pyrrole-based alkylating agent with a DNA nucleophile. However, 
analysis by HPLC and mass spectrometry revealed that no reaction occurred between 5.31 
and aniline. 
Future work in this area would initially be centred on modifying the synthetic route, so that 
the tricyclic structure would be introduced at a later stage to overcome any problems with 
solubility and purification. Also, alterations to the 5-(hydroxymethyl)pyrrole functionality 
to introduce better leaving groups, and hence enhance azafulvene formation, could result in 
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more facile DNA alkylation. Once the optimal synthetic route is detennined, a new series 
of structures would be prepared, and then assayed against the biological targets. 
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CHAPTER SIX 
EXPERIMENTAL 
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6.1 GENERAL METHODS AND EXPERIMENTAL PROCEDURES 
Melting Points 
All melting points were obtained on an Electrothermal apparatus and are uncorrected. 
Nuclear Magnetic Resonance 
Proton NlVIR spectra were obtained on a Varian Inova spectrometer, operating at 500 IYffiz. 
Carbon NMR spectra were obtained on a Varian Unity 300 spectrometer, operating at 75 
MHz, with a delay (D1) of 1 s. All spectra were obtained at 23°C. Chemical shifts are 
reported in parts per million (ppm) on the D scale. Solvents used for NMR analysis 
(reference peaks listed) included: DMSO-d6 (CHD2S0CD3 at DH 2.60 ppm, (CD3)zSO at Dc 
39.6 ppm); CDCh (CHCh at DH 7.25 ppm, CDCb at Dc 77.0 ppm); CD30D (CHD20D at 
DH 3.30 ppm, CD30D at Dc 49.3 ppm); CD3CN (CHD2CN at DH 2.00 ppm, CD3CN at Dc 
1.3 ppm); acetone-d6 (CHD2COCD3 at DH 2.17 ppm, (CD3)2CO at DC 29.2 ppm). Two-
dimensional NMR experiments included COSY, HSQC, HMBC and CIGAR, and all were 
obtained on the Varian Inova spectrometer operating at 500 MHz. The HSQC, HMBC and 
CIGAR experiments were all obtained with a delay (D1) of 1 s. 
Infrared Spectroscopy 
Infrared spectra were obtained using a Shimadzu 8201PC series FTIR interfaced with an 
Intel 486 PC operating Shimadzu's HyperIR software. Spectra were obtained in either 
CHCh (solution phase) or solid KEr (diffuse reflectance). 
Small Molecule Mass Spectrometry 
Electron impact (EI) mass spectra were detected on a Kratos MS80 RF A mass 
spectrometer operating at 4000 V (accelerating potential) and 70 eV (ionisation energy). 
The source temperature was 200-250°C. Electrospray ionisation (ESI) mass spectra were 
detected on a micromass LCT TOF mass spectrometer, with a probe voltage of 3200 V, 
temperature of 150°C and a source temperature of 80°C. Direct ionisation used 10 ilL of a 
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10 Jlg mL-1 solution, using a carrier solvent of 50% acetonitrile/FhO at a flow rate of 20 JlL 
min-I. Ionisation was assisted by the addition of 0.5% formic acid. 
Liquid Chromatography Mass Spectrometry 
Inhibitor-enzyme samples were analysed initially by electro spray ionisation mass 
spectrometry (ESI) using a Micromass LCT mass spectrometer scanning at 100-2500 
atomic mass units (scans every 0.9 s, 0.1 s delay). The source was at 80a C (ESI probe = 
150aC, nebuliser 190 L hr-I, desolvation = 350 L hr-I). Analysis by liquid 
chromatography mass spectrometry involved the use of a Waters 2790 LC, which was 
coupled to the Micromass LCT spectrometer mentioned above, with elution through a 
Waters 996 PDA Zorbax C3 column (150 mm x 2 mm x 5 Jlffi, flow 0.2 mL min-I). The 
mobile phase used a gradient of 100% [water/0.5% formic acid] to 40% [water/0.5% 
formic acid]/60% acetonitrile over 80 min, then to 100% acetonitrile over 5 min, held at 
100% acetonitrile for 10 min, then back to 100% [water/0.5% formic acid] over 5 min. 
Data was processed with Maxent® software. 
High Performance Liquid Chromatography 
Analytical HPLC was performed on a Shimadzu LC-10AD VP liquid chromatograph 
coupled to a SIL-10A VP autoinjector, a CTO-10A VP column oven set to 40aC and a 
SPD-MlOA VP photo diode array detector. The system was controlled by Shimadzu 
CLASS-VP (Version 5.02) software. Periodically, micro fractions were collected for 
analysis by mass spectrometry. For reverse phase HPLC a Phenomenex Prodigy C18 5-
ODS (311, 250 x 4.6 mm) column was used with a flow rate of 1 mL min-I with a standard 
HPLC solvent gradient system that comprised of variable concentrations of H20 (Milli-Q) 
containing 0.05% trifluoroacetic acid (TFA) and acetonitrile (HPLC grade). The gradient 
consisted of a 40 min run with the following steps 2 min of 90% [water/0.05% 
TFA]110% acetonitrile, followed by a linear gradient to 25% (water/0.05% TFA]175% 
acetonitrile over 12 min, maintained at 25% [waterlO.05% TFA]175% acetonitrile for 10 
min then a linear gradient to 100% acetonitrile over 2 min. This was held for 4 min then 
returned to 90% [water/0.05% TFA]/IO% acetonitrile over 2 min. The 90% [water/0.05% 
TF A ]/10% acetonitrile was maintained for 8 min to allow the column to re-equilibrate. 
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Microanalysis 
Microanalysis was performed at the University of Otago Microanalytical Laboratory. All 
reported values are within ±0.4% of the calculated value. 
Reagents, solvents and laboratory methodology 
Oven-dried glassware was used in all reactions carried out under an inert atmosphere 
(either dry dinitrogen or argon). All starting materials and reagents were obtained 
commercially unless otherwise stated. "Removal of the solvent (or volatiles) by 
evaporation under reduced pressure" refers to the process of bulk solvent removal by 
rotary evaporation (low vacuum pump) followed by application of high vacuum (oil pump) 
for a minimum of 30 min. Analytical thin layer chromatography (TLC) was performed on 
plastic-backed Merck Keiselgel KG60F254 silica plates, and visualised using short wave 
ultraviolet light, ninhydrin or Mary's dip. Flash chromatography was performed using 
230-400 mesh Merck Silica Gel 60 following established guidelines l under positive 
pressure. Kugelrohr distillations were performed under high vacuum (oil pump) with the 
slow application of heat to the specified temperature. THF and diethyl ether were distilled 
from sodium benzophenone ketyl under an inert atmosphere immediately prior to use. 
Dichloromethane, 1,2-dichloroethane, benzene and toluene were distilled from calcium 
hydride under an inert atmosphere. Petroleum ether refers to the fraction collected 
between 60-70°C. Ethyl acetate and petroleum ether were distilled from calcium hydride 
prior to their use in flash chromatography. DMF was dried by placing over 4 A molecular 
sieves, applying a high vacuum for 15 min, then flushed briefly with an inert atmosphere. 
This process was repeated twice more over 24 h, after which the DMF was stored over 4 A 
molecular sieves under an inert atmosphere. All other reagents and solvents were purified 
prior to use using literature procedures.2 
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General Procedure A: Acetylation of amines with acetyl chloride 
A stirred suspension of the aniline in dry acetyl chloride (~0.35 M) under an inert 
atmosphere was refluxed for 15 min, after which it was cooled to r.t. and the volatiles were 
removed by evaporation under reduced pressure. See individual experiments for details. 
General Procedure B: Amide hydrolysis with 4:1 ethanol/5 M aqueous sodium 
hydroxide3 
A stirred solution of the acetamide in 4:1 ethanoll5 M aqueous sodium hydroxide (~0.1 M) 
was refluxed for 1 h, after which it was cooled to r.t. and the solvent was removed by 
rotary evaporation. See individual experiments for details. 
General Procedure C: Nitroaniline reductions with platinum oxide 
A vigorously stirred suspension of the nitro aniline and platinum oxide (approximately 3:1 
w/w ratio of starting material to catalyst), in dry ethanol (~0.025 M) at r.t., was evacuated 
under reduced pressure (low vacuum pump), then flushed with hydrogen gas. This process 
was repeated twice more, and the suspension was then left to stir under hydrogen for the 
specified time. The catalyst was removed by filtration of the reaction mixture through 
Celite and the solvent was removed by evaporation under reduced pressure. See individual 
experiments for details. 
General Procedure D: Benzimidazole preparation with polyphosphoric acid4 
A stirred mixture of the diamine (1 equiv) and the pyridine derivative (1 equiv), in freshly 
prepared polyphosphoric acidS 00.4 M) under an inert atmosphere, was heated to 170-
180°C for 5 h. The reaction mixture was then poured onto ice (20 g), basified to pH ~8 
with 28% aqueous ammonium hydroxide, and the resulting solid was collected by 
filtration. See individual experiments for details. 
General Procedure E: Benzimidazole preparation with nitrobenzene6 
To a stirred solution of the diamine (1 equiv) in dry nitrobenzene (~0.2 M) at r.t. under an 
inert atmosphere was added 2-pyridinecarboxaldehyde (1 equiv). The resulting solution 
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was wanned to 150°C for 18 h, after which it was cooled to r.t. and the solvent was 
removed by Kugelrohr distillation (up to 160°C). See individual experiments for details. 
General Procedure F: Hydrolysis of formylpyrrole esters with potassium hydroxide 
A stirring solution of the fonnylpyrrole (1 equiv) and potassium hydroxide (4 equiv) in 
water (~0.2 M) was heated to 40-50DC for 2 h. After cooling to r.t., the solution was 
acidified to pH ~1 with concentrated hydrochloric acid and extracted with ether (6 x 20 
mL). The combined ethereal fractions were washed with water (2 x 20 mL), dried 
(MgS04)' and the solvent was removed by evaporation under reduced pressure. See 
individual experiments for details. 
General Procedure G: Acylation of ethyl IH-pyrrole-2-carboxylate (3.8) with an acid 
chloride7 
A solution of ethyl 1H-pyrrole-2-carboxylate (3.8,8 1 equiv) in 1,2-dichloromethane (~0.6 
M) was added dropwise over 5 min to a stirred suspension of the acid chloride (2 equiv) 
and zinc chloride (2 equiv) in 1,2-dichloromethane (~1.2 M), which had been cooled to 
oDe under an inert atmosphere. The suspension was heated to 50DC for 1 h, after which the 
resulting solution was poured onto ice-water and the organic layer was separated. The 
aqueous layer was extracted with ethyl acetate (40 mL), and the combined organic 
fractions were washed with aqueous saturated sodium hydrogen carbonate (30 mL), 
aqueous saturated brine (30 mL), dried (MgS04), and the solvent was removed by 
evaporation under reduced pressure. See individual experiments for details. 
General Procedure H: Hydrolysis of 5-acylpyrrole esters with potassium hydroxide 
A stirred solution of the 5-acylpyrrole (1 equiv) and potassium hydroxide (4 equiv) in 2:1 
water/THF (~0.15 M) was heated to 40-50DC for 2 h. After cooling to r.t., the solution was 
washed with ether (20 mL), acidified to pH ~ 1 with concentrated hydrochloric acid, and 
extracted with ether (5 x 20 mL). The combined ethereal fractions were dried (MgS04)' 
and the solvent was removed by evaporation under reduced pressure. See individual 
experiments for details. 
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General Procedure I: Couplings using 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride/l-hydroxybenzotriazole hydrate9 
To a stirred solution of the pyrrole acid (1 equiv) and the amino acid ester hydrochloride 
(1.1 equiv) in dry dichloromethane (~0.1 M), at r.t. under an inert atmosphere, were added 
1-(3-dimethylaminopropyl)-3-ethy1carbodiimide hydrochloride (1.3 equiv), 1-
hydroxybenzotriazole hydrate (1.5 equiv) and N,N-diisopropylethylamine (1.1 equiv). 
After 16 h, the solution was diluted with dichloromethane (10 mL), washed with 3 M 
aqueous hydrochloric acid (2 x 10 mL), water (2 x 10 mL), dried (MgS04), and the solvent 
was removed by evaporation under reduced pressure. See individual experiments for 
details. 
Modified General Procedure I 
The reaction was performed in the manner described in General Procedure I, except that 
the combined aqueous washings were back-extracted with dichloromethane (2 x 10 mL), 
and the combined organic fractions were then dried (MgS04), and the solvent was removed 
by evaporation under reduced pressure. See individual experiments for details. 
General Procedure J: Zinc borohydride reductions lO 
A stirred solution of the pyrrole (1 equiv), dissolved in dry ether (~0.1 M) under an inert 
atmosphere, was cooled to O°C. Zinc borohydride (2.2 equiv of a 0.14 M solution in ether) 
was added, and the resultant solution was stirred at O°C for 1 h. Water (1 mL), and then 
10% aqueous acetic acid (1 mL), were carefully added to quench the reaction. The 
separated aqueous phase was extracted with dichloromethane (2 x 10 mL), and the 
combined organic phases were washed with water (2 x 10 mL), saturated aqueous brine 
(10 mL), dried (MgS04)' and the solvent was removed by evaporation under reduced 
pressure. See individual experiments for details. 
Ge.neral Procedure K: Lithium borohydride reductions 
A stirred solution of the pyrrole (1 equiv), dissolved in dry THF (~0.03 M) under an inert 
atmosphere, was cooled to -78°C (dry ice/acetone). Lithium borohydride (2 equiv) was 
added, and the resultant solution was stirred at -78°C for 1 h, then warmed to r.t. and 
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stirred for an additional 1 h. Water (10 mL) was carefully added to quench the reaction. 
The solution was extracted with ethyl acetate (3 x 10 mL), the combined organic phases 
were washed with saturated aqueous brine (10 mL), dried (MgS04), and the solvent was 
removed by evaporation under reduced pressure. See individual experiments for details. 
Modification to General Procedure K 
The reaction was performed in the manner described in General Procedure I, except that 
dry ether was used in place in dry THF, and the reaction was stirred at -78°C for 1 h before 
workup. See individual experiments for details. 
General Procedure L: Esterification of carboxylic acids with diazomethane 
To a stirred solution of the acid (1 equiv) in dry THF (~0.075 M) was added a l2-fold 
excess of diazomethane in ether dropwise. After stirring at r.t. for 15 h, the solvent was 
removed by evaporation under reduced pressure. See individual experiments for details. 
General Procedure M: Couplings using benzotriazol-l-yloxytris(dimethylamino)-
phosphonium hexafluorophosphate11 
To a stirred solution of the pyrrole acid (1 equiv) and the amino acid ester hydrochloride 
(1.1 equiv), or the free amine of the amino acid ester (1.1 equiv), in dry dichloromethane 
(~O.l M) at r.t. under an inert atmosphere (shielded from light) were added benzotriazol-l-
yloxytris( dimethyl-amino )phosphonium hexafluorophosphate (1.1 equiv) and N,N-
diisopropylethylamine (Hiinig's base, 1.1 equiv). After 16 h, the solution was diluted with 
ethyl acetate (15 mL), washed with 1 M aqueous hydrochloric acid (10 mL), aqueous 
saturated sodium hydrogen carbonate (10 mL), aqueous saturated brine (10 mL), dried 
(MgS04), and the solvent was removed by evaporation under reduced pressure. See 
individual experiments for details. 
General Procedure N: Pyrrolizinone formation from 5-formylpyrroles with 
hydrocinnamoyl chloride 
To a stirred solution of the 5-formylpyrrole (1 equiv) in dry dichloromethane (~0.025 M), 
at r.t. under an inert atmosphere, was added 4-( dimethyl amino )pyridine (0.1 equiv), 
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followed by the dropwise addition of N,N-diisopropylethylamine (2 equiv). After 5 min, 
hydrocinnamoyl chloride (2 equiv) dissolved in dry dichloromethane (2 mL) was added 
dropwise over 5 min, and the resultant solution was stirred for 24 h. Ethyl acetate (10 mL) 
was added and the organic solvents were washed with 10% aqueous citric acid (10 mL), 
water (10 mL), saturated aqueous brine (10 mL), dried (MgS04), and the solvent was 
removed by evaporation under reduced pressure. See individual experiments for details. 
General Procedure 0: Esterification of dipeptide acids with methanol 
A stirred solution of the dipeptide carboxylic acid (1 equiv) was suspended in dry methanol 
(~0.2 M) at r.t. under an inert atmosphere. Oxalyl chloride (1.1 equiv) was added 
dropwise, followed by DMF (2 drops). The resultant solution was refluxed for 3 h, after 
which the solvent was removed by evaporation under reduced pressure. See individual 
experiments for details. 
General Procedure P: Reaction of aromatic amines with succinic anhydride in 
refluxing toluene12 
A stirred solution ofthe aromatic amine (1 equiv) and succinic anhydride (1 equiv) in dry 
toluene (~0.25 M) under an inert atmosphere was refluxed for 15 min. After cooling to r.t., 
the solid was collected by filtration and washed with cold petroleum ether. The material 
was dissolved in ethyl acetate (60 mL) and 5% aqueous sodium hydroxide (60 mL), the 
, 
layers were separated, and the organic phase was extracted with 5% aqueous sodium 
hydroxide (20 mL). The combined aqueous fractions were acidified to pH ~ 1 with 
concentrated hydrochloric acid, and the resultant solid was allowed to stand for 3 h, after 
which it was collected by filtration, washed with water (10 mL) and dried under reduced 
pressure. See individual experiments for details. 
Modification to General Procedure P 
The reaction was perfonned in the manner described in General Procedure P, except that 
the reaction mixture was refluxed for 1 h. 
Chapter Six - Experimental 173 
General Procedure Q: Succinimide formation from N-arylsuccinamic acids13 
A mixture of the N-arylsuccinamic acid (1 equiv) and anhydrous sodium acetate (0.33 
equiv) in dry acetic anhydride (~ 0.25 M), under an inert atmosphere, was heated to 70-
80°C for 4.5 h, after which it was cooled to r.t., poured onto water (60 mL), and extracted 
with dichloromethane (3 x 20 mL). The combined organic fractions were washed with 
aqueous saturated ammonium chloride (20 mL), dried (MgS04), and the solvent was 
removed by evaporation under reduced pressure. Residual solvent was removed by 
Kugelrohr distillation (up to 140°C) from the desired product. See individual experiments 
for details. 
General Procedure R: Succinimide reduction/ring opening with sodium 
borohydride 14 
To a stirred suspension of the succinimide (1 equiv) in 6:1 iso-propanol/water (~0.1 M) 
was added sodium borohydride (2.5 equiv), and the resulting suspension was stirred at r.t. 
for 17 h. See individual experiments for details. 
Modification to General Procedure R 
The reaction was performed in the manner described in General Procedure P, except that 
the disuccinimide was treated with 5 equiv of sodium borohydride. 
General Procedure S: Couplings using bis(2-oxo-3-oxazolidinyl)phosphinic chloride15 
To a stirred suspension of the pyrrole acid 3.9a (1 equiv), alcohol (1.5 equiv) and bis(2-
oxo-3-oxazolidinyl)phosphinic chloride (2 equiv) in dry dichloromethane (~0.07 M), at r.t. 
under an inert atmosphere, was added dry triethylamine (2 equiv). The resulting 
suspension was stirred for 64 h, after which it was diluted with ethyl acetate (20 mL), 
washed with 10% aqueous sodium bicarbonate (10 mL), saturated aqueous brine (10 mL), 
dried (MgS04), and the solvent was removed by evaporation under reduced pressure. See 
individual experiments for details. 
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6.2 EXPERIMENTAL WORK DESCRIBED IN CHAPTER TWO 
6.2.1 Preparation of the diamine intermediate 2.2a 
2.4 
4-Iodo-2-nitroaniline (2.5a)16 
1 I 2.6aR =Ac 
L---- 2.6b R 1 = H 
j 
2.2a 
174 
To a stirred suspension of 2-nitroaniline 2.4 (1.50 g, 11 mmol, 1 equiv) in 30% aqueous 
acetic acid (50 mL) at r.t. was added pyridine iodine monochloride (2.62 g, 11 mmol, 1 
equiv) in a portionwise fashion over 5 min. Stirring was continued for 30 min, after which 
the solid was collected by filtration and washed with water. The product was dried under 
reduced pressure (high vacuum) to give 2.5a (2.78 g, 97%) as an orange solid. 
mp 120-122°C (lit. 16 119-121°C). 
IH NMR (DMSO-d6, 500 MHz) 8 6.95 (d, 1H, J = 8.8 Hz, H6), 7.63 (s(br), 2H, Nfu), 7.70 
(dd, 1H, J = 2.0,8.8 Hz, H5), 8.29 (d, 1H, J = 2.0 Hz, H3). 
4-Iodo-2-nitroacetanilide (2.5b) 
The aniline 2.5a (2.0 g, 7.58 mmol) was treated with acetyl chloride by General Procedure 
A to give 2.5b (2.12 mg, 91 %) as a yellow solid. 
mp 109-110°C (lit.17 112°C). 
IH NMR (CDCh, 500 MHz) 8 2.28 (s, 3H, COCH3), 7.89 (dd, 1H, J= 2.0,8.8 Hz, H5), 
8.51 (d, 1H, J= 2.0 Hz, H3), 8.56 (d, 1H, J= 9.3 Hz, H6), 10.25 (s, 1H, NHCO). 
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(E)-2-Nitro-4-(2-phenylvinyl)acetanilide (2.6a) 
To a stirred solution of the acetanilide 2.5b (1.50 g, 4.90 mmol, 1 equiv), palladium acetate 
(110 mg, 0.49 mmol, 0.1 equiv) and tri-o-tolylphosphine (298 mg, 0.98 mmoI, 0.2 equiv) 
in dry acetonitrile (110 mL), under an inert atmosphere at r.t., was added dry styrene (2.55 
g, 24.5 mmoI, 5 equiv) and dry triethylamine (5 mL). The resulting solution was refluxed 
for 3 h, after which the solvent was removed by evaporation under reduced pressure. The 
crude product was purified by flash chromatography (ethyl acetate/petroleum ether 2:3, 
then ethyl acetate, then ethyl acetate/acetone 1: 1), followed by recrystallisation from ethyl 
acetate, to give 2.6a (704 mg, 51 %) as an orange solid. 
mp 181-183°C. 
IH NMR (CDCb, 500 MHz) 0 2.30 (s, 3H, COCH3), 7.09 (ABq, 2H, J = 16.6 Hz, 
CH=CH), 7.29(t, 1H,J=7.3Hz,ArH), 7.37 (t,2H,J 7.6 Hz, ArH), 7.51 (d,2H,J 7.3 
Hz, ArID, 7.79 (dd, 1H, J= 2.0,8.8 Hz, H5), 8.31 (d, 1H, J= 2.0 H3), 8.77 (d, 1H, J= 
8.8 10.32 (s(br), 1H, NHCO). 
13C NMR (CDCh, 75 MHz) 0 24.9 (COCH3), 122.3 (~, 122.5 (C3), 125.0, 130.0 
(CH=CH), 126.2, 127.8, 128.3, 135.8 (ArC), 132.4 (Q), 132.6 (C1), 132.7 (C1), 135.8 
(C2), 168.5 (COCH3). 
FTIR (KBr, diffuse refraction method) cm-1 1515.9, 1575.7, 1701.1,3062.7,3348.2. 
HRMS (El) 282.0996 (M+). C16H14N203 requires 282.1004. 
(E)-2-Nitro-4-(2-phenylvinyl)aniline (2.6b) 
The acetanilide 2.6a (600 mg, 2.13 mmol) was treated with 4:1 ethanol/5 M aqueous 
sodium hydroxide by General Procedure B. The resulting solid was washed with cold 
water (5 x 10 mL) and dried under reduced pressure (high vacuum) to give 2.6b (510 mg, 
quantitative yield) as a dark red solid. 
mp 203-205°C. 
IH NMR (CDCl), 500 MHz) 0 6.14 (s(br), 2H, Nlli), 6.82 (d, 1H, J 8.3 Hz, H6), 6.99 (s, 
2H, CH=CH), 7.25 (m, 1H, ArH), 7.35 (t, 2H, J 7.6 ArH), 7.48 (d, 2H, J = 7.3 Hz, 
ArID, 7.60 (dd, IH, J= 2.2,8.5 Hz, H5), 8.21 (d, 1H, 2.0 Hz, H3). 
13C NMR (CDCb, 75 MHz) 0 119.2 (C6), 124.0 (Q), 126.3, 128.7 (CH=CH), 126.4, 
127.7, 127.7, 137.0 (ArC), 127.1 (C1), 127.2 (~, 133.2 (Q), 143.9 ©). 
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FTIR (KBr, diffuse refraction method) cm-1 1523.7, 1556.4, 1581.5, 1645.2, 3062.1, 
3184.3,3338.6,3467.8. 
HRMS (EI) 240.0901 (M+). C14Hd'h02 requires 240.0899. 
4-(2-Phenylethyl)benzene-l,2-diamine (2.2a) 
The nitro aniline 2.6b (110 mg, 0.46 mmol) was reduced with platinum oxide under 
hydrogen for 17 h by General Procedure C. Recrystallisation of the crude product from 
ethanol/water gave 2.2a (93 mg, 96%) as a light purple solid. 
mp 76-79°C. 
IH NMR (CDCh, 500 MHz) 8 2.77, 2.85 (2 x m, 4H, CfuCfu), 6.54 (m, 2H, H3 plus H5 
or H6), 6.63 (d, IH, J = 7.8 Hz, H5 or H6), 7.18 (m, 3H, ArH), 7.27 (m, 2H, ArH). 
13C NMR (CDCh, 75 MHz) 8 37.3, 38.2 (CH2CH2), 116.8, 117.0, 119.9 (C3, C5, C6), 
125.7, 128.2, 128.4, 142.1 (ArC), 132.3, 134.1, 134.9 (Cl, C2, C4). 
FTIR (KBr, diffuse refraction method) cm-1 1569.9,2850.6,2931.6,3367.5. 
HRMS (EI) 212.1318 (M+). C14H16N2 requires 212.1314. 
6.2.2 Preparation of the diamine intermediate 2.2b 
~N02 ___ ~" ~NHRI _____ " ~NH2 
Ph~ Ph~ Ph~N02 
2.7 I 2.8aR1 =H 
~ 2.8bR1 =Ac 
2.9 
j 
~NH2 
Ph~NH2 
2.2b 
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4-Aminobiphenyl (2.8a) 
A vigorously stirred suspension of 4-nitrobiphenyl 2.7 (4.37 g, 21.9 mmol) and 10% 
palladium on carbon (approximately 1.50 g) in dry ethanol (45 mL) was evacuated under 
vacuum (low vacuum pump), then flushed with hydrogen gas. This process was repeated 
twice more, and the suspension was then left to stir at r.t. for 17 h. The catalyst was 
removed by filtration, and the solvent was removed by evaporation under reduced pressure 
to give 2.8a (3.55 g, 96%) as an off-white solid that was not subjected to further 
purification. 
mp 48-50°C (lit. 18 53-54°C). 
IH NMR (CDCh, 500 MHz) 8 3.71 (s(br), 2H, Nfu), 6.76 (d, 2H, J = 8.3 Hz, ArH), 7.26 
(t, IH, J= 7.3 Hz, ArB), 7.40 (m, 4H, ArH), 7.53 (d, 2H, 7.3 Hz, ArH). 
4-Acetamidobiphenyl (2.8b) 
The aminobiphenyl 2.8a (3.53 g, 20.9 mmol) was treated with acetyl chloride by General 
Procedure A to give 2.8b (4.41 g, quantitative yield) as a white solid. 
mp 172-173°C (lit. 19 171°C). 
IH NMR (CDCh + 2 drops DMSO-d6, 500 MHz) 8 1.90 (s, 3H, COCH3), 7.05 (t, IH, J 
7.3 Hz, ArH), 7.16 (t, 2H, J 7.6 Hz, ArH), 7.28 (m, 4H, ArH), 7.42 (d, 2H, J= 8.8 
ArH), 9.21 (s(br), IH, NHCO). 
4-Amino-3-nitrobiphenyl (2.9io 
To a stirred solution of the acetamidobiphenyl 2.8b (500 mg, 1.95 mmol), in dry glacial 
acetic acid (4.8 mL) under an inert atmosphere at 70°C, was added dropwise over 5 min a 
solution of fuming nitric acid (0.32 mL) in dry glacial acetic acid (4.8 mL). Mter stirring 
at 70°C for 1 h, the solution was poured onto cold water (30 mL), and the resulting solid 
was collected by filtration, washed with cold water and dried under reduced pressure (high 
vacuum) to give 4-acetamido-3-nitrobiphenyl as a yellow solid. This material was treated 
with 4: 1 ethano1J5 M aqueous sodium hydroxide by General Procedure B. The solid was 
collected by filtration and washed thoroughly with 10% aqueous sodium hydroxide. The 
product was dried under reduced pressure (high vacuum) to give 2.9 (384 mg, 76% yield 
over two steps) as a dark red solid. 
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mp 163-166°C (lit.20 mp 167-169°C). 
IH NMR (CDCh, 500 MHz) 3 6.10 (s(br), 2H, Nfu), 6.89 (d, 1H, J 8.8 Hz, ill), 7.33 (t, 
1H, J= 7.3 Hz, ArID, 7.43 (t, 2H, J= 7.8 Hz, ArH), 7.55 (m, 2H, ArH), 7.64 (dd, 1H, J= 
2.2,8.5 Hz, H6), 8.37 (d, 1H, J= 2.0 Hz, H2). 
3,4-Diaminobiphenyl (2.2b) 
The aminobiphenyl 2.9 (200 mg, 0.93 mmol) was reduced with platinum oxide and 
hydrogen for 6 h by General Procedure C. Recrystallisation of the crude product from 
benzene/petroleum ether gave 2.2b (141 mg, 82%) as a brown solid. 
mp 102-104°C (lit.21 103°C). 
IH NMR (CDCh, 500 MHz) 36.76 (d, 1H, J = 7.8 Hz, ill), 6.97 (m, 2H, H2 and H6), 7.26 
(t, IH, J = 7.3 Hz, ArID, 7.37 (t, 2H, J = 7.6 Hz, ArH), 7.51 (d, 2H, 7.3 Hz, ArH). 
6.2.3 Preparation of the benzimidazole 2.1c 
6' 
4 ~~5' 
-----...)1> 5:CC
1 
~ ~,,--/J 4' 
. ~ / 3' 
Me N 
7 H 
2.2c 2.1c 
5(6)-Methyl-2-(pyridin-2-ylmethyl)-lH-benzimidazole (2.1c) 
Method A 
3,4-Diaminotoluene 2.2c (300 mg, 2.46 mmol, 1 equiv) was reacted with 2-pyridylacetic 
acid hydrochloride (426 mg, 2.46 mmol, 1 equiv) by General Procedure D. The crude 
product was purified by flash chromatography on silica (ethyl acetate, then methanol), 
followed by recrystallisation from ethyl acetate/petroleum ether, to give 2.1c (274 mg, 
50%) as a light brown solid. 
mp 134-136°C 
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IHNMR (CD30D, 500 MHz) (5 2.42 (s, 3H, CH3), 4.38 (s, 2H, Cfu), 7.03 (dd, 1H, 1.5, 
8.3 Hz, H5(6)), 7.30 (m, 2H, H7 and H5'), 7.36 (m, 2H, H4 and H4'), 7.78 (dt, 1H, J= 2.0, 
7.8 Hz, 8.49 (d, 1H, J = 4.9 Hz, H6'). 
FTIR (KBr, diffuse refraction method) cm-1 1569.9, 1593.1, 2684.7, 2833.2, 2920.0, 
3014.5. 
HRMS (ES) 224.1183 (M++H). C1Ji14N3 requires 224.1188. 
MethodB 
3,4-Diaminotoluene 2.2c (300 mg, 2.46 mmol, 1 equiv) was reacted with 2-
pyridylacetonitrile (290 mg, 2.46 mmol, 1 equiv) by General Procedure D to give 2.1c (425 
mg, 78% crude mass return) as a dark purple solid. No purification was attempted due to 
the adequate amount of pure 2.1c obtained from Method A. 
mp 127-132°C. 
IH NMR data was identical to that above. 
Methode 
3,4-Diaminotoluene 2.2c (100 mg, 0.82 mmol, 1 equiv) and 2-pyridylacetic acid 
hydrochloride (142 mg, 0.82 mmol, 1 equiv) in 4 M hydrochloric acid (5 mL), under an 
inelt atmosphere, were heated to 120-130°C for 6 h. The reaction mixture was cooled to 
O°C, and the solid was collected by filtration and dried under reduced pressure (high 
pressure) to give 2.1c (dihydrochloride salt, 242 mg, quantitative mass return) as a grey 
solid. 
IH NMR (CD30D, 500 MHz) (52.33 (s, 3H, CH3), 4.22 (s, 2H, Cfu), 7.05 (m, 2H), 7.21 
(d, IH, J= 7.8 Hz), 8.04 (m, 2H), 8.61 (m, IH), 8.84 (m, 1H). 
No further analytical data was obtained due to product degradation. 
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6.2.4 Preparation of the benzimidazoles 2.14a-c 
~NH2 ___ ....... 5(y~\ t)'5' Rl~NH2 Rl~N~ 
1 2.2a R Ph(CH2h 
2.2b Rl Ph 
2.2cR1 Me 
7 H 3' 4' 
2.14a Rl Ph(CH2h 
2.14b Rl =Ph 
2.14cRI =Me 
5(6)-(2-Phenylethyl)-2-(pyridin-2-y 1)-lH-benzimidazole (2.14a) 
180 
Diamine 2.2a (80 mg, 0.38 mmol, 1 equiv) was treated with 2-pyridinecarboxaldehyde (40 
mg, 0.38 mmol, 1 equiv) by General Procedure E. The crude product was purified by flash 
chromatography on silica (ethyl acetate/petroleum ether, 3:1) to give 2.14a (48 mg, 43%) 
as a tan so lid. 
mp decomp. >35°C. 
IH NMR (CD3CN, 500 MHz) 0 3.03, 3.10 (2 x m, 4H, CH2Cfu), 7.23 (m, 2H, ArH and 
H5(6), 7.32 (m, 4H, ArH), 7.49 (m, 2H, H7 and H5'), 7.61 (d, IH, J 8.3 Hz, H4), 7.96 
(dt,IH, 1.5, 7.8 Hz, H4'), 8.38 (d, IH, J= 8.3 Hz, H3'), 8.71 (d, IH, 4.9 Hz, H6'). 
l3C NMR (CD3CN + 10 !-tL CF3C02H, 75 MHz) 0 38.4 (2C, 114.6 (C7), 115.0 
(C4), 124.3 (C3'), 127.l, 129.4, 129.6, 142.3 (ArC), 129.1 (C5'), 129.6 (C5(6), 130.6, 
132.5 (C4a, 139.7 (C4'), 141.9 (C2'), 143.3 (C6(5), 148.3 (Q2), 152.0 (C6'). 
FTIR (KBr, diffuse refraction method) cm-1 1569.9, 1596.9,2858.3,2929.7. 
HRMS (81) 299.l425 (M+). C20H17N3 requires 299.l423. 
This product (20 mg, 0.07 mmol) was dissolved in ethyl acetate (5 mL), and dry hydrogen 
chloride gas was bubbled through the solution until a solid formed. The solvent was 
removed by evaporation under reduced pressure to give 2.14a (dihydrochloride salt, 21 
mg, 84%) as a tan solid. 
mp 225-228°C. 
IH NMR (CD3CN plus 2 drops DMSO-d6, 500 MHz) 0 3.04, 3.16 (2 x m, 4H, CfuCfu), 
7.24 (m, IH, ArID, 7.31 (m, 4H, ArID, 7.49 (m, IH, H5(6), 7.70 (m, 2H, H7 and H5'), 
7.81 (d, IH, J 8.3 Hz, H4), 8.16 (dt, IH, J 2.0,7.8 Hz, 8.89 (d, lH, J= 4.4 Hz, 
H6'), 9.03 (d, IH, J 8.3 Hz, H3'). 
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5(6)-Phenyl-2-(pyridin-2-yl)-lH-benzimidazole (2.14b) 
Diamine 2.2b (100 mg, 0.54 mmol, 1 equiv) was treated with 2-pyridinecarboxaldehyde 
(58 mg, 0.54 mmol, 1 equiv) by General Procedure E. The crude material was purified by 
flash chromatography on silica (ethyl acetate/petroleum ether, 3:1) to give 2.14b (84 mg, 
57%) as a tan solid. An analytical sample was obtained by the diffusion of petroleum ether 
into a solution of2.14b dissolved in ethyl acetate. 
mp 161-163°C (lit.22 164-165°C). 
lH NMR (CD3CN, 500 MHz) 5 7.43 (m, 1H, ArH), 7.53 (m, 3H, ArH and 7.64 (m, 
1H, H5(6), 7.79 (m, 3H, ArH and H4), 7.99 (m, 2H, H7 and H4'), 8.43 (d, 1H, J 7.8 Hz, 
H3'), 8.75 (d, 1H, J 3.4 Hz, H6'). 
13C NMR (CD3CN + 10 ilL CF3C02H, 75 MHz) 5 113.1 (C7), 115.6 (C4), 124.4 (C3'), 
128.0 (C5(6), 128.5, 129.2, 130.2, 140.4 (ArC), 129.3 (C5'), 131.6 (C7a), 133.0 (C4a), 
139.6 (C4'), 141.7 (C6(5), 141.8 (C2'), 149.1 (C2), 152.0 (C6'). 
FTIR (KEr, diffuse refraction method) cm-1 1560.3, 1595.0,2360.7,3058.9. 
HRMS (El) 271.1111 (M+). C18H13N3 requires 271.1110. 
5( 6)-Meth yl-2-(pyridin-2-yl)-lH-benzimidazole (2.14c) 
3,4-Diaminotoluene 2.2c (125 mg, 1.02 mmol, 1 equiv) was treated with 2-
pyridinecarboxaldehyde (110 mg, 1.02 mmol, 1 equiv) by General Procedure E. The crude 
material was purified by flash chromatography on silica (ethyl acetate/acetone, 5:1), 
followed by Kugelrohr distillation (up to 230°C, product collected in second bulb), which 
afforded a residue that was triturated with ether/petroleum ether to give 2.14c (98 mg, 
46%) as a tan solid. 
mp 156-158°C (lit,22 159-160°C). 
IH NMR (CD3CN, 500 MHz) 5 2.53 (Cfu), 7.17 (m, 1H, H5(6), 7.49 (m, 2H, H7 and 
7.60 (d, 1H, J= 8.3 Hz, H4), 7.96 (dt, 1H, J= 1.5, 7.8 Hz, H4'), 8.38 (dd, 1H, J= 1.0, 
9.3 Hz, H3'), 8.71 (dd, 1H, J = 1.0,4.9 Hz, H6'). 
l3C NMR (CD3CN + 10 ilL CF3C02H, 75 MHz) 5 21.7 (CH3), 114.6 (C7), 114.8 (C.4), 
124.2 (C3'), 129.0 (C5'), 129.9 (C5), 130.3, 132.5 (C4a, C7a), l39.3 (C6), 139.5 (C4'), 
141.9 (C2'), 148.1 (C2), 152.0 (C6'). 
FTIR (KEr, diffuse refraction method) cm-1 1569.9, 1593.1,3051.2. 
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HRMS (EI) 209.0957 (Ml. C13HllN3 requires 209.0953. 
Micro. Calcd for C13HllN3: C, 74.62; H, 5.30; N, 20.08. Found: C, 74.46; H, 5.22; N, 
19.96. 
6.2.5 a-Chymotrypsin assay and results 
General Assay Conditions 
The colorimetric-based method23 was carried out in microtitre plates (twelve 1 x 8 well 
Titertek® microtitre strips), with absorbance readings taken in a BMG Labtechnologies 
Fluostar Galaxy 96-well plate reader. The enzyme and test solution were pre-incubated to 
ensure maximum inhibition before addition of the substrate, after which the optical density 
was measured at hourly intervals until the maximum measured absorbance exceeded 1.00 
absorbance units (typically 2 or 3 h). A lack of colour development indicated inhibition of 
enzyme-catalysed 4-nitroaniline release. Control samples were included in all cases. Each 
sample was assayed in triplicate. Methanol was used to dissolve the proposed inhibitor 
and for sample dilution, as it is water soluble and directly compatible with the assay 
system. 
a-Chymotrypsin Assay 
Solutions of the benzimidazoles 2.14a-c and 2.14a.2HCl were made to 10 ruM, 1.0 ruM, 
0.1 ruM, 10 /JM, 1.0 11M, 0.1 11M and 10 nM in methanol. Tris-HCI (50 ilL of a 0.4 M 
solution in water, pH 7.6), inhibitor solution (50 ilL), a-chymotrypsin (50 ilL, Sigma ex-
Bovine pancreas, 9 units mL-1 in 50 mM Tris-HCI, pH 7.6) and zinc chloride (50 ilL of a 
1.0 ruM solution in distilled water) or EDTA disodium dihydrate (50 ilL of a 5.0 ruM 
solution in distilled water) were added to each well of the microtitre plate. Incubation at 
37°C for 30 min was followed by the addition of N-succinyl-L-phenylalanine-4-
nitro anilide (100 ilL, 1 mg mL-1 solution in 50 mM Tris-HCl buffer, pH 7.6). The 
absorbance was read at 405 nm at hourly intervals until the maximum measured 
absorbance exceeded 1.00 absorbance units. Each inhibitor concentration was assayed in 
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triplicate and average absorbances were used to calculate the percentage (%) inhibition. 
The calculated percent inhibition values are a measure of the enzyme activity relative to 
that when no enzyme was present (no substrate turnover, 100% "inhibition") and when no 
inhibitor was present (full substrate turnover, 0% inhibition). To this end, sample blanks to 
determine the absorbance for each inhibitor concentration in the absence of enzyme were 
run concurrently, in which 50 mM Tris-HCI buffer (PH 7.6) replaced a-chymotrypsin. 
Maximum substrate turnover was determined by averaging the absorbance readings from 
six wells in which methanol replaced the inhibitor solution. All percentage (%) inhibition 
calculated values were rounded to the nearest 1 %. The ICso values were calculated by 
fitting the inhibitor concentration-percent inhibition data into Microsoft Excel®, with the 
inhibitor concentrations converted to their 10glO values. Activity of the test compounds in 
the presence of EDT A was performed in an analogous manner, except that the zinc 
chloride solution was replaced by EDTA disodium dihydrate in distilled water (50 ilL of a 
5.0 mM solution in distilled water) 
No. R! ICso (1lM) 
Zn2+ EDTA 
2.14a Ph(CH2)2 81 >17 
2.14b Ph >17 >17 
2.14c Me >167 681 
2.14a.2HCI Ph(CH2)2 82 >17 
Table 6.1. ICso values for 2.14a-c and 2.14a.2HCI in the presence of Zn2+ or EDTA. 
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6.3 EXPERIMENTAL WORK DESCRIBED IN CHAPTER THREE 
6.3.1 Preparation of the 5-(hydroxymethyl)pyrrole 3.13a and the C5-(hydroxy-
alkyl)pyrrole 3.14a-b 
n 
((NA C02Et 
H 
3.15 
J 
n OHC N C02R1 
H 
I I 3.16aR =Et 
L 3.16bR1 =H 
3.18a 
OHC +~ 
N C02Et 
H 
3.17a 
"----
Rl, n y '~/ "C02R2 
o H 
3.19a R 1 = Ph(CH2)2> R2 = Et 
3.19b Rl = Me, R2 = Et 
3.20a Rl = Ph(CH2h R2 = H 
3.20bR1 =Me,R2 =H 
RIM~yC02Me 
o H 0 =. 
"""Ph 
3.21 a R 1 = Ph(CH2)2 
3.21bR1 =Me 
j 
3.14aR1 =Ph(CH2)z,R2 OH 
3.14bRl =Me,R2 =OH 
3.14c Rl = Ph(CH2)2, R2 H 
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EthyI5-formyl-1H-pyrrole-2-carboxylate (3.16a)24 
Phosphorous oxychloride (6.89 g, 45 mmol, 1.1 equiv) was added dropwise over 15 min to 
stirred DMF (3.29 g, 45 mmol, 1.1 equiv) cooled to 10-20°C under a nitrogen atmosphere. 
1,2-Dichloroethane (10 mL) was added, followed by the portionwise addition of ethyl1H-
pyrrole-2-carboxylate 3.158 (5.65 g, 41 mmol, 1 equiv) dissolved in 1,2-dichloroethane (10 
mL) over 1 h. The solution was refluxed for 15 min, after which it was cooled to r.t. The 
solution was treated with sodium acetate trihydrate (27.2 g) in water (45 mL), and then 
refluxed for a further 15 min. The organic layer was separated, and the aqueous layer was 
extracted with ether (3 x 20 mL). The combined organic fractions were washed with 
saturated aqueous sodium hydrogen carbonate (3 x 20 mL), dried (MgS04) and the solvent 
was removed by evaporation under reduced pressure. The crude material was purified by 
flash chromatography on silica (ethyl acetate/petroleum ether, 2:3) to give two compounds. 
The first to elute was 3.16a (4.12 g, 61 % yield) as an orange solid. 
mp 70-73°C (lit.24 75°C). 
IH NMR (CDCb, 300 MHz) (5 1.37 (t, 3H, J= 7.3 Hz, CH2CH3), 4.37 (q, 2H, J= 7.2 Hz, 
CfuCH3), 6.93 (d,2H, 2.5 Hz, pyrrole H3 and fill, 9.65 (s, IH, CHO), 9.95 (s(br), 1H, 
pyrrole NH). 
The second to elute was 3.17a (1.68 g, 25%) as an orange solid. 
mp 100-103°C (lit.24 104-106°C). 
IH NMR (CDCh, 300 MHz) (5 1.35 (t, 3H, J = 7.3 Hz, CH2CH3), 4.34 (q, 2H, J = 7.2 Hz, 
CfuCH3), 7.30 (m, IH, pyrrole H3), 7.57 (t, 1H, J 1.5 pyrrole H5), 9.82 (s, 1H, 
CHO), 10.39 (s(br), 1H, pyrrole NH). 
5-Formyl-1H-pyrrole-2-carboxylic acid (3.16b) 
Pyrrole ester 3.16a (4.10 g, 25 mmol, 1 equiv) was hydrolysed with potassium hydroxide 
(5.61 g, 100 hmlol, 4 equiv) by General Procedure F to give 3.16b (2.03 g, 60%) as an 
orange solid. 
mp 198-204°C (lit.24 202-203°C). 
IH NMR (acetone-d6, 300 MHz) (5 7.05 (dd, 1H, J 1.8,3.8 pyrrole H3), 7.15 (dd, 1H, 
J = 1.8, 3.8 Hz, pyrrole H4), 9.89 (s, 1H, CHO), 11.82 (s(br), 1H, pyrrole NH). 
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Methyl N- [(5-formyl-lH-pyrrol-2-yl)carbonyl] -L-phenylalaninate (3.18a) 
PY!fole acid 3.16a (100 mg, 0.72 mmol, 1 equiv) was coupled with methyl L-
phenylalaninate hydrochloride (171 mg, 0.79 mmol, 1.1 equiv) by General Procedure 1. 
The crude product was purified by flash chromatography on silica (ethyl acetate/petroleum 
ether, 2:1) to give 3.18a (152 mg, 71 %) as a cream solid. 
mp 48-51 0c. 
lH NMR (CDCb, 500 MHz) 8 3.22 (m, 2H, CfuPh), 3.76 (s, 3H, COZCH3), 5.06 (m, 1H, 
]\ffiCH), 6.51 (d, IH, J= 7.3 Hz, J'lliCH), 6.61 (dd, IH, J= 2.7,4.2 Hz, pyrrole H3), 6.91 
(dd, 1H, J= 2.7,4.2 Hz, pyrrole H4), 7.10 (m, 2H, ArH), 7.27 (m, 3H, ArID, 9.61 (s, 1H, 
CHO), 10.11 (s(br), 1H, pyrrole J'lli). 
l3C NMR (CDCb, 75 MHz) 838.0, 52.6, 53.2, 111.2, 120.0, 127.2, 128.6, 129.3, 131.2, 
134.0, 135.5, 159.3, 171.9, 180.3. 
FTIR (CHCb) 1529.4, 1550.7, 1676.0, 1739.7,3020.3,3423.4. 
HRMS (ES) 301.1188 (M++H).C16H17Nz04 requires 301.1188. 
Methyl N-[(5-hydroxymethyl-lH-pyrrol-2-yl)carbonyl]-L-phenylalaninate (3.13a) 
The pyrrole 3.18a (106 mg, 0.35 mmol, 1 equiv) was reduced with zinc borohydride (5.55 
mL of a 0.14 M solution in ether, 0.78 mmol, 2.2 equiv) by General Procedure J. The 
crude product was purified by flash chromatography on silica (ethyl acetate/petroleum 
ether, 4:1) to give 3.13a (61 mg, 57%) as a tan solid. 
mp 105-107°C. 
lH NMR (CDCb, 500 MHz) 82.97 (s(br), 1H, CHzOH), 3.20 (m, 2H, PhCfu), 3.74 (s, 3H, 
COZCH3), 4.65 (s, 2H, CfuOH), 5.00 (m, 1H, J'lliCH), 6.08 (t, 1H, J = 3.2 Hz, pyrrole 
H4), 6.37 (d, 1H, J= 7.8 Hz, J'lliCH), 6.47 (t, IH, J= 3.2 Hz, pyrrole H3), 7.12 (d, 2H, J= 
7.3 Hz, ArH), 7.27 (m, 3H, ArID, 10.31 (s(br), 1H, pyrrole J'lli). 
l3C NMR (CDCb, 75 MHz) 837.9 (PhCHz), 52.4 (COZCH3), 53.2 (J'lliCH) , 57.2 
(CHzOH), 108.1 (pyrrole C4), 110.9 (pyrrole C3), 124.5 (pyrrole C2), 127.1, 128.5, 129.1, 
135.7 (ArC), 136.8 (pyrrole C5), 161.3 (QOJ'lli), 172.4 (QOz). 
FTIR (CHCb) 1525.6, 1637.5, 1739.7,3035.7,3435.0. 
HRMS (El) 302.1266 (M+). C16H1SNz04 requires 302.1267. 
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Micro. Calcd for C16HlSN204: C, 63.57; H, 6.00; N, 9.27. Found: C, 63.42; 5.90; N, 
9.38. 
EtbyI5-(3-pbenylpropionyl)-IH-pyrrole-2-carboxylate (3.19a) 
pyrrole ester 3.158 (2.91 g, 21 mmol, 1 equiv) was treated with hydrocinnamoyl chloride 
(7.04 g, 42 mmol, 2 equiv) by General Procedure G. Excess hydrocinnamic acid was 
removed by dissolving the crude material in ethyl acetate (50 mL) and washing the organic 
fraction with 1 M aqueous sodium hydroxide solution (4 x 20 mL), after which it was dried 
(MgS04). The crude product was purified by flash chromatography on silica (ethyl 
acetate/petroleum ether, 1 :4) to give 3.19a (2.0 g, 35%) as a cream residue. 
IH NMR (CDCb, 500 MHz) 01.36 (t, 3H, J= 7.1 Hz, CH2CH3), 3.04 (t, 2H, J= 7.3 Hz, 
PhCHzCH2), 3.13 (m, 2H, PhCH2CHz), 4.35 (q, 2H, J 7.2 Hz, CHzCH3), 6.81 (dd, 1H, J 
= 2.9, 3.9 Hz, pyrrole H3 or H4), 6.86 (dd, 1H, J = 2.4, 3.9 Hz, pyrrole H3 or H4), 7.18-
7.30 (m, 5H, ArH), 9.89 (s(br), 1H, pyrrole NH). 
13C NMR (CDCb, 75 MHz) 0 14.2 (CH2CH3), 30.2 (PhCH2CH2), 40.0 (PhCH2CH2), 61.1 
(CH2CH3), 115.4, 115.5 (pyrro1e C3 and C4), 126.2, 128.3, 128.5, 141.8 (ArC), 127.2 
(pyrrole C2), 133.7 (pyrrole C5), 160.3 (C02), 190.3 (CH2CO). 
FTIR (CHCb) 1548.7, 1604.7, 1662.5, 1710.7,2987.5,3006.8,3429.2. 
HRMS (EI) 271.1220 (Ml. C16H17N03 requires 271.1208. 
The 4-acyl isomer was not isolated. 
EtbyI5-acetyl-1H-pyrrole-2-carboxylate (3.19b)7 
Pyrrole ester 3.158 (4.0 g, 29 mmol, 1 equiv) was treated with acetyl chloride (4.51 g, 57 
mmol, 2 equiv) by General Procedure G. The crude product was purified by flash 
chromatography on silica (ethyl acetate/petroleum ether, 1:2) to give 3.19b (1.93 g, 37%) 
as a yellow solid. 
mp 54-57°C (lit.7 60-60.5°C). 
IH NMR (CDCb, 500 MHz) 0 1.36 (t, 3H, J = 7.3 Hz, CH2CH3), 2.46 (s, 3H, COCH3), 
4.34 (q, 2H, J= 7.2 Hz, CHzCH3), 6.83 (t, 1H, J 3.2 Hz, pyrrole H3 or H4), 6.87 (t, 1H, J 
= 3.2 Hz, pyrrole H3 or H4), 9.82 (s(br), 1H, pyrrole NH). 
The 4-acetyl isomer was not isolated. 
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5-(3-Phenylpropionyl)-lH-pyrrole-2-carboxylic acid (3.20a) 
Pyrrole ester 3.19a (801 mg, 2.95 mmol, 1 equiv) was hydrolysed with potassium 
hydroxide (663 mg, 11.8 mmol, 4 equiv) by General Procedure H to give 3.20a (616 mg, 
86%) as a brown solid. 
mp·181-183°C. 
IHNMR (acetone-d6, 500 MHz) 0 3.11 (t, 2H, J= 7.6 Hz, PhCfuCH2), 3.32 (t, 2H, J= 7.6 
Hz, PhCH2Cfu), 6.97 (dd, 1H, J 2.4, 3.9 Hz, pyrrole or H4), 7.15 (dd, 1H, J = 2.4, 
3.9 Hz, pyrrole or H4), 7.29 (m, 1H, ArID, 7.39 (m, 4H, ArH), 11.23 (s(br), 1H, 
pyrrole NH). 
l3C NMR (acetone-d6, 75 MHz) 030.1 (PhCH2CH2), 39.9 (PhCH2CH2),115.5, 115.8 
(pyrrole C3 and C4), 126.1, 128.5, 128.6, 141.6 (Arg, 127.9 (pyrrole C2), 134.8 (pyrrole 
C5), 161.2 (C02H), 190.0 (CH2CO). 
FTIR (KBr, diffuse refraction method) 1500.5, 1550.7, 1670.2, 1701.1, 2366.5, 2597.9, 
3197.8. 
HRMS (El) 243.0900 (M+). Cl~13N03 requires 243.0895. 
5-Acetyl-1H-pyrrole-2-carboxylic acid (3.20b) 
Pyrrole ester 3.19b (1.90 g, 10.5 mmol, 1 equiv) was hydrolysed with potassium hydroxide 
(2.35 g, 42.0 mmol, 4 equiv) by General Procedure H to give 3.20b (1.50 g, 93%) as a 
yellow solid. 
mp 185-187°C. 
IH NMR (acetone-d6, 500 MHz) 0 2.57 (s, 3H, CH3CO), 6.98 (dd, IH, J = 2.4, 3.9 
pyrrole H3 or H4), 7.11 (dd, 1H, J = 2.4, 3.9 Hz, pyrrole H3 or H4), 11.20 (s(br), 1H, 
pyrrole NID. 
J3C NMR (acetone-d6, 75 MHz) 025.5 (CH3CO), 115.5, 116.2 (pyrrole C3 and C4), 127.9 
(pyrrole C2), 135.1 (pyrrole C5), 161.2 (C02H), 188.2 (CH3CO). 
FTIR (KBr, diffuse refraction method) 1546.8, 1670.2, 2360.7, 2511.1, 2584.4, 3124.5, 
3436.9. 
HRMS (El) 153.0426 (M+). C7H7N03 requires 153.0426. 
Micro. Calcd for C7H7N03: C, 54.90; H, 4.61; N, 9.15. Found: C, 54.93; H, 4.55; N, 9.07. 
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Methyl N-{ [5-(3-phenylpropionyl)-lH-pyrrol-2-yl] carbonyl}-L-phenylalaninate 
(3.2la) 
189 
Pyrrole acid 3.20a (150 mg, 0.62 mmol, 1 equiv) was coupled with methyl L-
phenylalaninate hydrochloride (146 mg, 0.68 mmol, 1.1 equiv) by modified General 
Procedure 1. The crude product was purified by flash chromatography on silica (ethyl 
acetate/petroleum ether, 2:3) to give 3.2la (175 mg, 70%) as a brown residue. 
IH NMR (CDCh, 500 MHz) (5 3.03 (m, 2H, PhCfuCH2), 3.14 (m, 2H, PhCH2Cfu), 3.21 
(m, 2H, CfuPh), 3.75 (s, 3H, C02CH3), 5.05 (m, IH, NHCH), 6.46 (m, 2H, pyrrole H3 and 
NHCH), 6.78 (dd, IH, J 2.4,3.9 Hz, pyrrole H4), 7.10 (m, 2H, ArH), 7.17-7.30 (m, 8H, 
ArH), 10.00 (s(br), IH, pyrrole NH). 
l3C NMR (CDCb, 75 MHz) (530.3 (phCH2CH2), 37.9 (CHCH2Ph), 40.0 (PhCH2CH2), 
52.5 (C02CH3), 53.1 (NHCH), 11 0.4 (pyrrole C3), 115.5 (pyrrole C4), 126.2, 127.2, 128.3, 
128.5, 128.6, 129.3, 135.6, 140.9 (ArC), 129.7 (pyrrole C2), 133.3 (pyrrole C5), 159.4 
(CONH), 171.9 (C02Me), 190.0 (CH2CO). 
FTIR (CHCh) 1529.4, 1548.7, 1668.3, 1741.6,3008.7,3425.3. 
HRMS (ED 404.1745 ~). C24H24N203 requires 404.1736. 
Micro. Calcd for C24H24N204: C, 71.27; H, 5.98; N, 6.93. Found: C, 71.37; H, 6.15; N, 
7.10. 
Methyl N-[ (5-acetyl-1H-pyrrol-2-yl)carbonyl]-L-phenylalaninate (3.21 b) 
Pyrrole acid 3.20b (200 mg, 1.31 mmol, 1 equiv) was coupled with methyl L-
phenylalaninate hydrochloride (310 mg, 1.44 mmol, 1.1 equiv) by modified General 
Procedure 1. The crude product was purified by flash chromatography on silica (ethyl 
acetate/petroleum ether, 2:1) to give 3.2lb (375 mg, 91%) as a cream solid. An analytical 
sample was obtained by the diffusion of petroleum ether into a solution of 3.21b dissolved 
in ethyl acetate. 
mp 103-105°C. 
IH NMR (CDCh, 500 MHz) (5 2.42 (s, 3H, CH3CO), 3.20 (m, 2H, CfuPh), 3.75 (s, 3H, 
C02CH3), 5.06 (m, 1H, NHCH), 6.52 (dd, 1H, J= 2.9,3.9 Hz, pyrrole H3), 6.67 (d, 1H, J 
= 7.8 Hz, NHCH), 6.88 (dd, IH, J= 2.7, 4.2 Hz, pyrrole H4), 7.10 (m, 2H, ArH), 7.25 (m, 
3H, ArH), 10.11 (s(br), IH, pyrrole NH). 
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l3C NMR (CDCh, 75 MHz) 825.8 (CH3CO), 37.9 (CH2Ph), 52.5 (C02CH3), 53.2 
(NHCH), 110.9 (pyrro1e C3), 116.3 (pyrro1e C4), 127.2, 128.6, 129.2, 135.7 (ArC), 130.0 
(pyrro1e C2), 133.6 (pyrro1e C5), 159.4 (CONH), 172.1 (C02), 188.6 (CH3CO). 
FTIR (KBr, diffuse refraction method) 1546.8, 1654.8, 1741.6, 2956.7, 3031.9, 3112.9, 
3352.1. 
HRMS (EI) 314.1271 (Ml. C17H18N204 requires 314.1267. 
Micro. Calcd for C17H18N204: C, 64.96; H, 5.77; N, 8.91. Found: C, 65.13; H, 5.84; N, 
8.77. 
Methyl (RS)-N-{ [5-(1-hydroxy-3-phenylpropyl)-lH-pyrrol-2-yl] carbonyl}-L-phenyl-
alaninate (3.14a) 
The pyrro1e 3.21a (112 mg, 0.28 mmo1, 1 equiv) was reduced with zinc borohydride (4.35 
mL of a 0.14 M solution in ether, 0.61 mmo1, 2.2 equiv) by General Procedure J. The 
crude material was purified by flash chromatography on silica (ethyl acetate/petroleum 
ether, 1: 1) to give three compounds. The first fraction to elute contained a mixture of 
starting material 3.21a and the deoxygenated byproduct methyl N-[(5-(3-pheny1propy1)-
1H-pyrrol-2-y1)carbony1]-L-pheny1a1aninate 3.14c (41 mg). Spectral data for 3.14c (from 
mixture). 
IH NMR (CDCh, 500 MHz) 8 1.95 (m, 2H, Cfu), 2.63 (m, 4H, 2 x Cfu), 3.18 (m, 2H, 
CfuPh), 3.71 (s, 3H, C02CH3), 5.03 (m, 1H, NHCH), 5.93 (m, 1H, pyrro1e H4), 6.23 (d, 
IH, J = 7.8 Hz, NHCH), 6.45 (m, 1H, pyrro1e H3), 7.11-7.29 (m, 10H, ArH), 9.35 (s(br), 
1H, pyrro1e NH). 
HRMS (EI) 390.1953 (M+). C2~26N203 requires 390.1943. 
The second fraction to elute contained 3.14a (24 mg, 21%, 1:1 mixture of 
diastereoisomers) as a light yellow oil. 
IH ]\1NlR (CDCh, 500 MHz) 82.13 (m, 2H, PhCH2Cfu), 2.69-2.82 (m, 2H, PhCfuCH2), 
3.20 (m, 2H, CHCfuPh), 3.71 and 3.72 (s, each 3H, C02CH3, isomer A and B), 4.75 (m, 
1H, CHOH) , 5.02 (m, 1H, NHCH), 6.02 (m, 1H, pyrro1e H4), 6.42 (d, 1H, J = 7.3 Hz, 
NHCH), 6.48 (m, 1H, pyrro1e H3), 7.11-7.29 (m, 10H, ArH), 10.67 and 10.70 (s(br), each 
1H, pyrro1e NH, isomer A and B). 
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l3C NMR (CDCh, 75 MHz) 031.8 (PhCH2CH2), 38.2 (CHCH2Ph), 38.6 and 38.7 
(phCH2CH2, isomers A and B), 52.4 (C02CH3), 53.1 (NHCH) , 67.1 and 67.1 (CHOH, 
isomers A and B), 106.4 and 106.5 (pyrrole C4, isomers A and B), 110.7 (pyrrole C3), 
124.0 (pyrrole C2), 125.9, 127.2, 128.4, 128.5, 128.6, 129.3, 135.6, 141.6 (ArC), 140.1 
(pyrrole C5), 161.1 (CONH), 172.0 (C02Me). 
FTIR (CHCh) 1521.7, 1602.7, 1641.3, 1741.6,3012.6,3030.0,3436.9. 
HRMS (El) 388.1800 (M+-H20). C2Ji24N203 requires 388.1787. 
Methyl (RS)-N-{[5-(1-hydroxyethyl)-lH-pyrrol-2-yl]carbonyl}-L-phenylalaninate 
(3.14b) 
Method A 
The pyrrole 3.21b (150 mg, 0.48 mmol, r equiv) was reduced with lithium borohydride (21 
mg, 0.95 mmol, 2 equiv) according to General Procedure K. The crude product was 
partially purified flash chromatography on silica (ethyl acetate/petroleum ether, 4: 1) to 
give 3.14b (70 mg, 46%) as a slightly impure light green residue by NMR 
spectroscopy. 
IH NMR (CDCh, 500 MHz) 0 1.53 (m, 3H, CH3CHOH), 3.20 (m, 2H, CfuPh), 3.74 (s, 
3H, C02CH3), 4.90 (m, IH, CHOR), 5.03 (dd, IH, J= 5.9, 12.2 Hz, NHCH), 6.00 (s, IH, 
pyrrole H4), 6.48 (t, 1H, J = 2.7 Hz, pyrrole H3), 6.68 (m, IH, NHCH), 7.15 (d, 2H, J 
6.8 Hz, ArID, 7.26 (m, 3H, ArH), 10.71 and 10.73 (s(br), each 1H, pyrrole NH, isomers A 
and B). 
No further analytical data was obtained due to product degradation. 
6.3.2 Attempted preparation of the C5-(hydroxyalkyl)pyrrole 3.14b 
ft HO n OHC N C02Et ---'" y "~/ "C02R 1 
H Me H 
3.16a I 3.23a R 1 Et 
L 3.23bR1 H 
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Ethyl {RS)-5-{l-hydroxyethyl)-lH-pyrrole-2-carboxylate (3.23a) 
A stirred solution of the pyrrole ester 3.16a (400 mg, 2.39 mmol, 1 equiv) in dry THF (40 
mL) under an inert atmosphere was cooled to -23°C (dry ice/carbon tetrachloride). 
Methyllithium (1.50 mL of a 1.6 M solution in ether, 2.39 mmol, 1 equiv) was added over 
30 min, and the solution was stirred at -23°C for 2.5 h. After this, a further 1.50 mL of the 
methyllithium solution was added over 30 min, and the solution was again stirred at -23°C 
for 2.5 h. The resultant solution was poured onto an ether/ice bath, and once the ice had 
melted the layers were separated. The organic layer was washed with aqueous saturated 
brine (25 mL), water (2 x 25 mL), dried (MgS04), and the solvent was removed by 
evaporation under reduced pressure to yield 3.23a (418 mg, 95%) as a brown oil. (NOTE: 
In previous experiments, the title product was isolated from the crude material by flash 
chromatography on silica, using ethyl acetate/petroleum ether, 3:1, as the eluant.) 
IH NMR (CDCb, 500 MHz) 8 1.34 (t, 3H, J 7.1 Hz, CH2CH3), 1.55 (d, 3H, J 6.8 Hz, 
CfuCHOH), 3.08 (s(br), IH, CHOH), 4.29 (q, 2H, J = 7.2 Hz, CHzCH3), 4.96 (q, IH, J 
6.5 Hz, CH3CHOH), 6.05 (t, IH, J 3.2 Hz, pyrrole tH), 6.83 (t, IH, J 3.2 Hz, pyrrole 
H3), 9.77 (s(br), IH pyrrole NH). 
13C NMR (CDCb, 75 MHz) 8 14.4 (CH2CH3), 23.2 (CH3CHOH), 60.4 (QH2CH3), 64.0 
(CH3CHOH), 106.3 (pyrrole C4), 115.9 (pyrrole C3), 121.8 (pyrrole C2), 141.5 (pyrrole 
C5), 161.9 (C02), 
FTIR (CHCb) 1693.4,2983.7,3020.3,3446.6. 
HRMS (El) 183.0897 (M+). C9H13N03 requires 183.0895. 
Micro. Calcd for C9H13N03: C, 59.00; H, 7.15; N, 7.65. Found: C, 58.60; H, 7.22; N, 7.60. 
(RS)-5-{l-Hydroxyethyl)-lH-pyrrole-2-carboxylic acid (3.23b) 
A stirred solution of the pyrrole ester 3.23a (575 mg, 3.13 mmol, 1 equiv) in 1:1 
THF/water (lO mL) under an inert atmosphere was warmed to 40-50°C. Sodium 
hydroxide (377 mg, 9.42 mmol, 3 equiv) was added, and the progress of the reaction was 
monitored by TLC (ethyl acetate/petroleum ether, 1: 1). After 24 h, the solution was cooled 
to r.t., washed with ether (10 mL), cooled to O°C and acidified to pH ~4 by the dropwise 
addition of 1M aqueous hydrochloric acid. The resulting solution was extracted with ether 
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(3 X 15 mL), the combined ethereal extracts were washed with aqueous saturated brine (15 
mL), dried (MgS04), and the solvent was removed by evaporation under reduced pressure 
to give 3.23b (85 mg, 17%) as a purple solid. This product was used without further 
purification. 
mp11O-115°C. 
'H NMR (acetone-d6, 300 MHz) (5 1.59 (d, 3H, J 6.3 Hz, CH3CHOH), 4.43 (s(br), IH, 
CHOH), 5.02 (m, IH, CH3CHOH), 6.20 (t, IH, J 3.2 Hz, pyrrole H4), 6.87 (t, IH, J = 
3.2 Hz, pyrrole H3), 10.47 (s(br), IH, pyrrole NH). 
BC NMR (acetone-d6, 75 MHz) (523.2 (QH3CHOH), 63.3 (CH3CHOH), 105.9 (pyrrole 
C4), 115.6 (pyrrole C3), 121.8 (pyrrole C5), 143.2 (pyrrole C2), 161.8 (Q02H). 
FTIR (KBr, diffuse refraction method) 1651.0,3230.5,3419.6. 
HRMS (El) 155.0579 (M+). C7H9N03 requires 155.0582. 
Methyl (RS)-N-{[5-(1-hydroxyethyl)-lH-pyrrol-2-yl]carbonyl}-L-ph enylalanin ate 
(3.14b) 
MethodB 
Pyrrole acid 3.23b (20 mg, 0.13 mmol, 1 equiv) was coupled with methyl L-
phenylalaninate hydrochloride (31 mg, 0.14 mmol, 1.1 equiv) by General Procedure I, 
except in the workup whereby 0.1 M hydrochloric acid was used instead of the 3 M 
hydrochloric acid. The crude product was purified by flash chromatography on silica 
(ethyl acetate/petroleum ether, 4: 1) to give 3.14b (22 mg, 54%) as a colourless oil. 
'H NMR (CDCh, 500 MHz) (5 1.53 (m, 3H, CH3CHOH), 3.20 (m, 2H, CfuPh) , 3.73 (s, 
3H, C02CH3), 4.89-5.05 (m, 2H, CH3CHOH plus NHCH), 6.00 (d, IH, 2.0 Hz, pyrrole 
H4), 6.48 (m, IH, pyrrole H3) 6.55 (s(br), IH, NHCH), 7.13 (d, 2H, J 7.3 Hz, ArID, 
7.25 (m, 3H, ArH), 10.65 (s(br), IH, pyrrole NH). 
FTIR (CHCh) 1521.7, 1645.2, 1739.7,3022.2,3435.0. 
HRMS (El) 316.1423 (M+). C17H2oN204 requires 316.1423. 
No further analytical data was obtained due to product degradation. 
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6.3.3 Preparation of the 5-formylpyrroles 3.18d-i, and the 5-(hydroxymethyl)-
pyrroles 3.13b and 3.24 
n OHC N C02H 
H 
3.16b 
1 
1I\Q OHC""~/yN 
H 0 C02Me 
3.26 
j 
HO~q 
H ° C02Me 
3.24 
11\ ~ CO R2 -------, 
OHC" "~/ Y y 2 
H ° Rl 
3.18b, d-i 
3.18b 
3.18d 
3.18e 
3.18f 
3.18g 
3.18h 
3.18i 
Rl 
CH2CHMe2 
H 
CH2Ph 
CH2CHMe2 
CHMe2 
Me 
H 
3.13b 
R2 
Me 
Bn 
Et 
Et 
Me 
Me 
Me 
Methyl N-[(5-formyl-1H-pyrrol-2-yl)carbonyl]-L-leucinate (3.18b) 
The pyrrole acid 3.16b (100 mg, 0.72 mmol, 1 equiv) was coupled with methyl L-Ieucinate 
hydrochloride (144 mg, 0.79 mmol, 1.1 equiv) by General Procedure I. The crude product 
was purified by flash chromatography on silica (ethyl acetate/petroleum ether, 2:1) to give 
3.18b (116 mg, 61 %) as a cream solid. 
mp 139-142°C. 
IH NMR (CDCh, 500 MHz) () 0.96 (m, 6H, CH(Cfu)2), 1.61-1.77 (m, 3H, CfuCH(CH3)2), 
3.77 (s, 3H, C02Cfu), 4.83 (m, IH, NHCH), 6.62 (d, IH, 8.3 Hz, NHCH), 6.68 (d, IH, 
J = 2.4 Hz, pyrrole H3) 6.93 (d, IH, J = 2.9 Hz, pyrrole H4), 9.62 (s, IH, CHO), 10.18 
(s(br), IH, pyrrole NH). 
l3C NMR (CDCh, 75 MHz) () 21.9,22.8,24.9,41.7,50.9,52.6,111.0,120.0,131.2, 133.9, 
159.6, 173.7, 180.2. 
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FTIR (CHCh) 1529.4, 1550.7, 1676.0, 1739.7,2960.5,3018.4,3425.3. 
HRMS (El) 266.1266 (M+). C13HlSN204 requires 266.1267. 
Benzyl N-[ (5-formyl-lH-pyrrol-2-yl)carbonyl] glycinate (3.18d) 
195 
The pyrrole acid 3.16b (120 mg, 0.86 mmol, 1 equiv) was coupled with benzyl glycinate 
hydrochloride (191 mg, 0.95 mmol, 1.1 equiv) by General Procedure 1. The crude product 
was purified by flash chromatography on silica (ethyl acetate/petroleum ether, 3:2) to give 
3.18d (138 mg, 56%) as an orange solid. 
mp 137-139°C. 
IH NMR (CDCh, 500 MHz) 0 4.26 (d, 2H, J= 4.9 Hz, NHCfu), 5.22 (s, 2H, CfuPh), 6.69 
(dd, lH, J 2.4, 3.9 Hz, pyrrole H3), 6.73 (s(br), IH, NHCH2), 6.93 (dd, IH, J 2.4, 3.9 
Hz, pyrrole H4), 7.36 (m, 5H, ArID, 9.62 (s, lH, CHO), 10.30 (s(br), 1H, pyrrole NH). 
J3C NMR (CDCh, 75 MHz) 041.5 (NHCH2), 67.5 ~HzPh), 111.3 (pyrrole Q,), 120.0 
(pyrrole C4), 128.4, 128.6, 128.7, 131.0 (ArC), 134.0 (pyrrole C2), 134.9 (pyrrole ~, 
160.0 (CONH), 169.8 (C02), 180.3 (CHO). 
FTIR (CHCh) 1533.3, 1552.6, 1678.0, 1743.5,3031.9,3425.3. 
HRMS (El) 286.0952 (Ml. ClsH14N204 requires 286.0954. 
Micro. Calcd for ClsH14N204: C, 62.93; H, 4.93; N, 9.79. Found: C, 62.90; H, 4.86; N, 
10.09. 
Ethyl N-[ (5-formyl-lH-pyrrol-2-yl)carbonyl]-L-phenylalaninate (3.18e) 
The pyrrole acid 3.16b (80 mg, 0.58 mmol, 1 equiv) was coupled with ethyl L-
phenylalaninate hydrochloride (145 mg, 0.63 mmol, 1.1 equiv) by modified General 
Procedure 1. The crude product was purified by flash chromatography on silica (ethyl 
acetate/petroleum ether, 1: 1) to give 3.18e (104 mg, 58%) as a cream solid. 
mp42-45°C. 
IH NMR (CDCI3, 500 MHz) 0 1.28 (t, 3H, J = 7.1 Hz, CH2Cfu), 3.24 (m, 2H, CfuPh), 
4.23 (q, 2H, J 7.0 Hz, CfuCH3), 5.09 (m, 1H, NHCH), 6.63 (d, J 3.9 Hz, pyrrole 
6.81 (d, IH, J 7.8 Hz, NHCH), 6.93 (d, 1H, J = 4.4 Hz, pyrrole 7.16 (m, 2H, 
ArID, 7.27 (m, 3H, ArID, 9.61 (s, 1H, CHO), 10.50 (s(br), IH, pyrrole NH). 
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13C NMR (CDCh, 75 MHz) 0 14.1 (CH2CH3), 38.0 ~H2Ph), 53.3 (NHCH), 61.8 
(CH2CH3), 111.2 (pyrrole C3), 119.9 (pyrro1e C4), 127.2, 128.5, 129.3, 135.6 (Arg, 131.3 
(pyrrole C2), 134.0 (pyrrole C5), 159.3 (CONH), 171.5 (C02), 180.3 ~HO). 
FTIR (CHCh) 1529.4, 1550.7, 1676.0, 1733.9,2987.5,3423.4. 
HRMS (El) 314.1269 (M+). C17H18N204 requires 314.1267. 
Micro. Calcd for C17H18N204: C, 64.96; H, 5.77; N, 8.91. Found: C, 64.68; H, 5.98; N, 
9.20. 
Ethyl N-[(5-formyl-lH-pyrrol-2-yl)carbonyl]-L-lencinate (3.18t) 
The pyrrole acid 3.16b (80 mg, 0.58 mmol, 1 equiv) was coupled with ethyl L-leucinate 
hydrochloride (124 mg, 0.63 mmol, 1.1 equiv) by General Procedure 1. The crude product 
was purified by flash chromatography on silica (ethyl acetate/petroleum ether, 1: 1) to give 
3.18f (61 mg, 38%) as an orange oil. 
IH NMR (CDCh, 500 MHz) 0 0.95 (m, 6H, CH(CH3)2), 1.29 (t, 3H, J = 7.1 Hz, CH2Cfu), 
1.61-1.74 (m, 3H, C.thC!!), 4.22 (q, 2H, J= 7.2 Hz, C.thCH3), 4.81 (m, 1H, NHCH), 6.69 
(d, 1H, J 3.9 Hz, pyrrole H3), 6.90 (d, IH, J = 3.9 Hz, pyrrole H4), 6.98 (d, 1H, J = 8.3 
Hz, NHCH), 9.59 (s, 1H, CHO), 10.36 (s(br), IH, pyrrole NH). 
l3C NMR (CDCh, 75 MHz) 0 14.0 (CH2CH3), 21.5, 22.7 (CH(CH3)2), 24.8, 40.9 
(CH2CH), 50.9 (NHCH), 61.6 (CH2CH3), 111.7 (pyrrole .cJ), 119.5 (pyrrole C4), 131.4 
(pyrrole C2), 133.9 (pyrrole C5), 159.9 (CONH), 173.9 (C02)' 180.4 (CHO). 
FTIR (CHCh) 1529.4, 1550.7, 1676.0, 1732.0,2964.4,3010.7,3033.8,3425.3. 
HRMS (El) 280.1419 (Ml. C14H20N204 requires 280.1423. 
Micro. Calcd for C14H20N204: C, 59.99; H, 7.19; N, 9.99. Found: C, 60.06; H, 7.27; N, 
10.01. 
Methyl N-[ (5-formyl-lH-pyrrol-2-yl)carbonyl]-L-valinate (3.18g) 
The pyrrole acid 3.16b (120 mg, 0.86 mmol, 1 equiv) was coupled with methyl L-valinate 
hydrochloride (159 mg, 0.95 mmol, 1.1 equiv) by modified General Procedure 1. The 
crude product was purified by flash chromatography on silica (ethyl 
acetate/dichloromethane, 1:1) to give 3.18g (115 mg, 53%) as a cream solid. 
mp 146-148°C. 
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IH NMR (CDCh, 500 MHz) 8 0.97 (m, 6H, CH(CH3)2), 2.25 (m, 1H, CH(CH3)2), 3.77 (s, 
3H, C02CH3), 4.70 (m, 1H, NHCH), 6.74 (d, 1H, J= 4.6 Hz, pyrrole H3), 6.85 (d, 1H, J= 
8.3 Hz, NHCH), 6.95 (d, 1H, J = 4.4 Hz, pyrrole H4), 9.62 (s, 1H, CHO), 10.54 (s(br), 1H, 
pyrrole NH). 
l3C NMR (CDCh, 75 MHz) 817.9, 18.9 (CH(CH3)2), 31.6 (CH(CH3)2), 52.4 (C02CH3), 
57.2 (NHCH), 111.2 (pyrrole C3), 120.1 (pyrrole C4), 131.4 (pyrrole C2), 133.9 (pyrrole 
C5), 159.7 (CONH), 172.5 (C02), 180.3 (CHO). 
FTIR (CHCh) 1529.4, 1548.7, 1678.0, 1735.8,2968.2,3033.8,3425.3. 
HRMS (E1) 252.1113 (M+). C12H16N204 requires 252.1110. 
Micro. Calcd for C12Hl~204: C, 57.13; H, 6.39; N, 11.10. Found: C, 57.32; H, 6.46; N, 
11.16. 
Methyl N-[ (5-formyl-1H-pyrrol-2-yl)carbonyl]-L-alaninate (3.18h) 
The pyrrole acid 3.16b (75 mg, 0.54 mmol, 1 equiv) was coupled with methyl L-alaninate 
hydrochloride (83 mg, 0.59 mmol, 1.1 equiv) by General Procedure 1. The crude product 
was purified by flash chromatography on silica (ethyl acetate/petroleum ether, 3:1) to give 
3.18h (52 mg, 43%) as a cream solid. 
mp 123-126°C. 
NNIR (CDCb, 300 MHz) 8 1.51 (d, 3H, J = 6.8 Hz, CHCH3), 3.79 (s, 3H, C02CH3), 
4.79 (m, IH, NHCH), 6.68 (m, 1H, pyrrole H3), 6.77 (m, 1H, NHCH), 6.94 (dd, IH, J 
2.4,3.9 Hz, pyrrole H4), 9.62 (s, 1H, CHO), 10.27 (s(br), 1H, pyrrole NH). 
BC NMR (CDCh, 75 MHz) 8 18.4, 48.2, 52.7, 111.4, 120.0, 131.4, 134.0, 159.5, 173.6, 
180.4. 
FTIR (CHCI3) 1529.4, 1550.7, 1676.0, 1739.7,3008.7,3035.7,3423.4. 
HRMS (El) 224.0797 (Ml. ClOH12N20 4 requires 224.0797. 
Methyl N-[ (5-formyl-lH-pyrrol-2-yl)carbonyl]glycinate (3.18i) 
The pyrrole acid 3.16b (10 mg, 0.72 mmol, 1 equiv) was coupled with methyl glycinate 
hydrochloride (99 mg, 0.79 mmol, 1.1 equiv) by General Procedure M. The crude product 
was purified by flash chromatography on silica (ethyl acetate/petroleum ether, 3:1) to give 
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3.18i (66 mg, 44%) as a cream solid. An analytical sample was obtained by 
recrystallisation from ethyl acetate/petroleum ether to give a white crystalline solid. 
mp 209-211 °C. 
IH NMR (acetone-d6, 500 MHz) (') 3.81 (s, 3H, C02CH3), 4.24 (d, 2H, J = 5.9 Hz, 
NHCfu), 7.07 (m, IH, pyrrole or H4), 7.13 (m, 1H, pyrrole or H4), 8.26 (s(br), 1H, 
NHCHz), 9.85 (s, IH, CHO), 11.53 (s(br), IH, pyrrole NH). 
I3C NMR (acetone-d6 + 3 drops DMSO-d6, 75 MHz) (') 40.7 (NHCH2), 5l.4 (C02CH3), 
112.8 (pyrrole C3), l17.3 (pyrrole C4), 132.2 (pyrrole C2), 134.7 (pyrrole C5), 160.1 
(CONH), 170.3 (C02), 180.8 (QHO). 
FTIR (KEr, diffuse refraction method) 1560.3, 164l.3, 1685.7, 1724.2,3136.0, 321l.3, 
3373.3. 
HRMS (El) 210.0646 (Ml. C9H lON20 4 requires 21O.064l. 
Methyl N-[ (5-hydroxymethyl-1H-pyrrol-2-yl)carbonyl]-L-Ieucinate (3.13b) 
Method A 
The pyrrole 3.18b (l16 mg, 0.44 mmol, 1 equiv) was reduced with zinc borohydride (6.85 
mL of a 0.14 M solution in ether, 0.96 mmol, 2.2 equiv) by General Procedure J. The 
crude product was purified by flash chromatography on silica (ethyl acetate/petroleum 
ether, 4:1) to give 3.18b (49 mg, 42%) as a cream solid. 
mp 92-96°C. 
IH NMR (CDCb, 500 MHz) (') 0.94 (m, 6H, CH(CH3)z), 1.63-l.75 (m, 3H, CfuCH), 3.76 
(s, 3H, C02C!:b), 4.60 (d, 2H, J 2.9 Hz, CfuOH), 4.76 (m, IH, NHCH), 6.04 (dd, 1H, J 
= 2.4, 3.4 Hz, pyrrole H4), 6.57 (dd, 1H, J= 2.4,3.4 Hz, pyrrole H3), 6.62 (d, IH, J 8.8 
Hz, NHCH), 10.51 (s(br), IH, pyrro1e NH). 
l3C NMR (CDCb, 75 MHz) (') 21.6,22.8 (CH(CH3)2), 24.8 (CHzCH), 4l.0 (QH2CH), 50.7 
(NHCH), 52.4 (COZCH3), 57.3 (CHzOH), 107.9 (pyrrole C4), l10.9 (pyrrole C3), 124.6 
(pyrrole C2), 136.8 (pyrrole C5), 16l.7 (QONH), 174.5 (QOz). 
FTIR (CHCh) 1525.6, 164l.3, 1739.7,2958.6,3438.8. 
HRMS (El) 268.1418 (~). C13H2oN204 requires 268.1423. 
Micro. Calcd for C13H2oN204: C, 58.19; H, 7.51; N, 10.44. Found: C, 58.35; 7.37; N, 
10.36. 
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MethodB 
The pyrrole 3.18b (35 mg, 0.13 mmol, 1 equiv) was reduced with lithium borohydride (6 
mg, 0.26 mmol, 2 equiv) by modified General Procedure K. The crude product was 
purified by flash chromatography on silica (ethyl acetate/petroleum ether, 4:1) to give 
3.13b (23 mg, 66%) as an off-white solid. 
mp 94-97°C. 
IH NMR data was identical for that recorded above. 
Micro. Calcd for C13H20N204: C, 58.19; H, 7.51; N, 10.44. Found: C, 58.42; H, 7.29; N, 
10.51. 
Methyl N-[ (5-formyl-1H-pyrrol-2-yl)carbonyl]-L-prolinate (3.26) 
The pyrrole acid 3.16b (100 mg, 0.72 mmol, 1 equiv) was coupled with methyl L-prolinate 
hydrochloride (131 mg, 0.79 mmol, 1.1 equiv) by modified General Procedure 1. The 
crude product was purified by flash chromatography on silica (ethyl acetate/petroleum 
ether, 2:1 then 4:1) to give 3.26 (133 mg, 74%) as a white solid. 
mp decomp. >40°C. 
IH NMR (CDCh, 500 MHz) (5 2.01-2.27 (m, 4H, NCH2CfuCfuCH), 3.73 (s, 3H, 
C02CH3), 3.86 (m, 1H, NCH2a), 3.97 (m, 1H, NCfub), 4.70 (m, 1H, NCH), 6.69 (m, 1H, 
pyrrole H3), 6.92 (m, 1H, pyrrole H4), 9.63 (s, 1H, CHO), 10.38 (s(br), 1H, pyrrole NH). 
l3C NMR (CDCh, 75 MHz) (525.3, 28.6 (NCH2CH2CH2CH), 48.5 (NCH2), 52.3 
(C02CH3), 60.2 (NCH), 113.2 (pyrrole C3), 119.3 (pyrrole C4), 130.7 (pyrrole C2), 133.3 
(pyrrole C5), 159.5 (£ONH), 172.3 (£02),180.1 (CHO). 
FTIR (CHCh) 1544.9, 1616.2,1672.2,1745.5,3419.6. 
HRMS (El) 250.0952 (M+). C12H14N204 requires 250.0954. 
Micro. Calcd for C12H14N204: C, 57.59; H, 5.64; N, 11.19. Found: C, 57.63; H, 5.73; N, 
11.21. 
Methyl N-[(5-hydroxymethyl-1H-pyrrol-2-yl)carbonyl]-L-prolinate (3.24) 
The pyrrole 3.26 (120 mg, 0.48 mmol, 1 equiv) was reduced with zinc borohydride (7.54 
mL of a 0.14 M solution in ether, 1.05 mmol, 2.2 equiv) by General Procedure J. The 
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crude product was purified by flash chromatography on silica (ethyl acetate/acetone, 10:1) 
to give 3.24 (29 mg, 24%) as an orange oil. 
IH NMR (CDCh, 500 MHz) (5 2.03-2.24 (m, 4H, NCH2ClliClliCH), 3.44 (s(br), IH, OH), 
3.73 (s, 3H, C02Cfu), 3.85 (m, IH, NCllia), 3.95 (m, IH, NCllib), 4.61 (s, 2H, ClliOH), 
4.73 (m, IH, NCH), 6.13 (s, IH, pyrrole H4), 6.60 (s, lH, pyrrole H3), 10.75 (s(br) , IH, 
pyrrole NH). 
l3C NMR (CDCh, 75 MHz) (525.2, 28.8 (NCH2CH2CH2CH), 48.8 (NCH2), 52.4 
(C02CH3), 57.4 (CH2OH), 60.2 (NCH) , 108.2 (pyrrole C4), 113.8 (pyrrole C3), 124.6 
(pyrrole C2), 136.9 (pyrrole C5), 161.3 (CON), 172.8 (C02)' 
FTIR (CHCh) 1596.9, 1743.5,3010.7,3436.9,3691.5. 
HRMS (E1) 252.1119 (M+). C12H16N204 requires 252.1110. 
6.3.4 Preparation of the 5-formylpyrroles 3.29a-b, and the 5-(hydroxymethyl)-
pyrrole 3.25 
o R2 2 
H2N~l ~ 1 ~ N C02R ----__ l> N~l ~ ~\ H 0 R OHC N ( :. N C02Me HI H 
3.27a-b R3 H 
3 3.27c R H.H20 
3.28a-b R3 Me.HCI 
3.28cR3 Me 
H 0 [1 H 
3.29a-c 
j 
)/\ H 0 ~ 
HO,,-/ 'r.:/ nN~N~CO~Me 
H 0 ::: H 
3.27a/3.28a/3.29a CH2Ph H 
3.27b/3.28b/3.29b CH2CHMe2 H 
3.27c/3.28c/3.29c CH2Ph CH2CHMe2 "'Ph 
3.25 
Methyl N-(L-phenylalanyl)glycinate hydrochloride (3.28a) 
N-(L-Phenylalanyl)glycine 3.27a (180 mg, 0.80 romol, 1 equiv) was esterified with 
methanol by General Procedure O. The crude product was purified by flash 
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chromatography on silica (1: 1 ethyl acetate/methanol, visualising agent ninhydrin) to give 
3.28a (197 mg, 89%) as a white solid. 
mp 135-138°C (lit.25 136-138°C). 
IH NMR (CD30D, 500 MHz) () 3.05 (dd, IH, J = 8.3, 14.2 Hz, CfuaPh), 3.26 (dd, 1H, J 
5.9, 14.2 Hz, CfubPh), 3.73 (s, 3H, C02Cfu), 3.98 (s, 2H, NHCfu), 4.13 (~ IH, H2NCH), 
7.34 (m, 5H, ArB.). 
Methyl N-(L-Ieucyl)glycinate hydrochloride (3.28b) 
N-(L-Leucyl)glycine 3.27b (500 mg, 2.66 mmol, 1 equiv) was esterified with methanol by 
General Procedure O. The crude product was purified by flash chromatography on silica 
(ethyl acetate/methanol, 2:1, visualising agent ninhydrin) to give 3.28b in a quantitative 
yield as a hygroscopic white solid. 
IH NMR (CD30D, 500 MHz) () 1.01 (m, 6H, CH(Cfu)2), 1.65-1.78 (m, 3H, CfuCH), 3.73 
(s, 3H, C02CH3), 3.91 (m, IH, H2NCB.), 4.01 (ABq, 2H, J = 17.6 Hz, NHCfu). 
HRMS (ES) 203.1404 (M+·CI). C9Hl9N203 requires 203.1396. 
Methyl N-{N- [(S-formyl-lH-pyrrol-2-yl)carbonyJ]-L-phenylalanyl}glycinate (3.29a) 
The pyrrole acid 3.16b (51 mg, 0.37 mmol, 1 equiv) was coupled with the dipeptide 3.28a 
(110 mg, 0.40 mmol, 1.1 equiv) by General Procedure M. The crude product was purified 
by flash chromatography on silica (ethyl acetate/petroleum ether, 4:1) to give 3.29a (64 
mg, 49%) as a cream solid. 
mp decomp. 60-80°C, then melting at 209-211 °C. 
IH NMR (acetone-d6, 500 MHz) () 3.13 (dd, IH, J 9.5, 13.9 Hz, CfuaPh), 3.44 (dd, IH, J 
4.9,14.2 Hz, Cfu~h), 3.78 (s, 3H, C02CH3), 4.10 (d, 2H, J 5.9 Hz, NHCfu), 5.06 (m, 
IH, NHCB.), 7.05 (m, IH, pyrrole H3), 7.09 (m, IH, pyrrole IH), 7.29 (t, IH, J 7.3 Hz, 
ArH), 7.37 (t, 2H, J = 7.6 Hz, ArH), 7.45 (d, 2H, J 7.3 Hz, ArH), 7.93 (s(br), IH, 
NHCH2), 8.05 (d, IH, J = 8.8 Hz, NHCH), 9.80 (s, 1H, CHO), 11.45 (s(br), 1H, pyrrole 
NID· 
l3C NMR (acetone-d6, 75 MHz) () 37.8 (CH2Ph), 40.9 (NHCH2), 51.5 (C02CH3), 54.7 
(NHCH), 112.0 (pyrrole C3), 118.4 (pyrrole C4), 126.7, 128.5, 129.5, 138.1 (ArC), 132.1 
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(pyrrole C2), 134.7 (pyrrole C5), 159.8 (CONHCH), 170.2 (C02), 171.6 (CONHCH2)' 
180.4 (CHO). 
FTIR (KBr, diffuse refraction method) 1558.4, 1670.2, 1747.4,2341.4,2360.7,3288.4. 
HRMS (El) 357.1329 (M+). ClsHI9N30S requires 357.1325. 
Methyl N-{N-[ (5-formyl-lH-pyrrol-2-yl)carbonyl]-L-leucyl}glycinate (3.29b) 
The pyrrole acid 3.16b (120 mg, 0.86 mmol, 1 equiv) was coupled with the dipeptide 
3.28b (227 mg, 0.95 mmol, 1.1 equiv) by General Procedure M. The crude product was 
purified by flash chromatography on silica (ethyl acetate/petroleum ether, 4:1), followed 
by further flash chromatography on silica (ethyl acetate/acetone, 2:1), to give 3.29b (126 
mg, 45%) as an orange solid. 
mp decomp. >50°C. 
IH NMR (acetone-d6, 500 MHz) (5 0.93 (m, 6H, CH(CH3)2), 1.65-1.80 (m, 3H, CfuCH), 
3.65 (s, 3H, C02CH3), 3.95 (d, 2H, J = 5.9 Hz, NHCfu), 4.73 (m, IH, NHCH), 7.00 (s, 
2H, pyrrole H3 and H4), 7.76 (s(br), IH, NHCH2), 7.87 (d, IH, J = 8.3 Hz, NHCH), 9.71 
(s, 1H, CHO), 11.38 (s(br), 1H, pyrrole NH). 
l3C NMR (acetone-d6, 75 MHz) (521.2,22.7 (CH(CH3h), 24.8 (CH2CH), 40.8 (NHCH2), 
40.9 (CH2CH), 51.5 (C02CH3), 51.9 (NHCH) , 112.2 (pyrrole C3), 118.7 (pyrrole C4), 
132.2 (pyrrole C2), 134.7 (pyrrole C5), 160.2 (CONHCH), 170.3 (C02CH3), 172.8 
(QONHCH2), 180.5 (CHO). 
FTIR (KBr, diffuse refraction method) 1554.5, 1670.2, 1747.4,2958.6,3255.6,3413.8. 
HRMS (ES) 346.1372 (~+Na). C1sH21N3NaOS requires 346.1379. 
Methyl N-{N- [(5-formyl-lH-pyrrol-2-yl) carbonyl]-L-phenylalanyl}-L-Ieucinate (3.29c) 
N-(L-Phenylalanyl)-L-leucine hydrate 3.27c (200 mg, 0.67 mmol) was treated with 
diazomethane by General Procedure L to give methyl N-(L-phenylalanyl)-L-leucinate 
(3.28c, 202 mg) as a light brown oil. This dipeptide was coupled with the pyrrole acid 
3.16b (87 mg, 0.63 mmol, 1 equiv to 1.1 equiv of amine) by General Procedure M. The 
crude product was purified by flash chromatography on silica (ethyl acetate/petroleum 
ether, 3: 1), followed by diffusion of petroleum ether into a solution of the title product 
dissolved in ethyl acetate, to give 3.29c (135 mg, 52% over two steps) as a tan solid. 
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mp 100-103°C. 
IH NMR (CDCh, 500 MHz) 0 0.85 (m, 6H, CH(CH3h), 1.43-1.61 (m, 3H, CfuCH), 3.13 
(m, 2H, CfuPh), 3.73 (s, 3H, C02Cfu), 4.56 (m, 1H, Leu aID, 5.06 (q, 1H, J 7.3 Hz, 
Phe aID, 6.64 (dd, 1H, J= 2.4,3.9 Hz, pyrrole H3), 6.90 (m, 2H, pyrrole H4 plus NHCH), 
7.19 (m, 6H, ArH plus NHCH), 9.61 (s, 1H, CHO), 10.68 (s(br), 1H, pyrrole NH). 
I3C NMR (CDCh, 75 MHz) 022.1,22.6 (CH(CH3)2), 24.8, 41.6 (CH2CH), 38.8 (QH2Ph), 
51.0 (Leu aCH), 52.5 (C02CH3), 54.7 (phe aCH), 111.3 (pyrrole C3), 119.6 (pyrrole C4), 
126.9, 128.4, 129.4, 136.4 (ArC), 131.3 (pyrrole C2), 134.1 (pyrrole C5), 159.7 
(PyrCONH), 171.3 (CHCONH), 173.1 (C02), 180.3 (CHO). 
FTIR (KBr, diffuse refraction method) 1558.4, 1635.5, 1674.1, 1743.5,2958.6,3286.5. 
HRMS (ES) 414.2031 (M++H). C22H28N305 requires 414.2029. 
Methyl N-{N~[(5-hydroxymethyl-lH-pyrrol-2-yl)carbonyl]-L-phenylalanyl}-L-Ieucin­
ate (3.25) 
The pyrrole 3.29c (82 mg, 0.20 mmol, 1 equiv) was reduced with lithium borohydride (9 
mg, 0.40 mmol, 2 equiv) by General Procedure K. The crude product was purified by flash 
chromatography on silica (ethyl acetate), followed by diffusion of petroleum ether into a 
solution of the title product dissolved in ethyl acetate, to give 3.25 (56 mg, 68%) as a 
cream solid. 
mp decomp. >85°C. 
IH NMR (CDCb, 500 MHz) 0 0.84 (m, 6H, CH(CH3)2), 1.44-1.59 (m, 3H, CfuCH), 3.11 
(m, 2H, CfuPh), 3.69 (s, 3H, C02Cfu), 4.59 (m, 3H, Leu aH plus CfuOH), 5.05 (q, 1H, J 
7.7 Hz, Phe aH), 6.04 (t, lH, J = 2.9 Hz, pyrrole H4), 6.53 (m, 1H, pyrrole H3), 7.03 
(s(br), 1H, NHCH), 7.16 (m, 5H, ArH), 7.25 (s(br), IH, NHCH), 10.41 (s(br), lH, pyrrole 
NH). 
I3C NMR (CDCb, 75 MHz) 022.0,22.6 (CH(CH3)2), 24.7, 41.5 (CH2CID, 38.7 (CH2Ph), 
50.8 (Leu aCH), 52.3 (C02CH3), 54.5 (Phe aCH), 57.5 (CH20H), 108.1 (pyrrole C4), 
111.0 (pyrrole C3), 124.9 (pyrrole C2), 126.7, 128.4, 129.4, 136.3 (ArC), 136.7 (pyrrole 
C5), 161.2 (PyrCONH), 172.0 (CHCONH), 173.4 (C02), 
FTIR (KBr, diffuse refraction method) 1541.0, 1624.0, 1664.5, 1735.8,2958.6,3267.2. 
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HRMS (ES) 438.2023 (~+Na). C22H29N3NaOs requires 438.2005. 
6.3.5 Attempted preparation of the 4-(hydroxymethyl)pyrrole 3.26 
OHC 
~ N C02RJ 
H 
3.17b RI CH2Ph 3.30 3.31 
3.17c Rl H 
4-Formyl-lH-pyrrole-2-carboxylic acid (3.17c) 
The pyrrole 3.17b26 (152 mg, 0.66 mmol, 1 equiv) was hydrolysed with potassium 
hydroxide (149 mg, 2.65 mmol, 4 equiv) by General Procedure F. Residual benzyl alcohol 
was removed by Kugelrohr distillation (up to 120°C) to give 3.17c (71 mg, 77%) as a grey 
solid. 
mp decomp. >215°C (lit.24 220°C). 
IH NMR (acetone-d6, 300 1IIHz) (5 7.34 (m, 1H, pyrrole H3), 7.92 (m, 1H, pyrrole H5), 
9.97 (s, 1H, CHO), 11.69 (s(br), 1H, pyrrole NH). 
Methyl N-[(4-formyl-lH-pyrrol-2-yl)carbonyl]-L-phenylalaninate (3.30) 
The pyrrole acid 3.17c (58 mg, 0.42 mmol, 1 equiv) was coupled with L-phenylalanine 
methyl ester hydrochloride (99 mg, 0.46 mmol, 1.1 equiv) by modified General Procedure 
I. The crude product was purified by flash chromatography on silica (ethyl 
acetate/petroleum ether, 3:1) to give 3.30 (83 mg, 66%) as a tan solid. 
mp 150-152°C. 
IH NMR (CDCh, 500 MHz) (5 3.21 (m, 2H, CfuPh), 3.75 (s, 3H, C02C!b), 5.02 (m, 1H, 
NHCH), 6.54 (d, 1H, J= 7.3 Hz, NHCH), 7.00 (dd, 1H, J 1.5,2.4 Hz, pyrrole H3), 7.12 
(m, 2H, ArID, 7.27 (m, 3H, ArH), 7.51 (m, 1H, pyrrole H5), 9.80 (s, 1H, CHO), 10.41 
(s(br), 1H, pyrrole NB). 
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l3C NMR (CDCh, 75 MHz) 3 37.9 (CH2Ph), 52.5 (C02CH3), 53.3 (NHCH), 108.4 (pyrrole 
C3), 127.3 (2xC, pyrrole C2 and C4), 128.7, 129.1, 135.5 (ArC), 129.0 (pyrrole C5), 160.2 
(CONH), 171.7 (C02), 185.5 (QHO). 
FTIR (KBr, diffuse refraction method) 1535.2, 1629.7, 1654.8, 1735.8, 2362.6, 3211.3, 
3334.7. 
HRMS (ES) 301.1191 (M++H). C16H17N204 requires 301.1188. 
Methyl N-[ (4-hydroxymethyl-lH-pyrrol-2-yl)carbonyl]-L-phenylalaninate (3.31) 
The pyrrole 3.30 (43 mg, 0.14 mmol, 1 equiv) was reduced with lithium borohydride (6 
mg, 0.29 mmol, 2 equiv) according to General Procedure K. The crude product was 
purified by flash chromatography on silica (ethyl acetate/petroleum ether, 10:1) to give 
3.31 (12 mg, 28%) as a clear oil. An analytical sample was obtained by the diffusion of 
petroleum ether into a solution of 3.31 dissolved in ethyl acetate. 
mp 112-114°C. 
IH NMR (CDCh, 500 MHz) 3 3.19 (m, 2H, CfuPh), 3.76 (s, 3H, C02Cfu), 4.52 (s, 2H, 
CH20H), 5.03 (m, 1H, NHCH), 6.53 (m, 2H, NHCH and pyrrole H3), 6.84 (d, lH, J 1.5 
Hz, pyrrole H5), 7.15 (m, 2H, ArID, 7.27 (m, 3H, ArH), 9.41 (s(br), 1H, pyrrole NH). 
FTIR (KBr, diffuse refraction method) 1542.9, 1573.8, 1627.8, 1732.0, 1759.0, 2954.7, 
3274.9, 3382.9. 
No further analytical data was obtained due to product degradation. 
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6.3.6 Attempted preparation of the 5-(hydroxymethyl)pyrrole 3.13a by solid phase 
synthesis 
o 
R1HNyAo_ 
'Ph 
3.32a Rl FMOC 
3.32b Rl H 
3.35 
3.13a 
.. 
n H 0 OHC/~~/f(N~O­
H 0 -
'Ph 
3.33 
3.34 
N-[(5-Formyl-lH-pyrrol-2-yl)carbonyl]-L-phenylalanine Wang resin (3.33) 
N-(9-Fluorenylrnethoxycarbonyl)-L-phenylalanine Wang resin 3.32a (GL Biochem 
(Shanghai) Ltd., 100-200 mesh, loading 0,42 mmol g-l, 680 mg, 0.286 mmol, pre-dried 
under high vacuum for 16 h) was swollen with dry dichloromethane (5 mL) for 30 min, 
drained, and then re-suspended in 1:4 dry piperidine/dry dichloromethane (5 mL) and 
shaken at r.t. for 30 min. The resin was drained, washed with dry DMF (4 x 4 mL, 5 min), 
dry dichloromethane (3 x 4 mL, 5 min), and dried under high vacuum for 18 h. The resin 
was then swollen with dry dichloromethane (4 mL) for 30 min, drained, re-suspended in 
dry dichloromethane (4 mL), and the reaction syringe that contained the resin was shielded 
from light. Pyrrole acid 3.16b (159 mg, 1.14 mmol, 4 equiv) and benzotriazol-l-
yloxytris(dimethylamino)phosphonium hexafluorophosphate (505 mg, 1.14 mmol, 4 equiv) 
were added, and the mixture was shaken at r.t. for 5 min. N,N-Diisopropylethylamine (369 
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mg, 2.86 mmol, 10 equiv) was then added, and shaking was continued for 48 h. The resin 
was drained, washed with dry DMF (4 x 4 mL, 5 min), dry ether (2 x 4 mL, 5 min), dry 
dichloromethane (3 x 4 mL, 5 min) and dried under high vacuum for 18 h. 
N- [(5-Hydroxymethyl-1H-pyrrol-2-yl)carbonyIJ -L-phenylalanine (3.35) 
The resin 3.33 (loading 0.42 mmol it, 260 mg, 0.109 mmol, pre-dried under high vacuum 
for 16 h) was swollen with dry dichloromethane (4 mL) for 1 h, drained, washed with dry 
DMF (4 mL, 5 min), and then re-suspended in dry DMF (4 mL). Sodium borohydride (41 
mg, 1.09 mmol, 10 equiv) was added, and the resulting suspension was shaken for 24 h. 
The resin was drained, washed with dry DMF (3 x 4 mL, 5 min), dry ether (2 x 4 mL, 5 
min), dry dichloromethane (3 x 4 mL, 5 min) and dried under high vacuum for 18 h. The 
resin was then swollen with dry dichloromethane (2 mL) for 30 min, drained, re-suspended 
in 1:1 dry TFA/dry dichloromethane (4 mL) and shaken at r.t. for 2 h. The resin was 
drained, washed with dry TFA (2 x 4 mL, 5 min), dry dichloromethane (2 x 4 mL, 5 min) 
and dry THF (2 x 4 mL, 5 min). The combined washings were dried by evaporation under 
reduced pressure. Analysis by IH NMR spectroscopy revealed that degradation had 
occurred. 
Determination of Stability of 3.13a in 1:1 Trifluoroacetic AcidiDichloromethane 
The pyrrole 3.13a (2.0 mg) was dissolved in 1:1 dry TFA/dry dichloromethane (1 mL) and 
shaken at r.t. for 2 h. The solvent was removed by evaporation under reduced pressure to 
give a brown residue (4.9 mg). Analysis by IH NMR spectroscopy, thin layer 
chromatography and electrospray low resolution mass spectroscopy revealed degradation 
of pyrrole 3.13a. 
Determination of Stability of 3.18a in 1:1 Trifluoroacetic Acid/Dichloromethane 
The pyrrole 3.18a (25 mg) was dissolved in 1: 1 dry TF A/dry dichloromethane (4 mL) and 
shaken at r.t. for 2 h. The solvent was removed by evaporation under reduced pressure to 
give a brown residue (29 mg). Analysis by IH NMR spectroscopy revealed no degradation 
ofpyrrole 3.18a. 
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6.3.7 Attempted preparation ofthe 5-formylpyrrole 3.18a by solid phase synthesis 
JT\ R 0 
ORC" ":~( y N0o-
R 0 -
"Ph 
3.33 
3.13a 
• 
3.18a 
* JT\ ~ COR 
ORC" "!(' Y Y 2 
R 0 ::: 
"Ph 
3.36 
+ 
n ORC N C02R 
R 
3.16b 
Methyl N-[ (5-formyl-1H-pyrrol-2-yl)carbonyl]-L-phenylalaninate (3.18a) 
Method A 
The resin 3.33 was suspended in a mixture of dry benzene (3 mL), dry methanol (0.5 mL) 
and dry triethylamine (0.1 mL). Potassium cyanide (approximately 2 mg) was added, and 
the resulting suspension was refluxed for 48 h. The beads were drained, then washed with 
dry dichloromethane (3 x 4 mL, 5 min), dry THF (2 x 4 mL, 5 min) and dry methanol (2 x 
4 mL, 5 min). The combined filtrates were dried by evaporation under reduced pressure. 
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Analysis by IH NNIR spectroscopy did not reveal the presence of product, in comparison 
to the IH NMR spectrum of 3.18a previously prepared by solution phase chemistry. 
MethodB 
The resin 3.33 was swollen with dry dichloromethane (4 mL) for 30 min, drained, re-
suspended in 1:1 dry TFAIdry dichloromethane (4 mL) and shaken at r.t. for 2 h. The resin 
was drained, then washed with dry trifluoroacetic acid (2 x 4 mL, 5 min), dry THF (2 x 4 
mL, 5 min) and dry dichloromethane (4 mL, 5 min). The combined filtrates were dried by 
evaporation under reduced pressure. Attempted purification by flash chromatography on 
silica (ethyl acetate/benzene, 1 :4, then ethyl acetate/benzene, 1 :2, visualised with Mary's 
dip) gave an approximately 1:1 mixture of the pyrrole acid 3.16b and 3.36 (20 mg) by IH 
NMR spectroscopy. This mixture was treated with diazomethane by General Procedure L 
to give a complex mixture of materials by IH NMR spectroscopy, which could not be 
purified by flash chromatography on silica (ethyl acetate/petroleum ether, 2:3). 
6.3.8 Attempted preparation of the hydroxymethylpyrrole 3.31 by solution phase 
synthesis 
11\ ~ CORI 
OHC/ "~/ Y y 2 
H 0 .::: 
"Ph 
3.18aRI =Me 
3.36R1 =H 
3.35 
N- [(5-Formyl-1H-pyrrol-2-yl)carbonyl]-L-phenylalanine (3.36) 
A stirred solution of the pyrrole 3.18a (350 mg, 1.17 mmol, 1 equiv) and potassium 
carbonate (322 mg, 2.33 mmol, 2 equiv) in 10:1 methanol/water (27.5 mL) was refluxed 
for 18 h. After cooling to r.t., the methanol was removed by rotary evaporation, the 
resulting residue was dissolved in water (10 mL), 10% hydrochloric acid (10 mL) was 
added dropwise, and the resulting suspension was stirred for 15 min. Dichloromethane (20 
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mL) was added, stirring was continued for a further 15 min, and the layers were separated. 
The aqueous phase was extracted with dichloromethane (2 x 10 mL), the combined organic 
fractions were washed with saturated aqueous brine (10 mL), dried (MgS04), and the 
solvent was removed by evaporation under reduced pressure. The crude product was 
purified by flash chromatography on silica (ethyl acetate/acetone, 5:1) to give 3.36 (274 
mg, 82%) as a light orange solid. 
mp decomp. >60°C. 
lH NMR (CD3CN, 500 MHz) 0 3.14 (dd, 1H, J = 9.0, 13.9 Hz, C.tJiaPh), 3.34 (dd, 1H, J = 
5.4, 14.2 Hz, CfubPh), 4.87 (m, 1H, NHCH), 6.83 (m, 1H, pyrrole H3), 7.01 (dd, 1H, J = 
2.4, 3.9 Hz, pyrrole H±), 7.31 (m, 6H, NHCH and ArH), 9.67 (s, 1H, CHO), 10.67 (s(br), 
IH, pyrrole NH). 
13C NMR (CD3CN, 75 MHz) 037.7 (CHzPh), 54.6 (NHCH) , 112.5 (pyrrole C3), 119.9 
(pyrrole C4), 127.7, 129.4, 130.2, 138.2 (ArC), 132.2 (pyrrole C2), 135.4 (pyrrole C5), 
160.8 ~ONH), 173.1 (COzH), 181.6 ~HO). 
FTIR (KBr, diffuse refraction method) 1560.3, 1654.8,3051.2,3433.1. 
HRMS (El) 286.0961 (M+). C1GiI17NZ04 requires 286.0954. 
N-[(5-Hydroxymethyl-lH-pyrroI-2-yl)carbonyl]-L-phenylalanine (3.35) 
A stirred solution of the pyrrole 3.36 (82 mg, 0.29 mmol, 1 equiv) III 6: 1 iso-
propanol/water (3.5 mL) at O°C was added sodium borohydride (33 mg, 0.85 mmol, 3 
equiv) in two portions over 10 min. The resulting suspension was warmed to r.t. and 
stirred for 18 h, after which water (5 mL) was added, followed by acidification of the 
solution to pH ~ 1 by the dropwise addition of 1 M hydrochloric acid. The solution was 
extracted with ethyl acetate (3 x 10 mL), the combined organic fractions were washed with 
aqueous saturated brine (10 mL), dried (MgS04), and the solvent was removed by 
evaporation under reduced pressure. The crude product was purified by flash 
chromatography on silica (ethyl acetateldichloromethane, 4:1, then ethyl acetate/acetone, 
1 :1, then methanol) to give 3.35 (36 mg, 44%) as a brown residue. 
lH NMR (500 MHz, CD30D) 0 3.07 (m, IH, CfuaPh), 3.26 (m, IH, CfubPh), 4.44 (s, 2H, 
CfuOH), 4.80 (m, IH, NHCH), 6.09 (m, lH, pyrrole 
H3), 7.16-7.31 (m, 5H, ArH). 
6.72 (d, IH, J= 3.9 Hz, pyrrole 
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No further analytical data was obtained due to product degradation. 
6.3.9 a-Chymotrypsin assay and results 
General Assay Conditions 
See Section 6.2.5 earlier in this chapter for a summary of the General Assay Conditions. 
a-Chymotrypsin Assay 
Solutions of the pyrroles 3.13a-b, 3.14a, 3.24 and 3.25 were made to 1250 flg mL-t, 125 
Ilg mL-1 and 12.5 Ilg mL-1 in methanol. Tris-HCI (50 ilL of a 0.4 M solution in water, pH 
7.6), distilled water (50 ilL), inhibitor solution (50 ilL) and a-chymotrypsin (50 ilL, Sigma 
ex-Bovine pancreas, 9 units mL-1 in 50 mM Tris-HCI, pH 7.6) were added to each well of 
the microtitre plate. Incubation at 37°C for 30 min was followed by the addition of N-
succinyl-L-phenylalanine-4-nitroanilide (100 ilL, 1 mg mL-1 solution in 50 mM Tris-HCI 
buffer, pH 7.6). The absorbance was read at 405 urn at hourly intervals until the maximum 
measured absorbance exceeded 1. 00 absorbance units. Each inhibitor concentration was 
assayed in triplicate and average absorbances were used to calculate the percentage (%) 
inhibition. The calculated percent inhibition values are a measure of the enzyme activity 
relative to that when no enzyme was present (no substrate turnover, 100% "inhibition") 
and when no inhibitor was present (full substrate turnover, 0% inhibition). To this end, 
sample blanks to determine the absorbance for each inhibitor concentration in the absence 
of enzyme (i.e. no substrate turnover) were run concurrently, in which 50 mM Tris-HCI 
buffer, pH 7.6, replaced a-chymotrypsin. Maximum substrate turnover was determined by 
averaging the absorbance readings from six wells in which methanol replaced the inhibitor. 
All percentage (%) inhibition figures reported are rounded to the nearest 5%. The ICso for 
3.25 was determined was performing the assay in the same general manner as for the initial 
a-chymotrypsin assay, except that solution$ of 3.25 were made to 12.0 mM, 3.01 mM, 
0.75 mM, 0.19 mM, 47.0 IlM, 11.8 flM, 2.94 flM and 0.73 flM. Each inhibitor 
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concentration was assayed in triplicate. The ICso value was calculated by fitting the 
inhibitor concentration-percent inhibition data into Microsoft Excel®. 
No. R! R2 % Inhibition (Jlg mrl) 
1250 125 12.5 
3.13a H NH-L-PheOMe 75 35 45 
3.13b H NH-L-LeuOMe 10 5 20 
3.14a Ph(CHz)z NH-L-PheOMe 75 35 15 
3.24 H N-L-ProOMe 45 25 5 
3.25~ H NH-L-Phe-L-LeuOMe 100 20 15 
, ICso 108 JlM. 
Table 6.2. Inhibition of a-chymotrypsin by 3.13a-b, 3.14a, 3.24 and 3.25. 
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6.4 EXPERIMENTAL WORK DESCRIBED IN CHAPTER FOUR 
6.4.1 Preparation ofthe pyrrolizinones 4.11d-i 
Rl R2 
~~ COR2 'f{: ~,/C02R2 3.18d/4.11d H Bn OHC N Y 2 \ N f ~ 3.18e/4.11e CH2Ph Et H 0 R,l o Rl 3.18f/4.11f CH2CHMe2 Et 
3.18d-i 
0 3.18g14.11g CHMe2 Me 
Ph 
4.11d-i 3.18b/4.11b Me Me 
3.18i/4.11i H Me 
Benzyl N-[(2-benzyl-3-oxo-3H-pyrrolizin-5-yl)carbonyl]glycinate (4.11d) 
The pyrrole 3.18d (60 mg, 0.21 mmoI, 1 equiv) was treated with hydrocinnamoyl chloride 
(71 mg, 0.42 mmol, 2 equiv) by General Procedure N. The crude product was purified by 
flash chromatography on silica (ethyl acetate/petroleum ether, 2:3), fol1owed by removal of 
residual hydrocinnamic acid by Kugelrohr distillation (up to 160-170°C), to give 4.11d (35 
mg, 42%) as an orange solid. An analytical sample was obtained by the diffusion of 
petroleum ether into a solution of 4.11d dissolved in ethyl acetate. 
mp 138-139°C. 
UV (CH3CN) l"max 299 nm (8 5600 M-1cm-1), 431 nm (8 = 1530 M-1cm-1). 
IH NMR (CDCb, 500 MHz) 0 3.61 (d, 2H, J= 1.5 ClliPh), 4.25 (d, 2H, J= 4.9 Hz, 
NHClli), 5.21 (s, 2H, C02ClliPh), 5.97 (d, 1H, J = 3.4 Hz, pyrrolizin-3-one H7), 6.63 (t, 
lH, J 1.7 Hz, pyrrolizin-3-one HI), 6.88 (d, IH, J 3.4 Hz, pyrrolizin-3-one H6), 7.25 
(m, 4H, ArID, 7.34 (m, 6H, ArH), 9.34 (s(br), lH, NHCH2). 
13C NMR (CDCh, 75 MHz) 0 31.9 (CH2Ph), 41.7 (NHCH2), 67.1 (C02CH2Ph), 111.1 
(pyrrolizin-3-one C7), 124.4 (pyrrolizin-3-one C6), 126.9, 128.0, 128.4, 128.6, 128.8, 
128.8, 135.3, 136.9 (ArC), 130.3 (pyrrolizin-3-one C5), 132.3 (pyrrolizin-3-one Q), 137.0 
(pyrrolizin-3-one C2), 139.8 (pyrrolizin-3-one C8), 158.3 (QONH), 167.8 (pyrrolizin-3-
one C3), 169.5 (C02). 
FTIR (CHCb) 1562.2, 1581.5, 1647.1, 1726.2,3033.8,3284.5. 
HRMS (El) 400.1431 (Ml. C2Ji20N204 requires 400.1423. 
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Micro. Calcd for C24H20N204: C, 71.99; H, 5.03; N, 7.00. Found: C, 71.82; H, 5.20; N, 
7.24. 
Ethyl N- [(2-benzyl-3-oxo-3H-pyrrolizin-5-yl)carbonyl]-L-phenylalaninate ( 4.11 e) 
The pyrrole 3.18e (40 mg, 0.13 mmol, 1 equiv) was treated with hydrocinnamoyl chloride 
(43 mg, 0.25 mmol, 2 equiv) by General Procedure N. The crude product was purified by 
flash chromatography on silica (ether/petroleum ether, 3: 1), followed by removal of 
residual hydrocinnamic acid by Kugelrohr distillation (up to 160-200°C), to give 4.11e (19 
mg, 35%) as a red oiL 
UV (CH3CN) "'max 299 nm (8 8500 M-lcm-l), 432 nm (8 = 1920 M-1cm-1). 
lH NMR (CDCb, 500 MHz) 8 1.20 (t, 3H, J = 7.3 Hz, C02CH2CH3), 3.14 (m, 2H, 
CHCfuPh), 3.59 (s, 2H, CfuPh), 4.16 (q, 2H, J 7.0 Hz, C02CfuCH3), 4.94 (m, IH, 
NHCID, 5.93 (d, IH, J = 3.4 Hz, pyrrolizin-3-one H7), 6.60 (t, IH, J 1.5 Hz, pyrrolizin-
3-one HI), 6.83 (d, IH, J 2.9 Hz, pyrrolizin-3-one H6), 7.24 (m, 8H, ArID, 7.34 (m, 2H, 
ArH), 9.32 (d, IH, 7.3 Hz, NHCH). 
l3C NMR (CDCh, 75 MHz) 8 14.1 (C02CH2CH3), 31.9 (CH2Ph), 38.2 (CHCH2Ph), 54.3 
(NHCH), 61.3 (C02CH2CH3), 110.8 (pyrrolizin-3-one C7), 124.3 (pyrrolizin-3-one Q§), 
126.8, 126.9, 128.4, 128.8, 128.9, 129.3, 136.3, 136.9 (Arg, 130.4 (pyrrolizin-3-one C5), 
132.2 (pyrrolizin-3-one Cl), 137.1 (pyrrolizin-3-one C2), 139.7 (pyrrolizin-3-one C8), 
157.7 (CONH), 167.6 (pyrrolizin-3-one C3), 171.5 (C02). 
FTIR (CHCh) 1556.4, 1579.6, 1643.2, 1728.1,3012.6,3030.0,3271.0. 
HRMS (E1) 428.1750 (M+). C2£Ji24N204 requires 428.1736. 
Ethyl N-[ (2-benzyl-3-oxo-3H-pyrrolizin-5-yl)carbonyl]-L-Ieucinate (4.1 H) 
The pyrrole 3.18f (60 mg, 0.21 mmol, 1 equiv) was treated with hydrocinnamoyl chloride 
(72 mg, 0.43 mmol, 2 equiv) by General Procedure N. The crude product was purified by 
flash chromatography on silica (ethyl acetate/petroleum ether, 2:3), followed by removal of 
residual hydrocinnamic acid and starting material by Kugelrohr distillation (up to 160-
220°C), to give 4.1H (26 mg, 31 %) as an orange oil. An analytical sample was obtained 
by the diffusion of petroleum ether into a solution of 4.1H dissolved in ethyl acetate. 
mp 104-105°C. 
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UV (CH3CN) "'max 298 nm (I> = 7450 M-\m- l ), 429 nm (I> 1580 M-1cm-I). 
IH' NMR (CDCh, 500 MHz) 8 0.96 (m, 6H, CH(CH3)z), 1.27 (t, 3H, J 7.1 Hz, 
C02CH2CH3), 1.73 (m, 3H, CfuCID, 3.60 (s, 2H, CfuPh), 4.19 (q, 2H, J 7.2 Hz, 
C02Ctl2CH3), 4.69 (m, IH, NHCH), 5.94 (d, IH, J= 3.4 Hz, pyrrolizin-3-one H7), 6.59 (t, 
1H, J 1.7 Hz, pyrrolizin-3-one 6.85 (d, IH, J 3.4 Hz, pyrrolizin-3-one H6), 7.25 
(m, 3H, ArH), 7.33 (m, 2H, ArH), 9.21 (d, IH, J= 7.3 Hz, NHCH). 
13C NMR (CDCl], 75 MHz) 8 14.2 (C02CH2CH3), 21.9, 22.9 (CH(CH3)2), 25.0, 41.2 
(CH2CH), 31.9 (CH2Ph), 51.4 (NHCH), 61.2 (C02CH2CH3), 111.0 (pyrrolizin-3-one C7), 
124.3 (pyrrolizin-3-one C6), 126.9, 128.8, 128.9, 136.9 (ArC), 130.6 (pyrrolizin-3-one 
C5), 132.3 (pyrrolizin-3-one Cl), 137.0 (pyrrolizin-3-one C2), 139.7 (pyrrolizin-3-one 
C8), 157.9 (CONH), 167.9 (pyrrolizin-3-one C3), 172.7 (C02)' 
FTIR (CHCh) 1560.3, 1581.5, 1643.2, 1728.1,3037.7,3274.9. 
HRMS (El) 394.1887 (M+). C23H26N204 requires 394.1893. 
Micro. Calcd for C23H26N204: C, 70.03; H, 6.64; N, 7.10. Found: 70.20; H, 6.68; N, 7.39. 
Methyl N-[ (2-benzyl-3-oxo-3H-pyrrolizin-S-yl)carbonyl]-L-valinate (4.11 g) 
The pyrrole 3.18g (25 mg, 0.10 mmol, 1 equiv) was treated with hydrocinnamoyl chloride 
(33 mg, 0.20 mmol, 2 equiv) by General Procedure N. The crude product was purified by 
flash chromatography on silica (ether/petroleum ether, 3:1), followed by removal of 
residual hydrocinnamic acid by Kugelrohr distillation (up to 160-200°C), to give 4.llg (16 
mg, 44%) as a red oil. An analytical sample was obtained by the diffusion of petroleum 
ether into a solution of 4.llg dissolved in ethyl acetate. 
mp 93-94°C. 
UV (CH3CN) "'max 300 urn (s 7580 M-1cm-I), 434 urn (s = 1780 M-1cm-1). 
IH NMR (CDCh, 500 MHz) 8 1.03 (m, 6H, CH(CH3)2), 2.31 (m, 1H, CH(CH3)z), 3.61 (d, 
2H, 1.5 Hz, CfuPh), 3.74 (s, 3H, C02Cfu), 4.66 (m, 1H, NHCID, 5.94 (d, IH, J = 3.4 
Hz, pyrrolizin-3-one H7), 6.58 (t, 1H, J = 1.7 Hz, pyrrolizin-3-one HI), 6.86 (d, IH, J = 
3.4 Hz, pyrrolizin-3-one H6), 7.25 (m, 3H, ArID, 7.33 (m, 2H, ArH), 9.26 (d, IH, J = 7.8 
Hz,NHCH). 
BC NMR (CDCh, 75 MHz) 8 17.8, 19.2 (CH(Q.H3)2), 30.8 (CH(CH3)z), 31.9 (CH2Ph), 
52.1 (C02CH3), 57.9 (NHCH), 111.0 (pyrrolizin-3-one C7), 124.4 (pyrrolizin-3-one C6), 
Chapter Six Experimental 216 
126.9, 128.8, 128.9, 137.0 (ArC), 130.6 (pyrrolizin-3-one C5), 132.3 (pyrrolizin-3-one 
C1), 137.0 (pyrrolizin-3-one C2), 139.8 (pyrrolizin-3-one QID, 158.1 (CONH), 167.9 
(pyrrolizin-3-one C3), 172.2 (C02). 
FTIR (CHCh) 1560.3,1581.5,1643.2,1728.1,3020.3,3030.0. 
HRMS (El) 366.1581 (M+). C21H22N204 requires 366.1580. 
Micro. Calcd for C21H22N204: C, 68.84; H, 6.05; N, 7.65. Found: C, 68.71; H, 6.00; N, 
7.55. 
Methyl N-[ (2~benzyl-3-oxo-3H-pyrrolizin-5-yl)carbonyJ]-L-alaninate (4.11h) 
The pyrrole 3.18h (77 mg, 0.34 mmol, 1 equiv) was treated with hydrocinnamoyl chloride 
(116 mg, 0.69 mmol, 2 equiv) by General Procedure N. The crude product was purified by 
flash chromatography on silica (ether/petroleum ether, 5:1), followed by removal of 
residual hydrocinnamic acid by Kugelrohr distillation (up to 160-200°C), then flash 
chromatography on silica (ethyl acetate/petroleum ether, 1:1), to give 4.l1h (24 mg, 21%) 
as an orange oil. An analytical sample was obtained by the diffusion of petroleum ether 
into a solution of 4.l1h dissolved in ethyl acetate. Crystals suitable for X-ray 
crystallography were obtained. See Appendix for data. 
mp 93-95°C. 
UV (CH3CN) Amax 299 nm (8 8950 M-1cm-1), 434 nm (8 2190 M-1cm-1). 
IHNMR (CDCh, 500 MHz) (51.52 (d, 3H, J= 7.3 Hz, CHC!:IJ), 3.61 (s, 2H, CfuPh), 3.76 
(s, 3H, C02CH3), 4.71 (m, 1H, NHCID, 5.95 (d, IH, 3.4 Hz, pyrrolizin-3-one ill), 6.61 
(s, 1H, pyrrolizin-3-one HI), 6.86 (d, 1H, J = 3.4 Hz, pyrrolizin-3-one H6), 7.25 (m, 3H, 
ArH), 7.33 (m, 2H, ArID, 9.31 (d, 1H, J= 6.3 Hz, NHCH). 
13C NMR (CDCb, 75 MHz) (5 18.0 (CHCH3), 31.9 (CH2Ph), 48.5 (NHCH), 52.4 
(C02CH3), 111.0 (pyrrolizin-3-one C7), 124.3 (pyrrolizin-3-one C6), 126.9, 128.8, 128.9, 
136.9 (ArC), 130.5 (pyrrolizin-3-one C5), 132.3 (pyrrolizin-3-one C1), 137.0 (pyrrolizin-3-
one C2), 139.7 (pyrrolizin-3-one C8), 157.6 ~ONH), 167.9 (pyrrolizin-3-one C3), 173.2 
(C02)' 
FTIR (CHCb) 1581.5, 1647.1, 1726.2,3026.3. 
HRMS (El) 338.1274 (M+). C19HlSN204 requires 338.1267. 
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Micro. Calcd for C19H18N204: C, 67.45; H, 5.36; N, 8.28. Found: C, 67.42; H, 5.58; N, 
7.99. 
Methyl N-[ (2-benzyl-3-oxo-3H-pyrrolizin-S-yl)carbonyl]glycinate (4.11 i) 
The pyrrole 3.18i (35 mg, 0.17 mmol, 1 equiv) was treated with hydrocilll1amoyl chloride 
(56 mg, 0.33 mmol, 2 equiv) by General Procedure N. The crude product was purified by 
flash chromatography on silica (ethyl acetate/petroleum ether, 2:1) to give 4.11i (23 mg, 
43%) as an orange solid. An analytical sample was obtained by recrystallisation from 
ethyl acetate/petroleum ether to give orange plates. 
mp 149-150°C. 
UV (CH3CN) Amax 297 nm (8 7190 M-1cm-1), 433 nm (8 1860 M-1cm-1). 
IH NMR (CDCb, 500 MHz) 8 3.61 (s, 2H, ClliPh), 3.77 (s, 3H, C02CH3), 4.20 (d, 2H, J= 
5.4 Hz, NHClli), 5.96 (d, IH, 3.4 Hz, pyrrolizin-3-one H7), 6.61 (m, IH, pyrrolizin-3-
one HI), 6.87 (d, IH, J= 3.4 Hz, pyrrolizin-3-one H6), 7.25 (m, 3H, ArH), 7.33 (m,2H, 
ArH), 9.32 (s(br), IH, NHCH2). 
13C NMR (CDCb, 75 MHz) 8 32.0 (CH2Ph), 41.5 (NHCH2), 52.3 (C02CH3), 111.1 
(pyrrolizin-3-one C7), 124.4 (pyrrolizin-3-one C6), 126.9, 128.8, 128.8, 136.9 (ArC), 
130.3 (pyrrolizin-3-one C5), 132.3 (pyrrolizin-3-one Cl), 137.0 (pyrrolizin-3-one C2), 
139.8 (pyrrolizin-3-one C8), 158.3 (QONH), 167.9 (pyrrolizin-3-one C3), 170.1 (C02), 
FTIR (CHCb) 1562.2, 1581.5, 1647.1, 1724.2,3014.5,3294.4. 
HRMS (El) 324.1110 (M+). C18H16N204 requires 324.1110. 
Micro. Calcd for C18H16N204: C, 66.66; H, 4.97; N, 8.64. Found: C, 66.73; H, 5.22; N, 
8.65. 
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6.4.2 Preparation of the pyrrolizinones 4.17a-b 
3.29a/4.17a CH2Ph 
3.29b/4.17b CH2CHMe2 
218 
Methyl N-{N-[(2-benzyl-3-oxo-3H-pyrrolizin-5-yl)carbonyl]-L-phenylalanyl}glycinate 
(4.17a) 
The pyrrole 3.29a (31 mg, 0.09 mmol, 1 equiv) was treated with hydrocinnamoyl chloride 
(29 mg, 0.17 mmol, 2 equiv) by General Procedure N. The crude product was purified by 
flash chromatography on silica (ethyl acetate/petroleum ether, 7:1), followed by further 
flash chromatography on silica (ethyl acetate/dichloromethane, 3:1), to give 4.17a (14 mg, 
34%) as a red oil. An analytical sample was obtained by trituration with 1:1 ethyl 
acetate/petroleum ether to give a red solid. 
mp 149-152°C. 
UV (CH3CN) "-max 299 nm (8 = 5500 M-1cm-I), 432 nm (8 = 1570 M-1cm-I). 
IH NNIR (CDCh, 500 MHz) 0 3.11 (dd, IH, 8.5, 13.9 Hz, CHCthaPh), 3.30 (dd, IH, J 
= 6.3, 14.2 Hz, CHCfubPh), 3.60 (s, 2H, CfuPh), 3.70 (s, 3H, COZCH3), 3.99 (m, 2H, 
NHCfu):, 4.80 (q, IH, J = 7.2 Hz, NHCH), 5.93 (d, IH, J = 3.4 Hz, pyrrolizin-3-one H1), 
6.61 (s, IH, pyrrolizin-3-one HI), 6.68 (s(br), IH, NHCHz), 6.82 (d, 1H, J = 3.4 Hz, 
pyrrolizin-3-one H6), 7.18-7.36 (m, 10H, ArID, 9.34 (d, 1H, 7.3 Hz, NHCH). 
13C NMR (CDCb, 75 :MHz) 031.9 (CHzPh), 37.4 (CHCHzPh), 41.2 (NHCHz), 52.3 
(COZCH3), 55.4 (NHCH), 111.0 (pyrrolizin-3-one C7), 124.6 (pyrrolizin-3-one Q'D, 126.8, 
126.9, 128.5, 128.8, 128.9, 129.3, 136.9, 136.9 (ArC), 130.0 (pyrrolizin-3-one C5), 132.2 
(pyrrolizin-3-one Cl), 137.0 (pyrrolizin-3-one C2), 139.9 (pyrrolizin-3-one C8), 158.4 
(C01\THCH), 167.6 (pyrrolizin-3-one C3), 170.1 (COz), 171.1 (QONHCHz). 
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FTIR (KBr, diffuse refraction method) 1523.7, 1583.4, 1643.2, 1668.3, 1716.5, 1749.3, 
2923.9,3026.1,3085.9,3261.4,3315.4. 
HRMS (EI) 471.1792 (M+). C27H2SN30S requires 471.1795. 
Methyl N-{N-[ (2-benzyl-3-oxo-3H-pyrrolizin-5-yl)carbonyl]-L-Ieucyl} glycinate (4.17b) 
The pyrrole 3.29b (50 mg, 0.15 mmol, 1 equiv) was treated with hydrocinnamoyl chloride 
(52 mg, 0.31 mmol, 2 equiv) by General Procedure N. The crude product was purified by 
flash chromatography on silica (ethyl acetate/petroleum ether, 7:1), followed by further 
flash chromatography on silica (ethyl acetate/dichloromethane, 4:1), to give 4.17b (22 mg, 
33%) as a red oil. An analytical sample was obtained by the diffusion of petroleum ether 
into a solution of 4.17b dissolved in ethyl acetate. 
mp 134-137°C. 
UV (CH3CN) Awax 298 run (8 7100 M-1cm-1), 435 run (8 1840 M-1cm-1). 
IH NMR (CDCh, 500 MHz) 00.95 (m, 6H, CH(CH3)2), 1.73 (m, 2H, CfuaCID, 1.85 (m, 
IH, CfubCH), 3.60 (s, 2H, CfuPh), 3.72 (s, 3H, C02CH3), 4.03 (m, 2H, NHCfu), 4.57 (q, 
IH, 7.2 Hz, NHCID, 5.96 (d, IH, J = 3.4 Hz, pyrrolizin-3-one H7), 6.60 (d, IH, 1.5 
Hz, pyrrolizin-3-one HI), 6.86 (d, 2H, J = 2.9 Hz, pyrrolizin-3-one H6, NHCH2), 7.24 (m, 
3H, ArID, 7.33 (m, 2H, ArH), 9.17 (d, IH, J= 6.8 Hz, NHCH). 
l3C NMR (CDCh, 75 MHz) 021.9,23.0 (CH(CH3)2), 24.8 (CH2CH), 31.9 (CH2Ph), 39.9 
(CH2CH), 41.2 (NHCH2), 52.1 (NHCH) , 52.3 (COlCH3), 111.1 (pyrrolizin-3-one C7), 
124.6 (pyrrolizin-3-one C6), 126.9, 128.8, 128.9, 136.9 (ArC), 130.2 (pyrrolizin-3-one 
C5), 132.3 (pyrrolizin-3-one Cl), 137.0 (pyrrolizin-3-one C2), 139.9 (pyrrolizin-3-one 
C8), 158.5 (CONHCH), 167.9 (pyrrolizin-3-one C3), 170.2 (C02), 172.0 (CONHCH2). 
FTIR (KBr, diffuse refraction method) 1527.5, 1583.4, 1641.3, 1666.4, 1720.4, 1743.5, 
1751.2,2954.7,3327.0. 
HRMS (EI) 437.1951 (Ml. C24H27N30S requires 437.1951. 
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6.4.3 UV spectroscopic analysis of the pyrrolizinones 4.11a-i and 4.17a-b 
Ultraviolet spectra for the pyrrolizinones 4.11a-i and 4.17a-b were obtained using a GBC 
920 UVNIS spectrophotometer interfaced with an Intel 486 PC operating GBC's Spectral 
software version 1.5. Spectra were obtained in CH3CN, and 8 values were calculated from 
absorbances below 1.00 absorbance unit by dilution of the stock solutions of 4.11a-i and 
4.17a-b in CH3CN where necessary. 
No. Rl 
4.11a# CH2Ph 
4.11b# CH2CHMe2 
4.11c# H 
4.11d H 
4.11e CHzPh 
(3.18e) CHzPh 
4.1H CHzCHMez 
4.11g CHMez 
4.11h Me 
4.11i H 
(3.18i) H 
4.17a CHzPh 
4.17b CH2CHMez 
If ,k. PrevIOusly syntheSIsed 
* Not applicable 
R2 Amax (um) [8 (M-1 em-I)] Ratio E(-300nm/ 
E(-430nm) 
OMe 299 [6380],434 [1950] 3.27 
OMe 300 [5010],434 [1550] 3.23 
OBt 299 [8200],433 [2150] 3.81 
OBn 299 [5610],431 [1530] 3.67 
OBt 299 [8500],432 [1920] 4.45 
OBt 291 [28610] na* 
OBt 298 [7450],429 [1580J 4.71 
OMe 300 [7580J, 434 [1780J 4.25 
OMe 299 [8950J, 434 [2190] 4.09 
OMe 297 [7190],433 [1860] 3.86 
OMe 289 [16780] na* 
NHCHzCOzMe 299 [5500J, 432 [1570] 3.50 
NHCHzC02Me 298 [7100],435 [1840J 3.86 
Table 6.3. UV spectral data for pyrrolizinones 4.11a-i and 4.17a-b in acetonitrile. Data 
for 3.18e and 3.18i is included underneath their respective analogues 4.11e and 4.11i. 
Chapter Six - Experimental 221 
6.4.4 Fragmentation analysis of the pyrrolizinones 4.11a-i and 4.17a-b by LRMS 
LRMS analysis of the pyrrolizinones 4.11a-i and 4.17a-b was perfonned by electron 
impact ionisation mass spectrometry (see Section 6.1 for details). 
fP\ H \ N ~~ o Rl o 
Ph 4.21 
No. Rl mlzof mlz of ion 4.21 M+ - (mlz M+' - (mlz 4.21) 
M+ (% intensity) 4.21) corresponds to loss of: 
4.11a# CH2Ph 414.2 355.1 (6) 59.1 -C02Me 
4.11b# CH2CHMe2 380.2 321.2 (31) 59.0 -C02Me 
4.11c# H 338.1 265.1 (7) 73.0 -C02Et 
4.11d H 400.1 265.1 (8) 135.0 -C02CH2Ph 
4.11e CH2Ph 428.2 355.1 (7) 73.1 -C02Et 
4.1lf CH2CHMe2 394.2 321.2 (76) 73.0 -C02Et 
4.11g CHMe2 366.2 307.1 (46) 59.1 -C02Me 
4.11h Me 338.1 279.1 (40) 59.0 -C02Me 
4.11i H 324.1 265.1 (8) 59.0 -C02Me 
4.17a CH2Ph 471.2 355.2 (42) 116.0 -CONHCH2C02Me 
4.17b CH2CHMe2 437.2 321.2 (81) 116.0 -CONHCH2C02Me 
1t_ {21 
- PreVIously synthesIsed 
Table 6.4. LRMS data for 4.11a-i and 4.17a-b to give product ion 4.21. 
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6.4.4 Fragmentation analysis of the 5-formylpyrroles 3.18a-i and 3.29a-b by LRMS 
LRMS analysis of the 5-fonnylpyrroles 3.18a-i and 3.29a was perfonned by electron 
impact ionisation mass spectrometry, with the exception of 3.29b, which was analysed by 
electro spray ionisation mass spectrometry (see Section 6.1 for details). 
No. Rl mlzof 
M+ 
3.18a '" CH2Ph 300.1 
3.18b CH2CHMe2 266.1 
3.18c# H 
3.18d H 286.1 
3.18e CH2Ph 314.1 
3.18f CH2CHMe2 280.1 
3.18g CHMe2 252.1 
3.18h Me 224.1 
3.18i H 210.1 
3.29a CH2Ph 357.1 
3.29b CH2CHMe2 346.1 
n R 
aRc/' '~.(' if ~"\ 
R a If 
4.27 
mlz of ion 4.27 M+' - (mlz 
(% intensity) 4.27) 
241.1 (5) 59.0 
207.1 (38) 59.0 
73.0 
151.1 (18) 135.0 
241.1 (6) 73.0 
207.1 (47) 73.0 
193.1 (44) 59.1 
165.0 (98) 59.1 
151.1 (25) 59.0 
241.1 (25) 116.0 
207.1 (12) 139.0 
M+' - (mlz 4.27) 
corresponds to loss of: 
-C02Me 
-C02Me 
-C02Et 
-C02CH2Ph 
-C02Et 
-C02Et 
-C02Me 
-C02Me 
-C02Me 
-CONHCH2C02Me 
-CONHCH2C02Me - Na + 
* S~thesised by author, but mass spectrometry results were obtained from the previous 
study7 
# Previously synthesised27 
Table 6.5. LRMS data for 3.18a-i and 3.29a-b to give product ion 4.27. 
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EXPERIMENTAL WORK DESCRIBED IN CHAPTER FIVE 
6.5.1 Attempted preparation of the alcohol 5.18 by reduction of the acid 5.17a and 
derivatives 
5.16 
o 
RIOC~NH 
~ 
5.17aRl =OH--
5.17b Rl = OMe 
5.17cR1 =Cl ~-
N-(Naphthalen-1-yl)succinamic acid (5.17a) 
>< 
o 
HO~NH 
~ ~ 
5.18 
Naphthalen-l-ylamine 5.16 (1.43 g, 10 mmol, 1 equiv) was treated with succinic anhydride 
(1.0 g, 10 mmol, 1 equiv) by General Procedure P. After cooling to r.t., the solid was 
collected by filtration and washed with cold petroleum ether. The material was dissolved 
in ethyl acetate (60 mL) and 5% aqueous sodium hydroxide (60 mL), the layers were 
separated, and the organic phase was extracted with 5% aqueous sodium hydroxide (20 
mL). The combined aqueous fractions were acidified to pH ~1 with concentrated aqueous 
hydrochloric acid, and the solid that formed was collected by filtration, washed with water 
(10 mL) and dried under reduced pressure (high vacuum) to give 5.17a (2.21 g, 91%) as a 
white solid. 
mp 163-165°C. 
IH NMR (acetone-d6, 500 MHz) 0 2.87 (t, 2H, J = 6.6 Hz, Clli), 3.00 (d, 2H, J 6.3 Hz, 
Clli), 7.61 (m, 3H, ArH), 7.85 (d, 1H, J = 7.8 Hz, ArID, 8.03 (dd, 2H, J = 2.9, 5.9 Hz, 
ArH), 8.30 (dd, 1H, J 3.7, 7.6 Hz, ArID, 9.37 (s(br), 1H, CONH), 10.89 (s(br), 1H, 
C02ID· 
l3C NMR (acetone-d6, 75 MHz) 0 29.2*, 31.1 (CH2CH2), 121.1, 122.9, 124.9, 125.6, 
125.7, 125.9, 128.2, 134.2 (ArC), 170.9, 174.1 (QONH, C02H). 
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FTIR (KBr, diffuse refraction method) cm-1 1504.4, 1533.3, 1652.9, 1716.5, 2362.6, 
2985.6,3303.8. 
HRMS (BS) 244.0977 (M++H). C14H14N03 requires 244.0974. 
Micro. Calcd for C14H13N03: C, 69.12; H, 5.39; N, 5.76. Found: C, 69.20; H, 5.47; N, 
6.02. 
* Resonance at 0 29.2 ppm assigned from correlations observed in the HSQC and CIGAR 
NMR spectra. 
Methyl N-(naphthalen-l-yl)succinamate (5.17b) 
Acid 5.17a (500 mg, 2.06 mmol, 1 equiv) was treated with diazomethane by General 
Procedure L. The crude product was purified by flash chromatography (ethyl 
acetate/petroleum ether, 2:1) to give 5.17h (370 mg, 70%) as a white solid. An analytical 
sample was obtained by the diffusion of petroleum ether into a solution of 5.17h dissolved 
in ethyl acetate. 
mp 105-106°C. 
IH NMR (CDCh, 500 IvIHz) 0 2.83 (s, 4H, CfuClI2), 3.74 (s, 3H, C02Cfu), 7.44-7.55 (m, 
3H, ArID, 7.68 (d, IH, J 8.3 Hz, ArH), 7.85-7.96 (m, 4H, ArH plus CONH). 
I3C NMR (CDCh, 75 IvIHz) 0 29.5, 32.0 (CH2CH2), 52.0 (C02CH3), 120.9, 125.6, 125.7, 
125.9, 126.2, 127.1, 128.6, 132.3, 134.0 (ArC), 170.5, 173.8 (CONH, C02Me). 
FTIR (KBr, diffuse refraction method) cm-1 1504.4, 1544.9, 1668.3, 1749.3, 3037.7, 
3280.7. 
HRMS (BS) 258.1136 (M++H). C15H16N03 requires 258.1130. 
Micro. Calcd for C15H15N03: C, 70.02; H, 5.88; N, 5.44. Found: C, 70.06; H, 5.62; N, 
5.69. 
N-(Naphthalen-l-yl)succinamoyl chloride (5.17c) 
To a stirred suspension of the acid 5.17a (300 mg, 1.23 mmol, 1 equiv) in dry 
dichloromethane (8 mL) at r.t. under an inert atmosphere were added oxalyl chloride (313 
mg, 2.47 mmol, 2 equiv) and dry DMF (2 drops). Addition of the DMF briefly gave 
vigorous effervescence. After 1 h, the solvent was removed by evaporation under reduced 
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pressure to give a foaming solid. This product was used immediately without further 
purification or characterisation. 
6.5:2 Preparation of the 5-(hydroxymethyl)pyrrole 5.21 
5.16 5.19 
5.21 
N-(N aphthalen-1-yl)pyrrolidine-2,5-dione (5.19) 
5.18 
j 
n 0 
ORC/' "~/ yO~NH 
R 0 ~ 
~ 
5.20 
Naphthalen-1-ylamine 5.16 (1.00 g, 6.98 mmol, 1 equiv) was treated with succinic 
anhydride (699 mg, 6.98 mmol, 1 equiv) by General Procedure P to give a white solid. 
The resulting material was treated with anhydrous sodium acetate (191 mg, 2.33 mmol, 
0.33 equiv) according to General Procedure Q to give 5.19 (1.36 g, 86% over two steps) as 
a light pink solid. 
mp 153-154°C (lit. I 2 147-149°C). 
IH NMR (CDCh, 500 MHz) 0 2.96-3.09 (m, 4H, CfuCfu), 7.33 (dd, 1H, J = 1.0, 7.3 Hz, 
ArH), 7.53 (m, 4H, ArH), 7.93 (m, 2H, ArH). 
4-Hydroxy-N-(naphthalen-l-yl)butanamide (5.18) 
The succinimide 5.19 (1.36 g, 6.04 mmol, 1 equiv) was treated with sodium borohydride 
(571 mg, 15.1 mmol, 2.5 equiv) by General Procedure R. After filtration through Dowex-
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50W resin, the filtrate had its solvent removed by evaporation under reduced pressure. The 
crude product was purified by flash chromatography (ethyl acetate/methanol, 10: 1), 
followed by recrystallisation from ethyl acetate, to give 5.18 (983 mg, 71%) as a white 
solid. 
mp 102-104°C. 
IH NMR (CD30D, 500 MHz) (5 2.00 (m, 2H, CH2GfuCH2), 2.63 (t, 2H, J = 7.3 Hz, 
CH2CO), 3.70 (t, 2H, J 6.3 Hz, HOCH2), 7.50 (m, 3H, ArID, 7.57 (d, 1H, J = 7.3 Hz, 
ArH), 7.77 (d, 1H, 8.3 ArH), 7.89 (m, 1H, ArID, 7.98 (d, 1H, J= 7.8 Hz, ArID. 
13C NMR (CD30D, 75 MHz) (5 30.0 (CH2CH2CH2), 34.2 (CH2CO), 62.6 (HOCH2), 123.7, 
124.3,126.7,127.4,127.5,127.8,129.6,130.4,134.4, 135.9 (ArC), 175.7 (CONH). 
FTIR (KBr, diffuse refraction method) cm-l 1508.2, 1541.0, 1652.9,2950.9,3274.9. 
HRMS (EI) 229.1102 (Ml. CvJIl5N02 requires 229.1103. 
Micro. Calcd for C14H15N02: C, 73.34; H, 6.59; N, 6.11. Found: C, 73.22; H, 6.68; N, 
6.06. 
4-(N aphthalen-1-ylamino )-4-oxobutyl 5-hydroxymethyl-1H-pyrrole-2-carboxylate 
(5.21) 
Pyrrole acid 3.16b (100 mg, 0.72 mmol, 1 equiv) was coupled to alcohol 5.18 (247 mg, 
1.08 romol, 1.5 equiv) by General Procedure S. The crude product was purified by flash 
chromatography (ethyl acetate/petroleum ether, 2: 1) to give 4-(naphthalen-1-ylamino )-4-
oxobutyl 5-formyl-1H-pyrrole-2-carboxylate (5.20, 95 mg, 0.27 mmol, 1 equiv) as an 
orange solid that contained trace impurities by IH NMR spectroscopy. The pyrrole 5.20 
was reduced with lithium borohydride (12 mg, 0.54 romol, 2 equiv) by General Procedure 
K. The crude product was purified by flash chromatography (ethyl acetate/petroleum 
ether, 5:1, then ethyl acetate), followed by recrystallisation from ethyl acetate, to give 5.21 
(46 mg, 18% over two steps) as a white solid. 
mp 154-156°C. 
IH NMR (DMSO-d6, 500 MHz) (5 2.15 (m, 2H, CH2CfuCH2), 2.74 (t, 2H, J = 7.3 Hz, 
CfuCO), 4.37 (t, 2H, J 6.3 Hz, C02Cfu), 4.51 (d, 2H, J 5.4 Hz, HOCfu), 5.15 (t, lH, 
J = 5.9 Hz, HOCH2), 6.17 (m, IH, pyrrole H4), 6.86 (s, 1H, pyrrole H3), 7.60 (m, 3H, 
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ArH), 7.76 (d, 1H, J= 7.3 Hz, ArH), 7.85 (d, 1H, J= 8.3 Hz, ArH), 8.03 (m, 1H, ArH), 
8.14 (m, 1H, ArH), 10.05 (s(br), 1H, CONH), 11.73 (s(br), 1H, pyrro1e NH). 
l3C NMR (DMSO-d6, 75 MHz) (; 24.9 (CH2CH2CH2), 32.5 (CH2CO), 56.1 (HOCH2), 63.1 
(C02CH2), 108.2 (pyrrole C4), 115.7 (pyrrole C3), 121.2 (pyrrole C2) 122.0, 122.9, 125.4, 
125.8, 126.0, 126.2, 128.0, 128.3, 133.7, 133.9 (ArC), 139.4 (pyrrole C5), 160.7 (C02), 
171.6 (CONH). 
FTIR (KBr, diffuse refraction method) cm-1 1500.5, 1531.4, 1654.8, 1685.7, 3282.6, 
3433.1. 
HRMS (ES) 375.1321 (M++Na). C20H20N2Na04 requires 375.1321. 
Micro. Calcd for C2oH20N204: C, 68.17; H, 5.72; N, 7.95. Found: C, 68.17; H, 5.79; N, 
7.80. 
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6.5.5 Attempted preparation of the 5-(hydroxymetbyl)pyrrole 5.22 
5.24 
5.25 
j 
5.26 
O~ 11\ o~l~ OHC/~~/I( N -- - ----I I I 
H 0 H 
5.27 I 
• O~ 
HO 11\ O~~~~/I( N 
H 0 H 
5.22 
N-(Anthracen-2-yl)pyrrolidine-2,5-dione (5.25) 
228 
Anthracen-2-ylamine 5.24 (1.00 g, 5.17 mmol, 1 equiv) was treated with succinic 
anhydride (518 mg, 5.17 mmol, 1 equiv) by modified General Procedure P. The resulting 
material was treated with anhydrous sodium acetate (141 mg, 1.72 mmol, 0.33 equiv) by 
General Procedure Q to give 5.25 (1.27 g, 89% over two steps) as a brown solid. 
mp 260-263°C. 
IH NMR (CDCh, 500 MHz) 0 2.97 (s, 4H, CfuCfu), 7.35 (dd, 1H, J 2.0, 8.8 Hz, ArID, 
7.49 (m, 2H, ArH), 7.99 (m, 3H, ArID, 8.09 (d, IH, 8.8 Hz, ArH), 8.45 (s, 2H, ArH). 
l3C NMR (DMSO-d6, 75 MHz) 0 28.8 (CH2CH2), 125.0, 126.1, 126.2, 126.4, 126.7, 128.2, 
129.0,130.0,130.3,130.7,131.6,131.8 (ArC), 177.4 (2 x CO2). 
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FTIR (KBr, diffuse refraction method) cm-1 1581.5, 1624.0, 1716.5, 1770.5, 2947.0, 
3051.2. 
HRMS (El) 275.0952 (Ml. C1sH13N02 requires 275.0946. 
4-Hydroxy-N-( anthracen-2-yl) butanamide (5.26) 
The succinirnide 5.25 (370 mg, 1.34 mmol, 1 equiv) was treated with sodium borohydride 
(127 mg, 3.36 mmol, 2.5 equiv) by General Procedure R. The reaction mixture was 
acidified to pH ~ 1 by the dropwise addition of 1 M aqueous hydrochloric acid, and the iso-
propanol was removed by rotary evaporation. The resulting solid was collected by 
filtration, washed with cold water and dried under reduced pressure (high vacuum) to give 
slightly impure 5.25 (375 mg, quantitative mass return) as a light brown solid. This 
product was used without further purification. 
IH NMR (DMSO-d6, 500 MHz) (5 1.89 (m, 2H, CH2CfuCH2), 2.54 (m, 2H, CfuCO), 7.56 
(m, 2H, ArH), 7.65 (d, 1H, J 7.8 Hz, ArID, 8.12 (m, 3H, ArH), 8.51 (s, 1H, ArH), 8.58 
(m, 2H, ArH), 10.27 (s, 1 H, CONH). 
The HOCfu resonance was not observed due to the large fuO signal present in the 
spectrum of 5.26. 
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6.5.6 Preparation of the hydroxymethylpyrrole 5.31 
5.28 
HO~O~CD! NH N __ --------
r 1-"';: 
~ . ~ 
5.31 
N-(Quinolin-8-yl)pyrrolidine-2,5-dione (5.29) 
230 
5.29 
j 
5.30 
Quinolin-8-ylamine 5.28 (500 mg, 3.47 mmol, 1 equiv) was treated with succinic 
anhydride (347 mg, 3.47 mmol, 1 equiv) by General Procedure P. The resulting material 
was treated with sodium acetate (95 mg, 1.16 mmol, 0.33 equiv) by General Procedure Q 
to give 5.29 (620 mg, 79% over two steps) as a light brown solid. 
mp 134-136°C. 
lR NMR (CDCh, 500 MHz) 0 2.97, 3.13 (2 x m, 4H, ClliClli), 7.44 (dd, 1H, J 3.9,8.3 
Hz, ArID, 7.62 (m, 2H, ArR), 7.93 (dd, 1H, J 2.0, 7.8 Hz, ArID, 8.20 (dd, 1H, J 1.5, 
9.8 Hz, ArH), 8.87 (dd, 1H, 1.7,4.2 Hz, ArH). 
13C NMR (CDCh, 75 MHz) 0 29.0 (CH2CR2), 122.0, 126.2, 129.3, 129.7, 129.8, 136.6, 
150.8 (ArC), 176.9 (2 x CO2). 
FTIR (KBr, diffuse refraction method) cm-1 1502.4, 1701.1, 1778.2,2947.0,3051.2. 
HRMS (El) 226.0744 (M+). C13H lON20 2 requires 226.0742. 
Chapter Six Experimental 231 
4-(Quinolin -8-ylamino )-4-oxobutyl 5-hydroxymethyl-1H-pyrrole-2-carboxylate (5.31) 
The succinimide 5.22 (496 mg, 2.19 mmol, 1 equiv) was treated with sodium borohydride 
(207 mg, 5.48 mmol, 2.5 equiv) by General Procedure R After filtration through Dowex-
SOW resin, the filtrate had its solvent removed by evaporation under reduced pressure. The 
crude material was purified by flash chromatography ( ethyl acetate, then ethyl 
acetate/methanol, 10:1) to give 4-hydroxy-N-(quinolin-8-yl)butanamide (5.30, 335 mg) as 
a sticky white solid. 
lH NMR (CD30D, 500 MHz) 0 1.99 (m, 2H, CHzCfuCHz), 2.68 (t, 2H, J 7.6 Hz, 
CfuCO), 3.67 (t, 2H, J = 6.3 HOCfu), 7.53 (m, 2H, ArH), 7.61 (m, IH, ArID, 8.29 
(dd, IH, J 2.0,8.3 Hz, ArH), 8.62 (d, IH, J= 7.8 Hz, ArH), 8.86 (d, IH, J= 1.5,4.4 Hz, 
ArH). 
Pyrrole acid 3.16b (135 mg, 0.97 mmol, 1 equiv) was coupled to the alcohol (335 mg, 1.45 
mmol, 1.5 equiv) by General Procedure S. The crude material was purified by flash 
chromatography (ethyl acetate/petroleum ether, 2: 1) to give 4-( quinolin-8-ylamino )-4-
oxobutyl 5-formyl-1H-pyrrole-2-carboxylate (150 mg, 0.43 mmol, 1 equiv) as an orange 
solid that contained trace impurities by lH NMR spectroscopy. This pyrrole was reduced 
with lithium borohydride (19 mg, 0.85 mmol, 2 equiv) by General Procedure K. The crude 
material was purified by flash chromatography (ethyl acetate/petroleum ether, 4:1, then 
ethyl acetate), followed by recrysta1lisation from ethyl acetate/petroleum ether, to give 5.31 
(86 mg, 11 % over three steps) as a tan solid. 
mp 118-119°C. 
IH NMR (CDCb, 500 MHz) 0 2.25 (m, 2H, CHzCHzCH2), 2.57 (s(br), 1H, OH), 2.71 (t, 
2H, J 7.1 Hz, CHzCO), 4.39 (t, 2H, J= 6.3 Hz, COzCHz), 4.63 (s, 2H, HOCHz), 6.17 (t, 
lH, J 3.2 Hz, pyrrole H4), 6.83 (dd, IH, J 2.4,3.4 Hz, pyrrole ID), 7.43 (dd, 1H, J= 
4.4, 8.3 Hz, ArID, 7.51 (m, 2H, ArH), 8.14 (dd, IH, J = 1.7, 8.1 Hz, ArH), 8.74 (m, 2H, 
ArH), 9.77, 9.85 (2 x s(br), 2H, CONH and pyrrole NH). 
13C NMR (CDCh, 75 MHz) 0 24.2 (CH2CH2CH2), 33.7 (CH2CO), 56.7 (ROCH2), 62.5 
(C02CH2), 107.2 (pyrrole C4), 114.9 (pyrrole C3), 116.3, 121.2, 126.8, 127.4, 133.6, 
136.4, 137.2, 147.4 (ArC), 121.4 (pyrrole C2), 137.8 (pyrrole C5), 160.5 (C02), 170.3 
(CONH). 
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FTIR (KBr, diffuse refraction method) cm-1 1539.1, 1652.9, 1708.8, 2949.0, 3261.4, 
3348.2. 
HRMS (El) 353.1362 (M+). C19H19N304 requires 353.1376. 
Micro. Calcd for C19H19N304: C, 64.58; H, 5.42; N, 11.89. Found: C, 64.46; H, 5.59; N, 
11.65. 
6.5.7 Attempted preparation of the 5-(hydroxymethyl)pyrrole 5.32 
HO n O~ ~~~/I( NH 
HO ~.>< Vl~T~ N 
5.32 
N-(Acridin-9-yl)pyrrolidine-2,5-dione (5.34) 
j 
A stirred solution of acridin-9-ylamine 5.33 (600 mg, 3.09 mmol, 1 equiv) and succinic 
anhydride (309 mg, 3.09 mmol, 1 equiv) in dry DMF (15 mL), under an inert atmosphere, 
was refluxed for 30 min. After cooling to r.t., the solution was poured onto ice (10 g) and 
water (10 mL), and the resultant solid was allowed to stand for 3 h, after which it was 
collected by filtration, washed with water, and dried under reduced pressure (high 
pressure). This material was treated with anhydrous sodium acetate (84 mg, 1.03 mmol, 
0.33 equiv) by General Procedure Q to give 5.34 (301 mg, 35% over two steps) as a light 
brown solid. 
mp 269-272°C. 
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IH NMR (CDCb, 500 MHz) 8 3.24 (s, 4H, CfuCfu), 7.60 (m, 2H, ArID, 7.67 (d, 2H, J= 
8.3 Hz, ArID, 7.82 (m, 2H, ArH), 8.34 (d, 2H, J = 8.8 Hz, ArH). 
DC NMR (CDCb, 75 NIHz) 8 29.1 ~H2CH2)' 122.1, 127.6, 130.2, 130.6, 149.1 (Arg, 
175.7 (2 X CO2). 
FTIR. (KBr, diffuse refraction method) cm-l 1517.9, 1554.5, 1710.7, 1786.0, 2937.4, 
3058.9. 
HRMS (EI) 276.0907 (M+). C17H12N202 requires 276.0899. 
4-Hydroxy-N-(acridin-9-yl)butanamide (5.35) 
The succinimide 5.34 (500 mg, 1.81 mmol, 1 equiv) was treated with sodium borohydride 
(171 mg, 4.52 mmol, 2.5 equiv) by General Procedure R. After filtration through Dowex-
SOW resin, the resin was stirred in methanol for 30 min and filtered once again, the filtrates 
were combined, and the solvent was removed by evaporation under reduced pressure. The 
resulting material was passed through a short plug of silica (eluted with methanol) to give 
impure 5.35 (449 mg, 89% mass return) as a yellow solid. This product was used without 
further purification. 
IH NMR (CD30D, 500 MHz) 8 2.08 (m, 2H, CH2CfuCH2), 2.84 (t, 2H, J = 7.6 Hz, 
CfuCO), 3.76 (t, 2H, J = 6.3 Hz, HOCfu), 7.64 (m, 2H, ArH), 7.86 (m, 2H, ArID, 8.18 
(m, 4H, ArH). 
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6.5.8 Attempted preparation of the hydroxymethylpyrrole 5.36 
5.37 
j 
o ~ 0 
,....---- HO II ~"r~ ~OH ~N N N 
H H 
5.39 
O~~~ 0 /\ 0 I ~ 0/\ OHC~ ~N h- N h- N~ y~CHO 
H 0 H H 0 H 
5.40 
't 
o ~ 0 
HO n o~l V"T~ ~O~~OH ~~~/!( N N N II N 
H 0 H H 0 H 
5.36 
N,N-(Acridin-3,6-diyl)dipyrrolidine-2,5-dione (5.38) 
A stirred suspension of 3,6-diaminoacridine 5.37 (1.84 g, 8.79 mmol, 1.5 equiv) and 
succinic anhydride (1.94 g, 19.3 mmol, 3.3 equiv) in dry pyridine (20 mL), under an inert 
atmosphere, was refluxed for 2 h. After cooling to r.t., the solution was poured onto ice 
(20 g) and water (20 mL), and the resulting solid was allowed to stand for 2 h, after which 
it was collected by filtration, washed with cold water and dried under reduced pressure 
(high vacuum). This material was suspended in dry acetic anhydride (25 mL) under an 
inert atmosphere at r.t., to which was added anhydrous sodium acetate (481 mg, 5.86 
mmol, I equiv). Workup was performed as for General Procedure Q. The crude product 
was purified by flash chromatography on silica (ethyl acetate/acetone 2:1, then ethyl 
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acetate/acetone 1 :2, then acetone), followed by recrystallisation (ethyl acetate/petroleum 
ether), to give 5.38 (169 mg, 5% yield over two steps) as an orange solid. 
mp 337-339°C. 
IH NMR (acetone-d6, 500 MHz) 8 3.09 (s, 8H, 2 x CfuCfu), 7.72 (dd, 2H, J= 2.0,8.8 Hz, 
ArH), 8.29 (t, 2H, J= 1.0 Hz, ArH), 8.37 (d, 2H, J= 9.3 Hz, ArH), 9.26 (s, 1H, ArH). 
l3C NMR (DMSO-d6, 75 MHz) 8 28.8 (2 x CH2CH2), 125.3, 125.5, 126.4, 129.3, 134.9, 
136.7, 148.4 (ArC), 177.0 (4 x CO2). 
FTIR (KBr, diffuse refraction method) cm-1 1560.3, 1624.0, 1701.71 1782.1, 2947.0, 
2991.4. 
HRMS (El) 373.1068 (M+). C21HlSN304 requires 373.1063. 
4,4' -Hydroxy-N ,N'-( acridin-3,6-diyl)dibutanamide (5.39) 
The succinimide 5.38 (160 mg, 0.43 mmol, 1 equiv) was treated with sodium borohydride 
(171 mg, 4.52 mmol, 5 equiv) by modified General Procedure R. After filtration through 
Dowex-50W resin, the resin was stirred in methanol for 30 min and filtered once again, the 
filtrates were combined, and the solvent was removed by evaporation under reduced 
pressure. The resulting material was passed through a short plug of silica (eluted with 
methanol) to give 5.39 (449 mg, 89%) as a brown solid. This product was used without 
further purification. 
IH NMR (CD30D, 500 MHz) 8 1.89 (m, 4H, 2 x CH2CfuCH2), 2.42 (t, 4H, J = 7.3 Hz, 2 x 
CfuCO), 3.61 (t, 4H, J = 6.3 Hz, 2 x HOCfu), 6.81 (dd, 2H, J = 2.0, 8.3 Hz, ArH), 6.94 
(m, 3H, ArH), 7.11 (d, 2H, J= 2.0 Hz, ArH). 
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6.5.9 Preparation of the S-(hydroxymethyl)pyrrole 5.41 
---" HOJ]l 
N C02Et 
H 
3.16a 5.41 
EthyIS-hydroxymethyl-1H-pyrrole-2-carboxylate (5.41) 
Pyrrole ester 3.16a (150 mg, 0.90 mmol, 1 equiv) was reduced with lithium borohydride 
(39 mg, 1.79 mmol, 2equiv) by General Procedure K. The crude product was purified by 
flash chromatography on silica (ethyl acetate/petroleum ether, 1:1) to give 5.41 (115 mg, 
76%) as a white solid. 
mp 76-78°C. 
lH NMR (CDCb, 500 N1Hz) 8 1.35 (t, 3H, J= 7.1 Hz, CH2Cfu), 4.31 (q, 2H, J= 7.2 Hz, 
CfuCH3), 4.69 (s, 2H, HOCfu), 6.11 (t, IH, J = 3.2 Hz, pyrrole H4), 6.84 (dd, IH, J = 2.4, 
3.9 Hz, pyrrole H3), 9.51 (s(br), IH, pyrrole NH). 
l3C NMR (Acetone-d6, 75 MHz) 8 14.1 (CH2CH3), 57.0 (HOCH2), 59.6 (CH2CH3), 108.0 
(pyrrole C4), 115.2 (pyrrole C3), 122.4 (pyrrole C2), 138.7 (pyrrole C5), 160.7 (C02). 
FTIR (KBr, diffuse refraction method) 1502.4, 1683.7,2993.3,3286.5. 
HRMS (EI) 169.0739 (M+). CSHllN03 requires 169.0738. 
Micro. Calcd for CsHllN03 : C, 56.80; H, 6.55; N, 8.28. Found: C, 57.03; H, 6.63; N, 8.19. 
6.5.10 Biological Assays 
P388 Biological Assa~s 
This is an antitumour assay, whereby a dilution series of a prepared compound in methanol 
or 3:1 methanollDMF with P388 murine leukaemia cells is incubated for 72 h. The 
concentration of the sample required to reduce the P388 cell growth by 50%, compared to 
the control cells, is determined using the absorbance values obtained at 540 nm when the 
yellow MTT tetrazolium is reduced by healthy cells to produce purple coloured MTT 
formazan. The result is expressed as an ID50 in ~g mL-1 and ~M. 
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No. Solvent Sample concentration IDso IDso 
system* (mg mL-1)# (j.lg mL-1) (j.lM) 
A 10 87 611 
5.16 
B 20 165 468 
A 10 13 88 
5.28 
A 10 111 314 
B 1 2.0 9.4 
5.37 
HO~ N C02Et A 10 >125 >739 
H 
5.41 
*A 3:1 MeOHIDMF 
Table 6.6. Activity of 5.16, 5.21, 5.28, 5.31, 5.37 and 5.41 against the P388 murine 
leukaemia cell line. 
Antiviral Assay 
Aliquots, typically 40 j.lL, of a prepared compound are pipetted onto 6 mm diameter filter 
paper discs. The solvent is allowed to evaporate before the discs are placed directly onto 
BSC-1 cells (African Green Monkey Kidney), infected with either Herpes simplex type 1 
virus (ATCC VR 733), or Polio virus type 1 (pfizer vaccine strain). After a 24 h 
incubation period at 37°C in an atmosphere containing 1.5% carbon dioxide the wells are 
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examined using an inverted microscope. The assay is scored based on the size of viral 
inhibition and/or cytotoxic zones, and the type of cytotoxicity. 
No. PVl HSVI 
Antiviral Cytotoxic Antiviral Cytotoxic 
effects effects effects effects 
? 4+ ? 4+ 
ND ND ND ND 
?* 2+ ?* 2+ 
? 4+ ?* 3+ 
?* + ?* 2+ 
ND ND ND ND 
5.41' 
+ Activity tested in the solvent system and sample concentration specified in Table 5.1. 
# Activity tested in solvent system A at 10 mg mL"l. 
Table 6.7. Activity of 5.16, 5.21, 5.28, 5.31, 5.37 and 5.41 against the Polio type 1 virus 
(PV 1) and Herpes simplex type 1 virus (HSV 1). 
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Antimicrobial Assay 
Bacteria or fungi at a known concentration are mixed with a potato dextrose agar and 
poured into petri dishes so that after incubation a "lawn" of bacteria/fungi will grow over 
the entire dish. Samples of interest are pipetted onto 6 mm diameter paper discs and their 
solvents evaporated. These are then placed onto the above prepared seeded agar dishes 
(with appropriate solvent and positive controls) and incubated. Zones of inhibition are 
measured in millimetres as the radius from the centre of the disc to the edge of the 
inhibited zone. There are six test organisms: 
Bacteria: Escherichia coli (E coli), Bacillus subtilis (B sub)*, Pseudomonas aeruginosa (P 
aer) 
Fungi: Candida albicans (C alb), Trichophyton mentagrophytes (T ment)*, Cladosporium 
resinae (C res) 
* = most sensitive organisms. 
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No. Bacteria 
E coli Bsub 
4 3 
JI 
3 10 
2 10 
5.31'" 
HO~ N C02Et 
H 
5.41+ 
Gentamycin 10 
Chloramphenicol 13 
Nystatin 
Paer Calb 
1 10 
15 
1 1 
10 
10 
Fungi 
Tment 
22 
10 
1 
6 
3 
7 
240 
Cres 
10 
15 
3 
12 
Activity tested in the solvent system and sample concentration specified in Table 5.1. 
# Activity tested in solvent system A at 10 mgmL- l . 
~ No activity observed. 
Table 6.8. Activity of 5.16, 5.21, 5.28, 5.31, 5.37 and 5.41 against selected microbial 
speCIes. 
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CRYSTALLOGRAPHIC STRUCTURE DETERMINATION FOR COMPOlJND 
4.11h BY X-RAY ANALYSIS 
CO) 
Cel2) 
C(ll) Cel) ~ 
e( l3) 
C(IO) 
C(2) C(3) 
C(9) 
C(I4) 
C(16) 
Figure A 1. Labelled drawing of 4.11 h. 
Instrument 
Empirical formula 
Molecular weight 
Colour and shape 
Temperature 
Wavelength 
Crystal system 
Space group 
Unit cell dimensions 
Crystal size 
Volume 
z 
Density (calculated) 
Absorption coefficient 
F(OOO) 
() range for data collection 
0(19) 
~ C(I6) 
• C(5) C(19) N(4) 0(16) 
N(l?) 0(20) 
0(3) COs) 
C(27) 
Siemens P4 four circle dithactometer 
C) ,)I-i)xN204 
338.35 g mor t 
Orange block 
168(2)K 
0.71073 A (Mo-Ka radiation) 
Orthorhombic 
1222 
a = 7.880(4) A 
b = 13 .748(5) A 
c = 34.669( 16) A 
0.80 x 0.25 x 0.25 mm 
3756(3) A3 
8 
1.197 g cm-3 
0.085 mm-) 
1424 
2.65 to 26 .3 1°. 
COl) 
Appendix 
fudex ranges 
Reflections collected 
fudependent reflections 
Completeness to theta 26.31 0 
Absorption correction 
Max. and min. transmission 
Refmement method 
Data/restraints/parameters 
Goodness-of-fit on r 
Final R indices [1> 2cr(I)J 
R indices (all data) 
Absolute structure parameter 
Largest diff. peak and hole 
-9 ~ ~, -6 '5k 5, -42 .g ~3 
7633 
3570 [R(int) 0.0257J 
93.3 % 
Semi-empirical from equivalents 
0.9791 and 0.9351 
Full-matrix least-squares on r 
3570/01228 
1.070 
Rl = 0.0496, WR2 0.1506 
Rl = 0.0574, WR2 0.1577 
1.1(14) 
0.551 and -0.266 eA-3 
245 
The unique reflections were used in a full-matrix least-squares refinement. 1 The structure 
was solved by direct methods? Hydrogen atoms were fixed in idealised positions. All 
non-hydrogen atoms were refined with anisotropic displacement parameters. 
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Atom x y z U(eq) 
C(l) 10483(3) 1261(2) 8245(1) 34(1) 
C(2) 8839(3) 1234(2) 8146(1) 31(1) 
C(3) 8713(3) 1243(2) 7714(1) 29(1) 
C(5) 11376(3) 1254(2) 7239(1) 31(1) 
C(6) 13044(3) 1268(2) 7347(1) 37(1) 
C(7) 13136(3) 1281(2) 7760(1) 40(1) 
C(8) 11505(3) 1272(2) 7895(1) 34(1) 
C(9) 7266(3) 1202(2) 8393(1) 35(1) 
C(10) 7629(3) 1207(2) 8820(1) 35(1) 
C(ll) 8258(4) 2038(2) 8996(1) 47(1) 
C(12) 8600(4) 2053(3) 9388(1) 59(1) 
C(13) 8298(4) 1237(3) 9610(1) 61(1) 
C(14) 7675(5) 411(3) 9436(1) 65(1) 
C(15) 7341(4) 394(2) 9045(1) 50(1) 
C(16) 10737(3) 1227(2) 6837(1) 32(1) 
C(18) 8342(3) 1177(2) 6398(1) 36(1) 
C(19) 8630(3) 2105(2) 6172(1) 35(1) 
C(21) 8719(5) 2736(3) 5540(1) 67(1) 
C(22) 6436(4) 1001(2) 6432(1) 52(1) 
N(4) 10409(2) 1260(1) 7581(1) 30(1) 
N(17) 9047(2) 1247(2) 6784(1) 35(1) 
0(3) 7443(2) 1232(1) 7516(1) 37(1) 
0(16) 11749(2) 1194(1) 6567(1) 40(1) 
0(19) 8723(2) 2910(1) 6302(1) 41(1) 
0(20) 8652(3) 1896(1) 5793(1) 53(1) 
Table At. Atomic coordinates (x 10-4) and equivalent isotropic displacement parameters 
(A2 x 10-3) for 4.11h. U( eq) is defined as one third of the trace of the orthogonalized Uij 
tensor. 
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Bond Length (A) Bond Length (A) Bond Length (A) 
C(1)-C(2) 1.341(3) C(6)-C(7) 1.433(4) C(14)-C(15) 1.380(4) 
C(1)-C(8) 1.455(3) C(7)-C(8) 1.369(3) C(16)-O(16) 1.231(3) 
C(2)-C(3) 1.502(3) C(8)-N(4) 1.390(3) C(16)-N(17) 1.344(3) 
C(2)-C(9) 1.506(3) C(9)-C(10) 1.509(3) C(18)-N(17) 1.454(3) 
C(3)-O(3) 1.214(3) C(10)-C(15) 1.382(4) C(18)-C(19) 1.515(3) 
C(3)-N(4) 1.414(3) C(1 0 )-C(11) 1.387(4) C(18)-C(22) 1.526(4) 
C(5)-C(6) 1.366(3) C(1l)-C(12) 1.385(4) C(19)-O(19) 1.198(3) 
C(5)-N(4) 1.410(3) C(12)-C(13) 1.380(5) C(19)-O(20) 1.344(3) 
C(5)-C(16) 1.483(3) C(13)-C(14) 1.376(5) C(21)-O(20) 1.450(3) 
Table A2. Bond lengths (A) for 4.11h. 
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Bond Angle e) Bond Angle (0) 
C(2)-C(1 )-C(8) 108.80(18) C(12)-C(11 )-C(l 0) 120.9(3) 
C(1)-C(2)-C(3) 108.56(18) C(13)-C(12)-C(11 ) 120.1(3) 
C(l )-C(2)-C(9) 130.60(19) C(14)-C(13)-C(12) 119.2(3) 
C(3)-C(2)-C(9) 120.84(18) C(13)-C(14)-C(15) 120.8(3) 
O(3)-C(3)-N( 4) 126.55(18) C(14)-C(15)-C(10) 120.6(3) 
O(3)-C(3)-C(2) 128.2(2) 0(16)-C(16)-N( 1 7) 122.6(2) 
N( 4)-C(3)-C(2) 105.23(17) O( 16)-C(16)-C( 5) 119.7(2) 
C(6)-C(5)-N(4) 106.77(18) N(17)-C(16)-C(5) 117.61(19) 
C(6)-C(5)-C(16) 125.8(2) N(17)-C(18)-C(19) 111.38(19) 
N ( 4 )-C( 5)-C( 16) 127.41(19) N(17)-C(18)-C(22) 108.3(2) 
C( 5)-C( 6)-C(7) 108.9(2) C(19)-C(18)-C(22) 108.7(2) 
C(8)-C(7)-C( 6) 107.1(2) O(19)-C(19)-O(20) 124.5(2) 
C(7)-C(8)-N( 4) 108.32(19) O(19)-C(19)-C(18) 126.2(2) 
C(7)-C(8)-C(1 ) 143.7(2) O(20)-C(19)-C(18) 109.1(2) 
N( 4)-C(8)-C(1) 108.02(19) C(8)-N(4)-C(5) 108.91(17) 
C(2)-C(9)-C(10) 113.68(18) C(8)-N(4)-C(3) 109.38(17) 
C(15)-C(10)-C(11) 118.4(2) C(5)-N(4)-C(3) 141.70(17) 
C(15)-C(10)-C(9) 121.3(2) C(16)-N(17)-C(18) 120.13(19) 
C(ll )-C(1 0)-C(9) 120.2(2) C(19)-O(20)-C(21 ) 114.8(2) 
Table A3. Bond angles (0) for 4.11h. 
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Atom Ull U22 U33 U23 Ul3 U12 
C(l) 35(1) 37(1) 29(1) 2(1) -3(1) 4(1) 
C(2) 34(1) 29(1) 29(1) 2(1) 0(1) 0(1) 
C(3) 32(1) 25(1) 31(1) 2(1) 0(1) 2(1) 
C(5) 33(1) 27(1) 33(1) -1(1 ) 2(1) -4(1) 
C(6) 32(1) 37(1) 42(1) 1(1) 2(1) 2(1) 
C(7) 31(1) 50(1) 39(1) 0(1) -6(1) -1(1) 
C(8) 32(1) 37(1) 32(1) -1(1) -6(1) 2(1) 
C(9) 32(1) 42(1) 32(1) 1(1) -2(1) 0(1) 
C(10) 32(1) 44(1) 30(1) 4(1) 2(1) 6(1) 
C(ll) 50(2) 56(2) 35(1) 4(1) 0(1) -8(1) 
C(12) 52(2) 84(2) 41(2) -15(1) -3(1) -6(2) 
C(13) 65(2) 88(2) 31(1) 6(2) -2(1) 15(2) 
C(14) 79(2) 74(2) 43(2) 24(2) 6(2) 21(2) 
C(15) 59(2) 49(2) 42(1) 5(1) 9(1) 9(1) 
C(16) 37(1) 25(1) 33(1) 4(1) -1(1) -1(1) 
C(18) 41(1) 35(1) 33(1) 2(1) -4(1) -4(1) 
C(19) 30(1) 46(1) 30(1) 2(1) -1(1) 0(1) 
C(21) 88(2) 77(2) 37(1) 22(1) 1(2) -11(2) 
C(22) 46(2) 58(2) 51(2) 17(1) -15(1) -15(1) 
N(4) 28(1) 35(1) 28(1) 1(1) -3(1) -1(1) 
N(17) 32(1) 43(1) 29(1) 4(1) -1(1) -2(1) 
0(3) 29(1) 51(1) 32(1) 4(1) -4(1) -2(1) 
0(16) 40(1) 45(1) 34(1) 0(1) 6(1) -3(1) 
0(19) 42(1) 37(1) 43(1) 1(1) 1(1) -3(1) 
0(20) 75(1) 56(1) 28(1) 2(1) 0(1) -6(1) 
Table A4. Anisotropic displacement parameters (A2 x 10-3) for 4.11h. The anisotropic 
displacement factor exponent takes the fonn: _2p2[(ha*iUll + ... + 2hka*b*U12]. 
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Atom x y z U(eq) 
H(1) 10911 1270 8501 40 
H(6) 13987 1269 7177 44 
H(7) 14141 1293 7911 48 
H(9A) 6615 608 8329 42 
H(9B) 6546 1771 8330 42 
H(ll) 8457 2604 8846 56 
H(12) 9042 2625 9504 71 
H(13) 8519 1246 9879 74 
H(14) 7471 -154 9587 79 
H(15) 6910 -182 8930 60 
H(18) 8880 619 6259 43 
H(21A) 9793 3081 5580 101 
H(21B) 7770 3172 5599 101 
H(21C) 8640 2522 5271 101 
H(22A) 5915 1538 6576 77 
H(22B) 6235 389 6569 77 
H(22C) 5935 965 6174 77 
H(17) 8367 1304 6984 42 
Table AS. Hydrogen coordinates (x 10-4) and isotropic displacement parameters (A2 x 
103) for 4.11h. 
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Bond Angle e) Bond Angle e) 
C(8)-C(1 )-C(2)-C(3) -0.9(3) N ( 4)-C( 5)-C(16)-O(16) -177.8(2) 
C(8)-C(1 )-C(2)-C(9) 179.3(2) C(6)-C(5)-C(16)-N(17) -177.9(3) 
C(1 )-C(2)-C(3)-O(3) -179.4(2) N(4)-C(5)-C(16)-N(17) 2.7(3) 
C(9)-C(2)-C(3)-O(3) 0.5(3) N(17)-C(18)-C(19)-O(19) -30.2(4) 
C(l )-C(2)-C(3)-N( 4) 0.9(3) C(22)-C(18)-C(19)-O(19) 89.1(3) 
C(9)-C(2)-C(3)-N( 4) -179.2(2) N(17)-C(18)-C(19)-O(20) 153.9(2) 
N (4)-C( 5)-C( 6)-C(7) 0.2(3) C(22)-C(18)-C(19)-O(20) -86.8(3) 
C( 16)-C( 5)-C( 6)-C(7) -179.3(2) C(7)-C(8)-N( 4)-C(5) 0.5(3) 
C( 5)-C( 6)-C(7)-C(8) 0.1(3) C(1)-C(8)-N(4)-C(5) -179.0(2) 
C( 6)-C(7)-C(8)-N( 4) -0.4(3) C(7)-C(8)-N( 4)-C(3) 179.5(2) 
C( 6)-C(7)-C(8)-C(1) 178.8(3) C(1 )-C(8)-N( 4)-C(3) 0.0(2) 
C(2)-C(1 )-C(8)-C(7) -178.6(4) C(6)-C(5)-N(4)-C(8) -0.4(2) 
C(2)-C(1 )-C(8)-N( 4) 0.6(3) C(16)-C(5)-N( 4)-C(8) 179.0(2) 
C(1 )-C(2)-C(9)-C(1 0) 0.4(4) C(6)-C(5)-N(4)-C(3) -178.9(3) 
C(3)-C(2)-C(9)-C(10) -179.5(2) C( 16)-C( 5)-N ( 4)-C(3) 0.6(4) 
C(2)-C(9)-C(10)-C(15) -110.2(3) O(3)-C(3)-N(4)-C(8) 179.8(2) 
C(2)-C(9)-C(1 0)-C(11) 70.1(3) C(2)-C(3)-N(4)-C(8) -0.5(2) 
C(15)-C(1 O)-C(ll )-C(12) 0.4(4) O(3)-C(3)-N( 4)-C( 5) -1.8(4) 
C(9)-C(1 O)-C(ll )-C(12) -179.9(3) C(2)-C(3)-N(4)-C(S) 177.9(3) 
C(1O)-C(11)-C(12)-C(13) -0.7(5) O(16)-C(16)-N(17)-C(18) 3.4(4) 
C(11)-C(12)-C(13)-C(14) 0.7(5) C(S)-C(16)-N(17)-C(18) -177.14(18) 
C(12)-C(13 )-C(14)-C(15) -0.4(5) C(19)-C(18)-N(17)-C(16) -72.5(3) 
C(13)-C(14 )-C(lS)-C(l 0) 0.1(5) C(22)-C(18)-N(17)-C(16) 168.0(2) 
C(11 )-C(l 0)-C(lS)-C(14) 0.0(4) O(19)-C(19)-O(20)-C(21) -2.9(4) 
C(9)-C(10)-C(15)-C(14) -179.8(3) C(18)-C(19)-O(20)-C(21) 173.1(2) 
C( 6)-C( S)-C(16)-O( 16) 1.6(4) 
Table A6. Torsion angles e) for 4.11h. 
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